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 Abstract I
 
 
ABSTRACT 
Chiral molecules are versatile building blocks for the synthesis of pharmaceuticals and fine chemicals. 
α-amino acids (natural and non-natural ones) represent one major group among these chiral molecules 
having, with the exception of glycine, at least one chiral center. Besides fermentative production 
methods, amino acids are also synthesized chemically as racemates. Thus, for chiral applications, the 
enantiomers have to be separated. To overcome yield limitations of simple enantioseparation 
processes, which are generally limited to 50 %, the aim of this thesis was the development of new 
processes for the efficient production and separation of chiral amino acids by the combination of 
enzymatic racemization/isomerization and crystallization. To achieve this goal, two different 
approaches have been investigated starting from either racemic or enantiopure substrates: 
1) Enzyme-assisted preferential crystallization combines the crystallization of a single 
enantiomer from a racemic solution with enzymatic racemization of the remaining enantiomer. 
This concept is only applicable to the relatively small group of conglomerate forming 
racemates. Asparagine was identified as a suitable model substrate for preferential 
crystallization and enzymatic racemization using the purified amino acid racemase 
AArac2440 from Pseudomonas putida KT2440. A process for the dynamic resolution of L-
asparagine from a supersaturated racemic solution was developed in a 20 mL scale, and the 
product ee could be increased significantly by enzymatic racemization of the remaining D-
asparagine during crystallization. This process is a modification of a classical dynamic kinetic 
resolution, where product separation occurs via enantioselective crystallization instead of 
asymmetric transformation. 
2) The second approach focuses on the production of chiral allo-threonine from threonine by 
enzymatic isomerization and crystallization. Both enantiomers of the valuable allo-threonine 
have been produced with good yields from low-prized threonine using purified amino acid 
racemase AArac12996 from Pseudomonas putida NBRC12996. Product separation was 
performed by simple crystallization from the reaction solution, which was possible due to the 
lower solubility limit of allo-threonine compared to threonine. 
The presented approaches are samples of new promising methods for the production and separation of 
chiral amino acids. Further investigations on improved catalysts may expand the general application 
scope of these methods to even more versatile substance groups. 
II Kurzfassung  
 
 
KURZFASSUNG 
Chirale Moleküle finden u. A. Anwendung als vielseitig einsetzbare Intermediate in der Synthese von 
pharmazeutisch wirksamen Substanzen und Feinchemikalien. Natürliche wie auch unnatürliche α-
Aminosäuren, die mit Ausnahme von Glycin mindestens ein asymmetrisches C-Atom besitzen, stellen 
dabei eine wichtige Gruppe dieser chiralen Bausteine dar. Aminosäuren können sowohl fermentativ 
als auch mittels chemischer Synthese in Form von Racematen hergestellt werden. Für die Anwendung 
als chirale Intermediate muss somit gegebenenfalls eine Enantiomerentrennung erfolgen. Um die 
Ausbeute über die bei einfachen Trennverfahren üblichen 50 % zu steigern, sollten im Rahmen dieser 
Doktorarbeit neue und effiziente Prozesse zur Produktion und Abtrennung chiraler Aminosäuren 
entwickelt werden. Dies erfolgte durch die Kombination einer enzymatischen Racemisierung bzw. 
Isomerisierung mit einer Kristallisation zur Produktabtrennung. Ausgehend von entweder racemischen 
oder chiralen Aminosäuren wurden zwei verschiedene Prozessansätze untersucht: 
1) Die Enzymunterstützte bevorzugte Kristallisation vereint die Kristallisation eines einzelnen 
Enantiomers aus einer racemischen Lösung mit der enzymatischen Racemisierung des 
verbleibenden Enantiomers. Die bevorzugte Kristallisation kann nur für eine relativ kleine 
Gruppe der sogenannten konglomeratbildenden Racemate angewendet werden, zu der auch 
die proteinogene Aminosäure Asparagin zählt. Sie stellt zudem ein geeignetes Substrat der 
Aminosäureracemase AArac2440 aus Pseudomonas putida dar. Ein Modellprozess zur 
dynamischen Abtrennung von L-Asparagin aus einer übersättigten racemischen Lösung wurde 
im 20 mL Maßstab entwickelt. Durch die enzymatische Racemisierung des verbleibenden D-
Asparagins während der bevorzugten Kristallisation, konnte ein deutlicher Anstieg des 
Enantiomerenüberschusses in den Produktkristallen erzielt werden. Dieser Prozess kann als 
eine neue Variante der klassischen dynamisch kinetischen Racematspaltung angesehen 
werden, bei der die Produktabtrennung durch bevorzugte Kristallisation anstelle einer 
asymmetrischen Transformation erfolgt. 
2) Der zweite untersuchte Prozess umfasst die Produktion von chiralem allo-Threonin aus 
Threonin durch enzymatische Isomerisierung und Kristallisation. Beide Enantiomere des 
hochpreisigen allo-Threonins konnten mit guten Reinheiten und Ausbeuten aus dem 
preiswerten Ausgangsmaterial Threonin hergestellt werden. Die Isomerisierung von D- und L-
Threonin zu L- bzw. D-allo-Threonin erfolgte dabei mit Hilfe der reinen Aminosäureracemase 
AArac12996 aus Pseudomonas putida NBRC12996. Durch einfache Kristallisation des 
weniger löslichen allo-Threonins aus der Reaktionslösung konnte eine effiziente 
Produktabtrennung erreicht werden. 
Die hier präsentierten Prozesse zur Herstellung enantiomerenreiner Aminosäuren sind Beispiele 
für neue vielversprechende Methoden zur Produktion und Abtrennung chirale Aminosäuren. 
Durch die Entwicklung verbesserter Biokatalysatoren mit erweiterten Substratspektren, könnte die 
Anwendungsbreite dieser neuen Methoden auf weitere interessante chirale Stoffgruppen erweitert 
werden. 
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2 Introduction  
 
1 Introduction 
1.1 Biocatalysis 
1.1.1 Biocatalysis – an ancient art 
Humans have used biocatalysts already since about 6000 to 8000 years, when the old 
Egyptians utilized microorganisms such as yeast to brew beer and to bake bread. Processes 
like the fermentation of milk for cheese or yoghurt preparation or the production of vinegar 
by microbial oxidation followed. However, it took millenniums until the biological principles 
had been explored. It was only in 1833 when the French chemists Anselme Payen (1795-
1871) and Jean-François Persoz (1805-1868) isolated a starch hydrolyzing amylase complex 
from malt, which they called diastase (Payen et al., 1833). The scientific basis for biocatalytic 
reactions occurring during fermentation processes was first described in the middle of the 19th 
century by Louis Pasteur (1822-1895), who demonstrated the existence of microorganisms 
and their effect on fermentation in the so called “germ theory” (Walsh, 1913). At the same 
time Pasteur established the fundamentals of stereochemistry by the resolution of racemic 
tartaric acid (Pasteur, 1897) and identified the ability of microorganisms to degrade single 
enantiomers from racemates while the other one remains unmodified (Turner, 1998). 
However, it was not before the year 1877 when the German physiologist Wilhelm Kühne 
(1837-1900) used the term enzyme for the first time to describe non-living substances that 
were able to catalyze chemical reactions (Kühne, 1877). Another pioneer in enzyme catalysis 
was the German chemist Emil Fischer (1852-1919) who elucidated essential aspects of 
enzyme catalysis and showed that, besides whole cells, also enzymes are able to distinguish 
between chiral molecules (Fischer, 1894). Although the nature of enzymes was not clear at 
this point, they were already known to satisfy three criteria required for being a catalyst 
(Yuryev et al., 2010): 
1. The catalytic agent is not altered during the reaction. 
2. Small amounts of catalytic agent are adequate for the conversion of large amounts of 
substrate. 
3. The catalytic agent does not affect the final reaction equilibrium. 
A few years later, Eduard Buchner (1860-1917) showed that a cell-free extract of yeast cells 
was sufficient for the fermentation of sugar. He identified the soluble active ingredient as a 
protein and called it zymase (Buchner, 1897). Buchner thereby proved that enzyme catalysis 
was a chemical process not necessarily linked to living cells, and thus paved the way for 
modern biocatalytic processes. In 1926 Sumner was able to crystallize urease and thereby 
finally proofed that enzymes indeed were proteins (Sumner et al., 1950). 
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1.1.2 Biocatalysis in industry 
Nowadays, biocatalysis is an important tool for the chemical industry. In highly selective 
reactions it enables the synthesis of complex compounds. The success story of industrial 
applications of enzymes began in 1874, when Christian Hansen started the first company for 
the production of standardized enzyme preparations, namely rennet for cheese making 
(Buchholz et al., 2000). From thereon biocatalytic processes gained more and more influence 
for industrial food processing such as in chill-proofing of beer, the addition of malt extract 
(13500 t in 1922), or in dough making (Tauber, 1949). 
The discovery of the chemical structure and composition of DNA and RNA by Watson and 
Crick in 1953 and its meaning for protein expression initiated a new era of biotechnology 
(Watson et al., 1953). Due to the development of recombinant gene technologies enzymes 
became easily accessible on a large scale for commercial applications. The obvious 
advantages of biocatalysts over classical chemical catalysts, such as chemo-, regio- and 
enantioselectivity, mild reaction conditions, environmental friendliness, and high catalytic 
efficiencies, led to about 150 implemented biocatalytic processes in industry from the 1970’s 
until today (Woodley, 2008). For example, microorganisms are used for the production of 
bulk chemicals (e.g. methanol, ethanol, acryl amid), organic acids (e.g. citric acid, maleic 
acid, gluconic acid), polysaccharides (e.g. xanthan), vitamins (e.g. vitamins B and C, biotin), 
and amino acids (e.g. L-glutamate, L-threonine). Most of these products are applied in the 
food and feed industry as well as in the pharmaceutical or chemical industry. Besides, 
enzymes are used as additives in detergents and foods or for diagnostic purposes. Biocatalysis 
is particularly valuable for the production of fine chemicals, since the enzymes’ high regio- 
and enantioselectivity offers new routes to enantiopure complex molecules, which in many 
cases are hard to synthesize chemically. Despite their natural environment, enzymes can also 
be applied in non-conventional media such as organic solvents or ionic liquids which paves 
the way for synthetic routes with new substrates and/or products or altered selectivity 
(Würges et al., 2005). 
About 50 % of all industrial biotransformations are performed as batch processes in which 
approximately 1-10 % of the process costs can be attributed to the biocatalyst (Straathof et al., 
2002). Although many enzymes have substrate and product scopes that are much broader than 
the natural ones, in many cases the creation of robust and suitable biocatalysts by 
evolutionary methods has been advantageous. Thus, the process does not have to be adapted 
to the catalyst anymore, but the catalyst is developed for a commercially optimal process. In 
addition, the combination of chemo- and biocatalysis provides new opportunities for chiral 
syntheses. An example for the improvement of an industrial process by biocatalysis is the 
synthesis of cortisone. The chemical approach by Merck included 31 reaction steps and about 
615 kg of deoxycholic acid were required for the synthesis of 1 kg cortisone (220 $/g). By 
enzymatic hydroxylation of progesterone to 11α-hydroxyprogesterone by Rhizopus arrhizus, 
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the synthesis was simplified leading to a vast reduction of the production costs (6 $/g) 
(Yuryev et al., 2010). Figure 1 gives an overview about the world market of biotechnological 
processes and their share among chemical products in the year 2001 and the sales that were 
expected in 2010 (Festel et al., 2004). 
Figure 1: Sales of chemical products in the years 2001 and 2010 (expected) with share of biotechnological 
processes (Festel et al., 2004). 
 
Ran et al. shortly reviewed recent applications of biocatalysis for chemical syntheses at 
industrial scale (Ran et al., 2008). Nevertheless, the number and diversity of biocatalytic 
applications are modest probably due to limitations such as enzyme availability, substrate 
scope and operational stability. However, due to breakthroughs in the fields of genomics, 
evolutionary methods and rational protein design, many new industrial applications are 
expected (Schoemaker et al., 2003). 
 
1.1.3 Advantages and challenges of biocatalysis 
Compared to classical chemical synthesis biocatalysis provides many advantages: 
1. Selectivity: Enzymes are able to catalyze reactions with very high chemo-, regio- and 
enantioselectivity. This ability makes them particularly interesting for the production 
of fine chemicals and pharmaceutical intermediates, which are often, if at all, only 
accessible by chemical multi-step reactions. Using molecular biological methods, such 
as directed evolution and rational protein design, or reaction engineering, these 
properties can be adjusted according to the desired application. 
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2. Mild reaction conditions: Enzymes have the ability to reduce the activation energy for 
the catalyzed reaction and thus enable reactions under comparatively mild conditions. 
Usually temperatures between 15 °C and 80 °C, pH-values between pH 3 and pH 8 
and atmospheric pressure are applied for enzymatic reactions. Thereby, not only 
undesired side reactions like product isomerization or rearrangement can be reduced 
(Patel, 2006), but also additional protection and deprotection reactions can be avoided 
(Schmid et al., 2001). 
3. Efficient catalysis: Enzymes operate catalytically rather than stoichiometrically and 
thus are able to increase turnover numbers up to 108-1012 times (Frey et al., 2006). 
High product yields and purities are a result of extraordinary selectivity. 
4. Catalytic promiscuity: Enzymes offer an enormous range of different catalytic 
reactions. Depending on their source organism, they are adopted to the whole area of 
possible environmental properties occurring in the different ecological niches on earth. 
Although many enzymes only use very specific substrates in their physiological 
environment, the possible substrate scope is usually much broader than the natural one 
(Schoemaker et al., 2003). This allows the production of chemicals that do not occur 
in the natural organism’s metabolism. An example is the synthesis of propane-1,3-diol 
from glucose by recombinant E. coli (Sturmer et al., 2006). 
5. Environmental friendliness: Due to their nature, enzymes usually operate in aqueous 
solutions and buffers and without the need of organic solvents, thus producing less 
toxic waste compared to chemical processes. Enzyme catalyzed reactions are rarely 
endo- or exothermic, thereby reducing the energy that is required for heating or 
cooling during the process. In contrast to classical chemical syntheses, where heavy 
metals are often used as catalysts, enzymes are completely bio-degradable. In addition, 
biocatalytic reactions normally use (C6)n-sources from renewable resources such as 
glucose, which makes them nearly CO2-neutral. 
However, due to limitations mainly caused by poor enzyme availability, stability and a 
narrow reaction scope, biocatalysis also has to face challenges: 
1. Downstream processing: Product purification is the final and often cost intensive step 
of biocatalytic processes. Due to natural evolution, enzymes usually operate under 
comparatively low substrate and product concentrations (in contrast to chemical 
reactions) far from those required in industrial processes. This hampers downstream 
processing since large amounts of water have to be removed. Alternative methods 
involve multi-phase reaction media for in situ product removal, such as liquid-liquid 
extraction, which is usually done by organic solvents. 
2. Cofactor regeneration: One major limitation of numerous reactions is the necessary 
regeneration of reduced cofactors (NADH, NADPH) during redoxreactions. The 
enzyme-coupled approach uses a coenzyme for cofactor regeneration either in vivo 
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during whole cell biotransformations, or by the addition of the coenzyme (e.g. formate 
dehydrogenase). The substrate-coupled approach uses only one enzyme and an 
auxiliary cosubstrate, which is oxidized for cofactor regeneration (e.g. oxidation of 
2-propanol to acetone). Another method for cofactor regeneration is the 
electrochemical approach. Here electrons are supplied by an electrode and transferred 
via mediators (e.g. rhodium complexes) to the reduced cofactors (Goldberg et al., 
2007). 
3. Long development times: New developments in biocatalysis tend to take several 
months from lab to production scale, which is much too long for many companies that 
have to fulfill customers’ needs usually in a much shorter time. Hence, these time-
consuming developments led to a loss of investors in the biotechnological sector 
(Hoffritz, 2007). A close cooperation between industry and academic research with 
the aim of further catalyst and process development is a powerful tool to overcome 
this bottleneck. Clusters of biotech- and pharmaceutical companies as well as 
academic facilities like CLIB 2021 are pointing in the right direction (CLIB2021, 
2007). 
Both, advantages and challenges are summarized in Figure 2. 
 
 
Figure 2: Advantages and challenges of industrial biocatalysis. 
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However, the general challenge that industrial biocatalysis still has to face, is to change the 
mind-set of organic chemists for the use of enzymes in chemo-enzymatic syntheses. Since 
classical chemical methods have been used for decades, biocatalysis is often only objected as 
the last opportunity if everything else had failed (Thayer, 2006). 
 
1.2 Chirality in industry 
1.2.1 Chiral compounds in chemical and pharmaceutical industry 
Chirality is a key factor for the safety and efficacy of many drugs. Due to the chiral nature of 
living organisms (Breslow et al., 2009; Lee et al., 2010) chiral compounds can have 
dramatically different biological activities and toxicities. In more than 40 % of 
enantiomerically pure products, chirality originates from a chiral precursor. Thus, the 
production of single enantiomers as building blocks for the pharmaceutical and chemical 
industry has become increasingly important. In general, there are two different approaches for 
the de novo synthesis of enantiomerically pure compounds. Either an achiral starting material 
is converted to a chiral non-racemic product or a racemic mixture is resolved to yield an 
enantiomerically pure compound. In addition, single enantiomers can be resolved from 
racemates for example by crystallization (production of (S)-naproxen) or chromatography 
(separation of D,L-tert-leucine) (Bommarius et al., 1998). 
Of course, single enantiomers can also be produced by chemical or chemo-enzymatic 
synthesis, but biocatalysis often offers advantages over classical chemical synthesis methods, 
as enzyme catalyzed reactions usually are highly selective (Patel, 2008). Not only driven by 
the strict policies of the Food and Drug Administration (FDA) for the development of new 
stereoisomeric drugs (FDA, 1992), the share of chiral pharmaceuticals has increased 
significantly during the last decade from ca. 25 % in 1999 to ca. 54 % in 2007 (Schulze et al., 
1999; Ran et al., 2008). 
Considering the market for chiral intermediates, which was expected to reach at least US $ 30 
billion by the year 2010 with annual growth rates of more than 10 % (Archer et al., 2009), it 
is obvious that also production methods involving biocatalytic steps gain importance in this 
field. Therefore, already in the year 2008 the share of biocatalysis for the production of chiral 
intermediates was estimated to 20 % (Patel, 2008). 
 
1.2.2 Nomenclature of chiral centers 
The most common way to describe the absolute configuration of a chiral center of organic 
molecules is the Cahn-Ingold-Prelog (CIP) convention. The groups that are attached to a 
chiral center are ranked by their priority starting with the highest one. The molecule is then 
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oriented in space, so that the substituent with the lowest priority points away from the 
observer. The sense of rotation of a curve passing through the substituents with priorities 1, 2 
and 3 distinguishes the stereoisomers into R (rectus, Latin for right) or S (sinister, Latin for 
left, Scheme 1 left). 
Another nomenclature is the DL-system (devised by Emil Fischer in 1891) which relies on the 
chemical correlation of the configuration of the chiral center to D-glyceraldehyde. All bonds 
are depicted as horizontal or vertical lines. The carbon chain is depicted vertically with the 
C1-atom at the top. Depending on the direction of the substituent with the highest priority at 
the chiral C-atom, the isomer is either named D (dextro, Greek for right) or L (levo, Greek for 
left) (Scheme 1, right). The DL-nomenclature is unrelated to the rotation direction of polarized 
light which is indicated by (+) or (−) and is only used for carbohydrates and amino acids, 
where the DL-nomenclature has been applied traditionally (Stryer, 2007). 
  
Scheme 1: Enantiomers of alanine. Left: Cahn-Ingold-Prelog nomenclature. Right: DL-nomenclature, 
represented in the Fischer-projection. 
 
1.2.3 Asymmetric biocatalysis in industry 
Despite the great achievements of chemists with respect to creating chirale molecules, the 
recognition and creation of chiral centers is an intrinsic property of life. Enzymes offer 
opportunities for resolving existing chiral centers (e.g. kinetic resolution with hydrolases; 
(Schulze et al., 1999)) or, even more interesting, to create new chiral centers via asymmetric 
reactions such as the reduction of carbonyl compounds using dehydrogenases or via 
carboligation by lyases (Woodley, 2008). In addition, biocatalysis often provides a direct one-
step approach to a desired intermediate without any protection/deprotection steps, which are 
often required using chemical syntheses. Thereby, biocatalysis leads to a drastic reduction of 
process steps and the associated E-factor (Environmental factor: E-factor = total waste [kg] / 
product [kg]; (Sheldon, 1994)). Companies which involve biocatalysis for the synthesis of 
chiral intermediates are for example Evonic, BASF, Avecia, Lonza, DSM, Daicel, Kaneka, 
Dow-Pharma, Codexis, Merck, Schering-Plough, GlaxoSmithKline and Pfizer. Progress in 
cultivation technology, molecular cloning, site-directed mutagenesis and directed evolution of 
biocatalysts have gained access to a variety of enzymes as tools for asymmetric biocatalysis, 
which is already considered an excellent competitive technology for chemical syntheses. 
Numerous examples for chemo-enzymatic syntheses of various biologically active 
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compounds or precursors thereof can be found in literature. A good survey is given by Patel 
(Patel, 2008). 
Besides de novo syntheses of chiral compounds, the development of methods for the 
preparation of optically pure compounds from racemates by deracemization or dynamic 
kinetic resolution is one of the present challenges in asymmetric synthesis. 
 
1.3 Chiral resolution methods 
Besides the advances in asymmetric syntheses, the optical resolution of racemates is still the 
most important approach for industrial synthesis of enantiopure compounds (Ebbers et al., 
1997). Since enantiomers have identical chemical and physical properties (apart from the 
optical rotation of linearly polarized light) separation can be quite elaborate. Possible methods 
include preferential crystallization of one enantiomer (Lorenz et al., 2006; Lorenz et al., 
2007), resolution by formation of diastereomers, asymmetric transformations (Fogassy et al., 
2006), and separation by chromatography based on chiral interactions (Francotte, 2001). In 
the following paragraphs enzyme catalyzed resolution of racemates, as well as the preferential 
crystallization of single enantiomers from racemic solutions will be explained in more detail. 
 
1.3.1 Enzyme catalyzed resolution of racemates 
Enzyme catalyzed resolution of racemates may be achieved via two different approaches: 
(dynamic) kinetic resolution and deracemization. 
Classical kinetic resolution, the conversion of one enantiomer of a racemate to a product, is 
hampered by a maximum theoretical yield of 50 %. A more elegant and efficient way is the 
so-called dynamic kinetic resolution (DKR), where an in situ racemization step of the non-
converted enantiomer is implemented into the process (Bäckvall, 2008). As a consequence, 
the enantiopure product is obtained in theoretically 100 % yield (Scheme 2). Racemization 
can be obtained either by thermal treatment, chemically (acids, bases) or enzymatically using 
racemases. 
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Scheme 2: Comparison of classical kinetic resolution and dynamic kinetic resolution processes. SS and SR: 
substrate enantiomers; P: product; k: catalytic rate constant; krac: racemization constant. 
 
Another related approach for the complete transformation of a racemate into one single 
enantiomer is the so-called deracemization. In this case two enantiomers are interconverted by 
a stereoinversion process so that a racemate is transformed to a non-racemic mixture. 
Deracemization reactions usually involve redox processes via the corresponding imine 
(Scheme 3), as shown for the interconversion of α-amino acids by an enantioselective amino 
acid oxidase and a chemical reducing agent (Enright et al., 2003). 
 
Scheme 3: Deracemization of racemic α-amino acid 
by combination of an enantioselective amino acid 
oxidase with a non-selective reduction. 
 
Good reviews about DKR and deracemization processes can be found in literature (Stecher et 
al., 1997; May et al., 2002; Turner, 2004). 
 
1.3.2 Preferential crystallization 
Preferential crystallization (PC) is an interesting method for the optical resolution of racemic 
solutions which is applicable to conglomerate forming systems. In contrast to racemic 
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compounds, which consist of equimolar amounts of two enantiomers embedded in a regular 
pattern within the crystal, a conglomerate is a mixture of two crystalline enantiomers that are, 
in principle, mechanically separable. A third type of crystalline racemates are the so-called 
solid solutions (Jacques et al., 1994). 
Due to the attempt of a system to reach its thermodynamic equilibrium, the direct 
crystallization of enantiopure crystals from a conglomerate forming system is an attractive 
procedure. The principle of this kinetically controlled crystallization is shown in Figure 3. 
The driving force for PC is provided by supersaturation of the racemic solution. This can be 
achieved most easily by cooling the solution from its saturation temperature Tsat to its 
crystallization temperature Tcryst, at which it is supersaturated but still within the metastable 
zone (region in which no spontaneous crystallization is likely to occur). Within this zone the 
solution will return to its thermodynamic equilibrium with delay. There the liquid phase is 
racemic and the solid phase consists of a mixture of crystals of both enantiomers. By seeding 
the supersaturated solution with enantiopure crystals, a homochiral surface area for crystal 
growth is offered. Therefore, the liquid phase composition does not shift directly from the 
starting composition (A) to the equilibrium composition (C), but follows a trajectory from (A) 
over (B) to (C). As long as the trajectory does not alter its linear direction, it is possible to 
collect enantiopure crystals. Detailed treatises of this process can be found in literature 
(Jacques et al., 1994; Rodrigo et al., 2004; Lorenz et al., 2006). Conglomerate forming 
systems are rare and can be estimated to about 10 % of all racemates (Collet, 1999). 
 
Figure 3: Principle of preferential crystallization (PC) of D-enantiomer for conglomerate forming systems in a 
ternary phase diagram. By cooling the solution from the saturation temperature (Tsat) to the crystallization 
temperature (Tcryst) the system becomes supersaturated. PC is initiated by seeding with enantiopure crystals. The 
arrow represents the shift of the solution composition during PC. 
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1.3.3 Enzyme-assisted preferential crystallization 
By combination of PC with enzymatic in situ racemization in solution, the formation of an 
enantiomeric excess, and thus crystallization of the counter-enantiomer, can be avoided. In 
contrast to DKR, where resolution is achieved by chiral biotransformation to an easy 
separable product (Scheme 2, right), the desired enantiomer is separated by crystallization. 
The enzyme catalyzes the auxiliary racemization reaction. 
 
Scheme 4: Enzyme-assisted preferential crystallization. 
SS and SR: substrate enantiomers; P: crystalline product; 
kcryst: crystallization constant; krac: racemization constant. 
 
1.4 α-amino acids 
α-amino acids (AA) are indispensible building blocks of life (Leuchtenberger et al., 2005) and 
therefore are of great importance for biologically active compounds such as proteins, natural 
antibiotics, nucleotides or neurotransmitter (e.g. GABA). AA consist of an amino group 
(-NH2), a carboxyl group (-COOH), a hydrogen (-H), and a characteristic rest (residue), which 
determines the chemical properties of each AA (Scheme 5). These groups can be bound to the 
central chiral C-atom (*) in two different sterical conformations leading to L- and D-isomers 
of each AA. Natural proteins are built up of the 20 proteinogenic L-AA (encoded by the 
universal genetic code) and thus giving them their chiral properties (Stryer, 2007). Most 
proteinogenic AA bear only one chiral center. Exceptions are threonine and isoleucine which 
possess two chiral centers at α- and β-position. Structural motifs thereof are found in many 
biological molecules making AA particularly interesting for synthetic applications. 
 
Scheme 5: Structures of chiral α-amino acids consisting of amino 
group, carboxyl group, hydrogen, and characteristic rest substituted to 
chiral C-atom. Left: one chiral center. Right: two chiral centers 
(threonine R: OH, isoleucine R: CH2CH3). 
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There are fourteen L-AA which can be essential for human and/or animal nutrition (Bercovici 
et al., 1995). Although significantly less frequent, there are also several D-AA occurring in 
nature. D-alanine, D-glutamate and D-2-aminoadipic acid (non-proteinogenic), for example, 
are found in the cell walls of microorganisms or in certain secondary metabolites. Moreover, 
D-serine functions as a signaling molecule in mammalian brains and D-aspartate is a mediator 
in endocrine systems (Yoshimura et al., 2003). In a variety of organisms such as yeasts, 
archaea, plants, insects and other eucaryots further D-amino acids have been found. These D-
AA are only a few among hundreds of structurally varied proteinogenic AA found in peptides 
of cell walls and capsules of numerous bacteria and fungi as well as in various natural 
antibiotics (Soloshonok et al., 2009). Due to their versatile occurrence in living organisms, 
natural and non-natural AA represent one group of key molecules for life sciences. 
 
1.4.1 Production methods of amino acids 
The production of AA is a multibillion dollar business, including the 20 proteinogenic ones 
and a variety of other naturally and non-naturally occurring AA. There are four major 
production methods for AA: extraction from protein hydrolysates, chemical synthesis, 
fermentation, and biocatalysis. Mainly the last two biotechnological processes have 
contributed to the rapid development of the AA market since the 1980s (Leuchtenberger et 
al., 2005). 
Fermentation of AA is the method of choice for large-scale productions of L-AA. 
Microorganisms which convert nutrients to various components using their natural or 
designed metabolic pathways for production of the desired AA are used. Raw materials, such 
as glucose or corn syrup, are used as a carbon source (Scheme 6). Today there are highly 
efficient industrial fermentation processes for several AA. For example L-glutamate is 
produced as a flavor enhancer in a scale of 1.2 million tons/year mainly by Ajinomoto Group, 
and about 600000 tons/year of L-lysine are produced by Evonik using Corynebacterium 
glutamicum. An efficient fermentation process for L-cysteine (4500 tons/year) has been 
developed recently by Wacker AG (Gröger et al., 2009). 
 
Scheme 6: Selected amino acids produced via fermentation. 
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Further examples for the fermentative production of AA are L-threonine (40000 tons/year), L-
phenylalanine (13000 tons/year) and L-valine (1000 tons/year) (Eggeling et al., 2006). 
While natural AA are mainly produced by fermentation, non-natural ones and derivatives 
thereof can be produced by a broad range of versatile biocatalytic technologies, which are 
mainly based on enzymatic approaches using hydrolases, oxidoreductases and lyases for 
enzymatic resolution, DKR or asymmetric synthesis. An example for the enzyme catalyzed 
production of an L-AA is the addition of ammonia to cinnamic acid using lyases yielding the 
synthetic sweetener L-phenylalanine (Scheme 7). Several DKR processes for the biocatalytic 
production of natural and non-natural L-AA have been established by Evonik, such as the 
resolution of chemically synthesized racemic N-acetyl-AA using a stereospecific L-acylase 
from Aspergillus oryzae, which hydrolyzes only the L-enantiomer. The free L-AA is then 
separated by crystallization while the remaining N-acetyl-D-AA is recycled by thermal 
racemization (May et al., 2002). A detailed review about biocatalytic production methods of 
AA using different enzymatic approaches was published by Gröger and Dietz (Gröger et al., 
2009). 
 
 
Scheme 7: Enzyme catalyzed production of L-phenylalanine by the addition of 
ammonia to cinnamic acid using phenylalanine lyase. 
 
1.4.2 Industrial applications of amino acids 
Due to their functionality and special features arising from chirality, AA are widely applied in 
the pharmaceutical, agrochemical and food industry. L-glutamate for example is used as a 
flavor enhancer or glycine as sweetener by the food industry. The pharmaceutical industry 
requires in particular essential AA for infusions or dietary foods. In addition, there is a huge 
market for AA (mainly methionine and lysine) as feed additives for pig and poultry nutrition. 
For synthetic applications, natural as well as synthetic AA have been used as a chiral pool for 
the preparation of numerous biologically and pharmacologically active compounds. Examples 
are Valaciclovir, a reverse-transcriptase inhibitor used against herpes simplex, which is based 
on L-valine (Drauz, 1997) and carbapenem antibiotics incorporating chiral allo-threonine 
derivatives. New peptide drugs, synthesized from AA building blocks, are increasingly 
developed. Besides, tailor-made AA have gained increasing importance for the preparation of 
new synthetic enzymes, hormones and immunestimulants. Furthermore, sterically modified 
AA have found fundamental applications in the rational de novo design of peptides and 
peptidomimetics with enhanced metabolic stability and altered physiological functions 
(Soloshonok et al., 2009).  
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In particular, D-AA are becoming increasingly important building blocks for the production of 
pharmaceuticals and fine chemicals and as chiral auxiliaries in organic syntheses. 
Applications of D-AA for example include their use as key components in β-lactam 
antibiotics (e.g. D-phenylglycine), fertility drugs and anticoagulants (Patel, 2008). Presently 
there are more than 20 D-AA produced at pilot- or technical scale, being not only frequently 
more potent than the corresponding L-AA, but also often more stable in vivo against enzyme 
degradation (Bommarius et al., 1998; Straathof et al., 2002). 
The total market for proteinogenic AA in the year 2004 was estimated to approximately US $ 
4.5 billion. The biggest contribution was made by feed AA (56 %), followed by AA used in 
the food sector (32 %). The remaining AA are required in the pharmaceutical and cosmetics 
industry mainly for chiral syntheses of active ingredients (Figure 4). According to a study by 
the Business Communication Company, the AA market for synthetic applications alone was 
expected to reach US $ 1 billion in the year 2009 with an annual growth rate of 7 %. While 
biotechnological and pharmaceutical applications account for about half of the total, they are 
rising fastest with an average annual growth rate of 9.8 % (Brown, 2005). 
 
Figure 4: Global amino acid market in the year 2004. Overall volume: US $ 4.5 billion. 
 
Considering the ubiquitous presence of AA, it is apparent that important markets for them 
have developed within the pharmaceutical-, food- and feed industry including the products 
listed above. 
 
1.4.3 Asparagine 
Asparagine (Asn) is a non-essential hydrophilic proteinogenic α-amino acid which is involved 
in the metabolic control of cell functions in nerve and brain tissue. Asn has a carboxyamide 
side chain (Scheme 8). The biosynthesis of Asn starts from oxalacetate and proceeds via 
aspartate (Asp), which is subsequently amidated using glutamate as an amine donor (Stryer, 
2007). 
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Scheme 8: Enantiomers of asparagine. 
 
Asn is not an essential AA for humans and higher animals and thus is not used as food or feed 
additive. However, due to its crystallization properties it was chosen as a model substrate for 
enzyme-assisted preferential crystallization. Besides threonine it is the only proteinogenic AA 
acid that forms conglomerates as solid racemate (chapter 1.3.2). L-Asn can be produced at 
small scale by extraction from protein hydrolysates or by enzymatic amidation of Asp using 
asparagine synthetase. 
1.4.4 Threonine and its stereoisomers 
Threonine (Thr) is a polar β-hydroxy-α-amino acid. Like isoleucine it is one of the two 
proteinogenic AA with two chiral centers and thus exists in four distinct stereoisomeric forms 
(Scheme 9). Both cis-isomers as well as both trans-isomers are mirror-images (enantiomers) 
of each other. The trans-isomers of Thr are called allo-threonine (allo-Thr) and differ from 
Thr by the stereoconformation of the α-amino and the β-hydroxy groups, which are pointing 
into opposite directions. Thr and allo-Thr are called diastereomers. 
 
Scheme 9: Stereoisomers of threonine. 
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L-Thr is an essential AA and is produced mainly by fermentation with optimized strains of 
Escherichia coli and Serratia marcescens (Leuchtenberger et al., 2005). The enzymes for the 
synthesis of L-Thr (e.g. threonine synthase) are overexpressed so that L-Thr can be produced 
in high concentrations up to 100 g/L (Ikeda et al., 2003). Down-stream processing is 
performed after biomass separation and pH adjustment by concentration and crystallization 
(Hermann, 2003). Main producers are Ajinomoto, ADM and Evonik with annual production 
rates of about 40000 tons (Eggeling et al., 2006). 
The vast bulk of L-Thr is used as feed additive as it is the limiting AA in growing pigs and 
poultry. However, enantiomerically pure β-substituted α-amino acids, including the 
stereoisomers of Thr, are valuable building blocks for the synthesis of peptidomimetics and 
enzyme inhibitors. The incorporation of a β-substituent into an α-amino acid generally leads 
to restricted conformational flexibility in peptides, offering the prospect for the development 
of high affinity ligands for receptors (Enright et al., 2003). Hence, each isomer is a useful 
intermediate for the synthesis of chiral compounds such as antibiotics (Kataoka et al., 1998). 
allo-Thr is a constituent of many biologically active peptides since its functionalized β-carbon 
is involved in many biomolecular recognition processes. Examples for bioactive compounds 
having Thr-residues are phytotoxic syringopeptins, the antiviral agent viscosin (Burke et al., 
1989), the antibiotic cyclodepsipeptide complex CDPC 3510 isolated from Fusarium (Flippin 
et al., 1989), or the glycopeptidolipid antigens from mycobacteria responsible for pulmonary 
and disseminated infectious diseases particular in AIDS patients. The incorporation of D-allo-
Thr instead of L-Thr in the backbone of peptides and proteins increases resistance towards 
proteolysis. By conserving the natural (R)-stereochemistry at the β-carbon while inverting the 
α-configuration, enzymatic attacks can be inhibited. Moreover, peptide analogues with allo-
Thr may have an enzyme-inhibitory effect, since the β-hydroxy group acts as recognition site 
in many enzymatic processes. An extensive list of bioactive compounds with allo-Thr 
residues is given by Wipf and Miller (Wipf et al., 1993). 
In plants and microorganisms, Thr is synthesized from Asp via α-aspartyl-semialdehyde and 
homoserine which undergoes O-phosphorylation. The resulting O-phospho-homoserine is 
then hydrolyzed with relocation of the OH-group (Chassagnole et al., 2001). 
In spite of its biological relevance, the use of allo-Thr for large-scale syntheses is hampered 
by high costs of multi-step production processes and careful purification steps (see 
Discussion). 
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1.5 Enzymes and their classification 
Enzymes are proteins that catalyze chemical reactions by decreasing the activation energy and 
thus increasing the reaction rate. In general they do not alter the reaction equilibrium itself but 
increase the speed at which it is reached. This is achieved by stabilizing the transition state of 
the reactants from which they decay into one or more products. The activity of enzymes is 
given in Units (U) and is defined as the amount of enzyme that catalyzes the conversion of 
one µmol of substrate per minute at standard conditions. 
According to the Nomenclature Committee of the International Union of Biochemistry and 
Molecular Biology (NC-IUBMB) enzymes are divided into six main classes due to their 
reaction specificity (Table 1). Each class is divided into further subclasses and groups 
assigning a defined EC number (enzyme commission number) to every single enzyme. This 
enzyme code consists of the letters EC followed by 4 numbers separated by dots. The first 
number defines the enzyme class, whereas the following numbers sub-classify the enzyme 
according to its natural type of reaction, the substrate and the coenzyme (if required). 
 
Table 1: Classification of enzymes according to NC-IUBMB. 
Enzyme class Catalyzed reaction Major subclasses 
1. Oxidoreductases redox reactions 
(transfer of electrons) 
dehydrogenases, oxidases, 
reductases, peroxidases, 
catalases, oxygenases, 
hydroxylases 
 
2. Transferases transfer of functional groups transketolases, transaminases, 
kinases 
 
3. Hydrolases hydrolysis reactions proteases, lipases, esterases, 
glycosidases, peptidases, 
amidases, amylases 
 
4. Lyases addition of groups to double 
bonds or formation of double 
bonds by non-hydrolytic 
cleavage 
 
decarboxylases, aldolases, (de-) 
hydratases, synthases 
5. Isomerases transfer of groups within 
molecule for structural or 
geometrical rearrangement 
 
racemases, epimerases, mutases 
6. Ligases ligation of two substrates by 
condensation reactions coupled 
to ATP cleavage (formation of 
C-C, C-S, C-N, C-O bonds) 
carboxylases, synthetases 
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1.6 Racemases 
1.6.1 Overview 
Racemization is defined as the irreversible formation of a racemate from a pure enantiomer 
and is associated with the loss of optical activity (Ebbers et al., 1997). Therefore, it can be 
described as an energetic ‘downhill’ reaction due to an increase of entropy and is thus often 
considered as an undesired side reaction rather than a useful biotransformation (Eliel et al., 
2001). 
Although L-amino acids are predominant in living organisms, also D-amino acids play an 
important role, for example in bacterial cell walls, as already referred to in chapter 1.4. Most 
of them are produced by racemization from the corresponding L-amino acids by racemases 
(Scheme 10). Therefore, these enzymes, which belong to the group of isomerases (EC 
5.1.X.X), play an important role in the D-amino acid metabolism of most living organisms. 
With the exception of phenylalanine racemase (EC 5.1.1.11), which requires ATP for 
catalysis, amino acid racemases can be divided into two major groups, differing in their 
catalytic mechanisms for racemization: 
a) pyridoxal-5’-phosphate-dependent racemases: racemization occurs via an unstable 
chiral Schiff-base intermediate (e.g. amino acid racemase, alanine racemase) 
b) pyridoxal-5’-phosphate-independent: racemization occurs via a two-base mechanism 
without a cofactor (e.g. glutamate racemase, proline racemase) 
 
 
Scheme 10: Racemization of α-amino acid by amino acid racemase. 
 
Pyridoxal-5’-phosphate (PLP, Scheme 11) is a biologically active phosphorylated derivative 
of vitamin B6 and represents one of nature’s most versatile cofactors (Schneider et al., 2000). 
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Scheme 11, left: Pyridoxal-5’-phosphate (PLP). Right: PLP bound to an α-amino acid (red) 
as a Schiff-base. 
 
According to the classification of Christen and coworkers, who classified PLP-dependent 
enzymes depending on the carbon atom involved in the reaction, amino acid racemases 
belong to the α-class of PLP-dependent enzymes (Alexander et al., 1994). Another 
classification was proposed by Grishin (Grishin et al., 1995) who classified PLP-dependent 
enzymes based on amino acid sequence alignments into 5 different fold types: 
Fold Type I:  aspartate amino transferase family 
Fold Type II:  tryptophan synthase family 
Fold Type III: alanine racemase family 
Fold Type IV:  D-amino acid aminotransferase family 
Fold Type V:  glycogen phosphorylase 
Since the amino acid racemases used in this work are PLP-dependent enzymes of Fold Type 
III, only this group of racemases will be described in more detail. 
 
1.6.2 Structure, function and catalytic mechanism of PLP-dependent amino 
acid racemases 
In this thesis two different amino acid racemases with broad substrate specificity from 
Pseudomonas putida strains KT2440 and NBRC12996 (EC 5.1.1.10) have been used. 
According to their origin they are entitled AArac2440 and AArac12996. Both enzymes share 
a AA sequence identity of 94 % and belong to Fold Type III. Each monomer consists of 409 
amino acids (ca. 44 kDa per monomer). According to the crystal structure of alanine racemase 
from Pseudomonas aeruginosa (EC 5.1.1.1) each monomer consists of a classical α/β-barrel 
and a second β-strand domain. PLP is bound within the active center with the phosphate 
anchored to the N-terminus of an α-helix, H-bond interactions to the 3’-OH group, and is 
covalently bound to a lysine side chain via a Schiff-base (Schneider et al., 2000; Eliot et al., 
2004). 
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PLP mediates the base-catalyzed α-proton abstraction via an unstable chiral Schiff-base 
intermediate between the α-amino acid and the aromatic aldehyde. Thereby, racemization of 
the substrate can be divided into three major steps (Scheme 12). 
 
Scheme 12: Catalytic mechanism of PLP-dependent amino acid racemases 
via a Schiff-base intermediate. Inactive state: internal Schiff-base; 1) 
external Schiff-base; 2) resonance-stabilized quinoid-type carbanion 
intermediate; 3) reprotonation of α-carbanion. 
 
In the inactive state (absence of substrate) PLP is bound covalently to the ε-amino group of a 
lysine residue in the active center via an internal Schiff-base (aldimine). When the amino acid 
substrate enters the active center PLP is transferred from the lysine residue to the α-amino 
group of the amino acid to form an external Schiff-base (1). The α-proton of the substrate is 
then abstracted by a tyrosine residue in the active center to form a resonance-stabilized 
quinoid-type achiral carbanion intermediate (2). Racemization further proceeds via 
reprotonation of the α-carbanion which can occur from both sides yielding both enantiomers 
(3) (Reynolds et al., 1991; Schnell et al., 2003; Yoshimura et al., 2010). 
According to the stereochemical properties of the substrate, amino acid racemases can also 
catalyze the isomerization of diastereomers such as threonine (Scheme 13). Since only the 
stereoconformation of the α-amino group is affected by the amino acid racemase, while the β-
hydroxy group remains unmodified, isomerization of L- and D-threonine yields the 
corresponding allo-forms. 
22 Introduction  
 
 
Scheme 13: Isomerization of L- and D-threonine by amino acid racemase. 
 
1.6.3 Applications of amino acid racemases 
Racemases are increasingly used for dynamic kinetic resolutions (DKR) or as auxiliary 
enzymes in biocatalytic recycling processes. One noteworthy example is the biocatalytic 
synthesis of L-tryptophan performed by a coupled reaction of tryptophan synthase and an 
amino acid racemase starting from racemic serine and indole in a DKR process (Scheme 14). 
Under optimized conditions about 110 g/L of L-tryptophan was formed after 24 h of 
incubation in a 200 L reactor using whole cells of E. coli and P. putida (Ishiwata et al., 1990). 
Further examples are the preparation of labeled aromatic amino acids such as L-tyrosine, L-
DOPA and L-tryptophan using alanine racemase, the use of glutamate racemase in auxiliary 
processes for the production of D-phenylalanine and D-tyrosine, and the production of D-
glutamate involving glutamate racemase (Schnell et al., 2003). 
 
Scheme 14: Synthesis of L-tryptophan in a DKR process using amino acid 
racemase. Tryptophan synthase enantioselectively catalyzes the β-
substitution reaction of L-serine to form L-tryptophan, while the amino acid 
racemase catalyzes the simultaneous racemization of serine. 
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2 Aim of the thesis 
The general aim of this thesis is the development of processes for racemase supported 
crystallization of chiral amino acids (AA). To achieve this goal, two different approaches 
should be investigated starting from either racemic or enantiopure substrates: 
1) Enzyme-assisted preferential crystallization 
By the combination of preferential crystallization (crystallization of a single 
enantiomer from a racemic solution) with enzymatic racemization of the remaining 
enantiomer, yield limitations of classical chiral resolution processes, which are usually 
limited to a maximum yield of 50 %, should be overcome. This concept can only be 
applied to conglomerate forming racemates, since preferential crystallization from 
racemic solutions is limited to them. Due to only little information about conglomerate 
forming AA in literature, suitable substrates (racemic AA) for this process have to be 
identified beforehand. Therefore, crystallization properties (conglomerate forming 
system or racemic compound) and potential acceptance as substrate for enzymatic 
racemization have to be investigated. In order to set up an appropriate process, suitable 
substrate/enzyme pairs have to be characterized with regard to optimal process 
temperature, pH, stability and kinetic parameters (Vmax, Km). 
After successful identification and characterization of a suitable model substrate, a 
process for preferential crystallization of chiral AA with integrated enzymatic 
racemization for an increased maximum yield, should be established. 
 
2) Enzymatic production of chiral allo-threonine from bulk threonine 
Due to the limited substrate range for enzyme-assisted preferential crystallization, 
another approach for the production of chiral AA, by combination of crystallization 
and enzymatic isomerization, should be investigated. This approach focuses on the 
isomerization of diastereomers with sufficiently different solubility limits in the 
applied medium. A suitable substrate is the cheap bulk AA L-Thr which can be 
isomerized to the high-priced allo-Thr, a valuable intermediate for pharmaceutical 
applications, using amino acid racemases. The produced allo-Thr can be removed 
easily by crystallization. 
After evaluation of racemases with sufficient activity for the isomerization of Thr, a 
lab-scale process for the production of chiral D-and L-allo-Thr should be developed. 
Two related amino acid racemases (EC 5.1.1.10) with broad substrate range from P. putida 
KT2440 and P. putida NBRC12996 are available. For the application as biocatalyst during 
crystallization processes, these enzymes have to be overexpressed in E. coli and purified to 
homogeneity. 
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a b s t r a c t
The demand for enantiopure substances, e.g. for pharmaceutical applications or fine chemical production,
continues to increase. This has led to the development of numerous stereoselective synthesis methods.
Nevertheless a large number of chemical syntheses still result in racemic mixtures making a subse-
quent enantioseparation step necessary and thus are restricted to a maximum yield of 50%. Our work
focuses on strategies to overcome this limitation by combining physicochemical separation processes
with enzymatic racemization of the unwanted enantiomer in order to produce enantiopure amino acids.
This paper deals with the production and characterization of a suitable amino acid racemase with broad
substrate specificity (EC 5.1.1.10) from Pseudomonas putida which we cloned into Escherichia coli. Two
enzyme lyophilizates of different purity were obtained from which the crude (CL) was sufficient for the
racemization of methionine (Met) and the pure (PL) was used for asparagine (Asn). Racemization reac-
tions ofD-/L-Asn inH2O andD-/L-Met in 95vol.% 100mMKPi-buffer, 5 vol.%methanol (MeOH) at different
pH values and temperatures were characterized. The studied range of reaction parameters was chosen in
dependency on planned enantioseparation processes. We found increasing Vmax values when tempera-
ture was risen stepwise from 20 to 40 ◦C for both systems and when pH was shifted from 6 to 8 for the
Met system. The presented results provide the basis for engineering enzyme-assisted physicochemical
enantioseparation processes.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
Chirality in nature and living systems is of great impact for a
variety of active compounds interacting with them. The molecular
building blocks of life, such as amino acids and sugars that form
peptides, proteins and polysaccharides exist of chiral structures.
Thus, optically pure enantiomers are of great interest for the fine
chemical and pharmaceutical industry [1,2]. Despite an increasing
number of stereoselective synthesis there are still a lot of reactions
∗ Corresponding author. Tel.: +49 2461 614388; fax: +49 2461 613870.
E-mail addresses: k.wuerges@fz-juelich.de (K. Würges),
petrusevska@mpi-magdeburg.mpg.de (K. Petrusevska),
s.serci@fz-juelich.de (S. Serci), s.wilhelm@fz-juelich.de (S. Wilhelm),
c.wandrey@fz-juelich.de (C. Wandrey),
seidel-morgenstern@mpi-magdeburg.mpg.de (A. Seidel-Morgenstern),
mpelsner@mpi-magdeburg.mpg.de (M.P. Elsner), s.luetz@fz-juelich.de (S. Lütz).
that lead to racemic mixtures of the desired homochiral products.
The scientificandeconomic relevanceofhomochiral substanceshas
led to the development of numerous separation techniques based
for example on chromatography [3–5], crystallization [6,7] and
stereoselective biotransformations [8,9] just to mention a few. A
majordrawbackof these resolutions is theyieldwhich is principally
limited to a maximum of 50%. An attractive solution to overcome
this limitation is the combination of a physicochemical separation
process e.g. chromatography [10] orpreferential crystallization (PC)
[11] with an enzymatic process to reracemise the unwanted enan-
tiomer [12,13]. In contrast to stereoselective biotransformations,
such as the reduction of prochiral ketones to optically active alco-
hols [14,15]where only one enantiomer can beproduced by a single
biocatalyst, here L- and D-enantiomers can be obtained according
to the chosen process route.
Since enantiopure amino acids (AA) are of great industrial rel-
evance, e.g. L-Met for infusion solutions or food additives (ca.
600 t/year), AAare an interesting substancegroup for this approach.
1381-1177/$ – see front matter © 2008 Elsevier B.V. All rights reserved.
doi:10.1016/j.molcatb.2008.10.006
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Table 1
Bacterial strains and plasmids used for cloning of AA racemase 5.1.1.10 and transformation into competent cell line.
Strains/plasmids Genotype/phenotype Reference/source
P. putida KT2440 DSM6125 Nelson et al., 2002 [26]
E. coli DH5 supE44 (lacZYA-argF)U196 (80lacZM15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 Woodcock et al., 1989 [27]
E. coli BL21 (DE3) F− ompT hsdSB(rB− mB−) gal dcm (cIts857 ind1 Sam7 nin5 lacUV5-T7 gene1) Studier and Moffat, 1986 [28]
pET22b T7-expression vector for E. coli, PelB signal sequence, Apr Novagen
Therefore we chose to use an already well known amino acid race-
mase with a broad specificity (EC 5.1.1.10) [16] as biocatalyst which
was cloned into E. coli BL21 (DE3). We analyzed kinetic properties
of twodifferently pure enzymepreparationswith respect to racem-
ization of the enantiomers of methionine (Met) and asparagine
(Asn). Met, which is a racemic compound forming system and thus
can be enantioseperated by PC [7], has been chosen as possible
substrate for the application in an integrated enzymatic racem-
ization process with chromatographic enantioseparation; Asn has
been chosen because it is a suitable substance for enantiosepa-
ration by PC. Bechtold and coworkers [17] recently presented a
detailed characterization of an amino acid racemase from Pseu-
domonas putida DSM 3263 (which is identical to the one used in
our study) in which they concentrated on the racemization of D-
and L-Met in organic-aqueous solutions. Our work is focusing on
two different reaction systems: (1) racemization of D- and L-Met in
95vol.% 100mM KPi-buffer (pH 7.0), 5 vol.% MeOH, which has been
chosen suitable for the combination with chromatographic enan-
tioseparation of methionine. (2) Racemization of D- and L-Asn in
H2O which can be separated by PC. PC can be an interesting and
highly efficient method for the optical resolution of conglomerate
forming substances. In contrast to racemic compounds where both
enantiomers coexist in one unit cell, a conglomerate is defined as
a mechanical mixture of crystals of both enantiomers [18]. Nev-
ertheless, only a few natural amino acids do belong to the group
of conglomerates such as threonine (Thr) and asparagine [19]. PC
of Thr in aqueous solutions has already been studied in detail by
Elsner et al. [11] and others [20,21]. To the best of our knowledge so
far there is neither published data about preferential crystallization
nor about racemization of Asn.
2. Experimental
2.1. Materials
NaCl and (NH4)2SO4 were obtained from KMF Laborchemie
Handels GmbH (Lohmar, Germany), yeast extract and NaH2PO4
were purchased from Merck (Darmstadt, Germany). Isopropyl--
D-thiogalactopyranosid (IPTG) andcarbenicillindisodiumsaltwere
obtained from Carl Roth GmbH (Karlsruhe, Germany), pyridoxal-
5′-phosphate (PLP) was obtained from Serva Feinbiochemica
(Heidelberg, Germany). Diethylaminoethyl (DEAE) sepharose fast
flow was purchased from Amersham Biosciences (UK). For SDS-
polyacrylamid gel electrophoresis the NuPAGE test kit from
Invitrogen (Carlsbad, CA, USA) and the Precision Plus ProteinTM
Standard Dual Color from Bio-Rad (Hercules, CA, USA) were used.
Ultrapure water (Milli-Q by Millipore, Schwalbach, Germany) has
been used exclusively during all procedures. All other chemicals
were either purchased from Sigma–Aldrich or Fluka (Munich, Ger-
many) and were of the highest available purity.
2.2. Cloning and transformation
Bacterial strains and plasmids. The strains and plasmids used are
listed in Table 1. P. putida KT2440 and E. coli DH5 were used
for cloning experiments and E. coli BL21 (DE3) as a heterologous
expression host for plasmid-encoded racemase (orf PP3722).
Media and growth conditions. LB medium was routinely used
to cultivate E. coli strains. Precultures for all experiments were
prepared overnight in 5ml LB medium in glass tubes at 37 ◦C.
Plasmid-carrying E. coli cells were selected with 100g/mL ampi-
cillin.
DNA manipulation and PCR. DNA fragments were amplified
by PCR standard methods. DNA modifying enzymes (Fermentas,
St. Leon-Rot, Germany) were used according to manufacturer’s
instructions. Plasmid DNA was prepared using the “HiSpeed Plas-
mid Midi” kit (Qiagen, Hilden, Germany).
PCR amplification, cloning and expression of racemase. Genomic
DNAwas isolated fromP. putidaKT2440byusing theDNeasyTissue-
Kit (Qiagen). The gene was amplified by PCR. The PCR conditions
used with Primers aaRaz NdeI up 5′-CAA CAT ATG CCC TTT CGC CGT
ACC-3′ and aaRaz XhoI down 5′-TTT CTC GAG TCA GTC GAC GAG TAT
CTT-3′ were as follows: initial denaturation 5min at 98 ◦C, 35 cycles
of 98 ◦C for 45 s, 56 ◦C for 45 s, 72 ◦C for 60 s and a final elongation
10min at 72 ◦C.
TripleMaster polymerase used in PCR was purchased from
Eppendorf (Hamburg, Germany). PCR was performed according to
the manufacturer’s recommendations. The size of the PCR prod-
uct was checked on a 1% agarose gel and the product was excised
from the gel and purified with a “Perfect Gel-Cleanup-Kit” (Eppen-
dorf) used according to the manufacturer’s protocol. The fragment
was digested with NdeI/XhoI and ligated in pET22b which was
hydrolyzed by the same restriction enzymes. E. coli DH5 was
transformed with the resulting ligation.
Recombinant plasmids were identified and further character-
ized by restriction enzyme digestion. The DNA sequence of the
amplified racemase was verified by DNA sequencing (Sequiserve,
Vaterstetten, Germany).
E. coli BL21 (DE3)was transformedwith the expression plasmid.
A single colonywas inoculated to LBmedium containing 0.4% (w/v)
glucose and 100g/mL ampicillin and grown at 37 ◦C on a shaking
incubator until an optical density at 580nm of 0.5 was reached.
IPTG was then added to a final concentration of 0.4mM for induc-
tion of expression. The induced cells were incubated at 37 ◦C for
2h and harvested by centrifugation at 14,000 rpm for 15min. The
expression was analyzed by SDS-PAGE.
2.3. Fermentation of recombinant E. coli BL21 (DE3)
E. coli BL21 (DE3) was grown in a modified LB medium con-
taining 0.5% (w/w) trypton, 0.25% (w/w) yeast extract, 0.25% (w/w)
NaCl, 0.025% (w/w) MgSO4 heptahydrate, 0.013% (w/w) NaH2PO4,
0.5% (w/w) D(+)-glucose monohydrate and 50g/mL carbenicillin
disodium salt. A 50mL preculture was grown for 6h at 37 ◦C and
200 rpm in a 250-mL shaking flask after inoculation with 1mL of
the cryoculture (stored at −80 ◦C). 5 times 200mL of aforemen-
tioned LB medium in 1 L shaking flasks were inoculated with 10mL
of the preculture to yield a volume of about 1 L starting culture for
large scale fermentation. The starting culture was grown over night
(18h) at 27 ◦C and 200 rpm until it reached an OD600 of 4.7. A fed-
batch fermentationwasperformed inaprocess-controlled stainless
steel bioreactor (Chemup, Richard Stihler GmbH & Co KG, Lahr,
Germany) with a working volume of 30 L (pH 7.0, 500 rpm, 37 ◦C).
12 K. Würges et al. / Journal of Molecular Catalysis B: Enzymatic 58 (2009) 10–16
Table 2
Specific activities and yields of crude lyophilizate, resuspended precipitate and lyophilizate of pooled activeDEAE chromatography fractions. Specific activitiesweremeasured
at 35 ◦C and an initial substrate concentration of 200mM L-Asn in H2O.
Step Mass/volume Protein concentration Specific activity [U/gprot] Total activity [U] Yield
Crude lyophilizate 10,000mg 77% 381 2940 100%
(NH4)2SO4-precipitation 27.5mL 69.7mg/mL 560 1074 37%
DEAE chromatography and lyophilization 175mg 68% 3703 441 15%
Therefore 20 L of LB medium (as described above but containing 2%
(w/w) D(+)-glucose monohydrate and 0.02vol.% antifoam in addi-
tion) were fed into the reactor and inoculated with 1 L starting
culture. The expression of the recombinant amino acid racemase
was inducedwith 100mol/L IPTG after 3hwhen the fermentation
broth reached an OD600 of about 5.5. After induction D(+)-glucose
monohydratewas fed to the fermentation broth (ca. 30 g/h) and the
temperature was decreased to 27 ◦C. After 24h 750g cells (biowet-
mass, BWM) were harvested by centrifugation (20min, 15,000g,
4 ◦C) and washed with 0.85% NaCl.
2.4. Purification of racemase
The overproduced racemase was released from the cytosol of
E. coli BL21 (DE3) by ultrasonic cell-disruption in a continuous
flow-cell sonifier (Branson W250, Danbury, CT, USA) from a 20%
(w/w) cell suspension in 10mM KPi-buffer, pH 7.0 (containing
50M PLP and lysozyme from hen egg white) at 4 ◦C. Cell debris
were removed by centrifugation (20min, 20,000g, 4 ◦C), the super-
natantwas frozen portionwise at −20 ◦C, lyophilized for about 48h
and stored at 4 ◦C until it was used. A total mass of 93g of crude
lyophilizate (CL) could be obtained.
For further purification 10g of CL were dissolved in 1000mL of
10mM KPi, pH 7.0, and 176.0 g of (NH4)2SO4 (30% saturation) were
added to the solution. After 30min the precipitate was removed
by centrifugation (20min, 10,000g, 4 ◦C) and additional 163.3 g
of (NH4)2SO4 (55% saturation) were added to the supernatant
(1008mL). The now forming precipitatewas again removed by cen-
trifugation; the pellet was resuspended in 100mL of 10mM KPi,
pH 7.0, and filtrated (pore size 0.8m). 111mL of filtrate were
washed with two volumes of H2O in an Amicon-cell (membrane:
Pall Omega 10kDa, A: 41.8 cm2) and afterwards concentrated to
30mL (all steps were done in an ice bath for cooling).
The concentrate was then applied with a flow of 5mL/min to a
DEAE-sepharosecolumn(5×25 cm,operatedbyÄKTApurifier from
Amersham Biosciences, Uppsala, Sweden) which had been equi-
librated with 5 column volumes of 10mM KPi, pH 7.0. After the
column had been washed (10mL/min) with 2 volumes of the same
buffer but containing 50mM NaCl, the enzyme was eluted with
the buffer supplemented with 100mM NaCl. The active fractions,
which have a specific absorption maximum at 420nm, emerged
at the beginning of elution and were pooled. The pooled fractions
were washed with 3×90mL of 10mM KPi, pH 7.0, in an Amicon-
cell (membrane: Pall Omega 10kDa, A: 41.8 cm2) and concentrated
to 10mL. The enzyme solution was then frozen in liquid nitrogen
and lyophilized. 175mg of pure lyophilizate (PL) (light yellow pow-
der) were obtained. To prevent a loss of the cofactor PLP during
purification all buffers contained 20M of PLP.
2.5. Analytics
Enzyme assays were done at 650 rpm in 1.5mL Eppendorf
reaction vials which were placed in an Eppendorf Thermomixer.
Calibrations were performed under assay conditions in the range
of estimated analyte concentrations.
Methionine. Activities for racemization of Met solutions were
measured by following the enantiomeric composition of the reac-
tion medium via HPLC (Crownpak CR(+) column (0.4 cm×15 cm),
Daicel Chem. Ind.; HClO4, pH 2; T=25 ◦C; 0.6mL/min, Vinj = 5L;
abs = 200nm). For kinetic studies activities of CL were measured
as follows: 0.1mg/mL of CL were added to 95vol.% 100mM KPi-
buffer, 5 vol.% MeOH, containing L- and D-Met ranging from about
7 to 200mM. Initial reaction rates were determined by taking
samples at three points of time. Therefore 100mg reaction solu-
tion were diluted with 900mg of HClO4, pH 1.0, to stop the
reaction and analyzed by HPLC to determine their enantiomeric
composition. The slope of product formation, which was calcu-
lated by linear regression using Microsoft Excel, represents the
initial reaction rates for the particular substrate concentration.
(All samples were taken in duplicate, results represent mean val-
ues.)
Asparagine. Kinetic studies of PL were performed in aqueous
L- and D-Asn solutions containing approximately between 20 and
250mM Asn (depending on solubility at certain temperature) with
concentrations of 0.1mg PL per mL. Activity assays were done
as described above but analyzed under different HPLC conditions
(HClO4, pH 1; T=0 ◦C; 0.4mL/min).
A control showed that neither methionine nor asparagine
racemize spontaneously after dilution with HClO4, pH 1 (done by
HPLC analysis after 1h incubation time).
Protein determination. Protein concentrations of both enzyme
preparationsweredeterminedat 30 ◦Cbya standardBradford assay
[22] using a Shimadzu UV-1601 photometer.
SDS-PAGE. Gel electrophoresis was performed according to the
manufacturer’s instructions using the NuPAGE test kit by Invitro-
gen. A total protein loading of about 1g for CL and about 0.1g for
PL each were applied to a gel pocket. A protein standard solution
was applied to a nearby pocket and electrophoresis was performed
at 200V for 45min. After developing and incubating the gel, it was
scanned with a desktop scanner.
3. Results and discussion
3.1. Enzyme purification
The recombinant amino acid racemase was purified from E. coli
BL21 (DE3) in two independent steps leading to twodifferentlypure
enzyme preparations. Lyophilization of the cell-free protein extract
(from 750g BWM) gave 93g of crude lyophilizate (CL) with a pro-
tein concentration of 77wt%. While CL showed no other reactions
onMet than racemization (constantmass balance over several days
determined byHPLC) it exhibited a so far unidentified side reaction
on Asn that lead to a degradation of the L-enantiomer. Therefore
10g of CL were further purified as described resulting in 175mg
of pure lyophilizate (PL) with a protein concentration of 68wt%.
Table 2 summarizes specific activities and yields of the purification
steps. Thepurified enzymepreparationdid not show the aforemen-
tioned side reaction on L-Asn anymore. Fig. 1 shows the SDS-PAGE
protein band patterns of both preparations. While CL is a mixture
of all proteins present in the cytoplasm of E. coli BL21 (DE3), the
band pattern for PL shows only one sharp band below50kDawhich
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Fig. 1. SDS-PAGE of crude lyophilizate (CL), pure lyophilizate (PL) and protein stan-
dard (PS, molecular weights are given in kDa). The protein loading was about 1g
for CL and 0.1g for PL. PL exhibits only one sharp band below 50kDa, while CL
shows a composition of all intracellular proteins. The right lane (-) represents an
empty lane without any protein loading.
matches the MW of the cloned amino acid racemase (homodimer
of 2× ca. 45kDa).
3.2. Enzyme kinetics
The amino acid racemase which has been used for this work
follows a reversible three-step Michaelis–Menten mechanism and
uses PLP as cofactor. While no substrate is present, PLP is bound
to a lysine residue in the active site via an internal Schiff-base.
When a substrate molecule enters the active site, PLP is transferred
from Lys to the -amino group of the substrate to form an external
Schiff-base. Racemization proceeds then via abstraction of the -
hydrogen atom to form a quinoid-type carbanion intermediate and
subsequent reprotonation on the opposite or the original side. A
more detailed description of the catalytic mechanism can be found
elsewhere [12,23,24].
The racemization can be described by a reversible three-step
mechanism where the conversion of the L- to the D-substrate
Fig. 2. Experimentaldata forD-methionine racemizationwithCL shownbysymbols.
Lines show data calculated by non-linear fitting for racemization of D-Met using Km
and Vmax shown in Table 3 Solvent: 95vol.% 100mM KPi-buffer (pH 7.0), 5 vol.%
MeOH.
enzyme complex is pooled into one step:
E + L-AA k1
k−1
E(L-AA)
k2
k−2
E(D-AA)
k3
k−3
E + D-AA (scheme 1)
with
Km,L =
k−1k−2 + k−1k3 + k2k3
k1(k−2 + k2 + k3)
; Km,D =
k−1k−2 + k−1k3 + k2k3
k−3(k−1 + k−2 + k2)
where E is the racemase, ki are the reaction rate constants for the
single reactions and Km,L/D are the dissociation constants for the
substrate/product binding to the enzyme for forward andbackward
reactions (under assumption that complex formation is not the rate
limiting step).
From (scheme 1) the reaction rate can be derived as
rL = CE ·
(Vmax /D/Km,D) · CD − (Vmax /L/Km,L) · CL
1 + (CL/Km,L) + (CD/Km,D)
, rD = −rL, (1)
where rD and rL are the reaction rates for the formation of
D-AA and L-AA respectively, CE is the enzyme concentration
and Vmax,L/D are the maximum mass specific reaction rates (in
molmin−1 g−1enzyme preparation) for the racemization of either L- or
D-AA. With approaching the equilibrium condition (racemic com-
position) the driving force of the reaction (numerator in Eq. (1))
becomes 0. The Haldane relationship (Eq. (2)) describes the rela-
tion between the equilibrium constant Keq of a reaction and the
forward and backward kinetic constants of the catalyzed reaction.
Under equilibrium conditions Keq must be 1:
Keq = CLCD
= Vmax,D
Km,D
:
Vmax,L
Km,L
= 1 (2)
3.2.1. Methionine
Km and Vmax values were determined for the racemization of
D- and L-Met solutions with CL in 95vol.% 100mM KPi-buffer (pH
7.0), 5 vol.% MeOH at T=20–40 ◦C (with step of 5 ◦C) as well as at
pH 6, 7 and 8 at 25 ◦C. Figs. 2–4 show the results of the kinetic
studies for D- and L-Met racemization. Initial rates were measured
as described above. In all cases less than5%of the initial enantiomer
concentration was isomerized to allow for initial rate conditions.
Vmax values increase for D- and L-Met racemization with rising
temperature (about 1.5-fold for L-Met from 20 to 40 ◦C) and pH
values (about 2.5-fold for L-Met from pH 6 to pH 8). Noticeable
here is the switch of Vmax values for D- and L-Met at pH 8. While
at pH 6 and 7Vmax(L-Met) is slightly higher than Vmax(D-Met), at pH
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Fig. 3. Experimental data for L-methionine racemizationwithCL shownby symbols.
Lines show data calculated by non-linear fitting for racemization of L-Met using Km
and Vmax shown in Table 3 Solvent: 95vol.% 100mM KPi-buffer (pH 7.0), 5 vol.%
MeOH.
Fig. 4. Experimental data for L- (circles) and D-(squares) methionine racemization
with CL. Lines show data calculated by non-linear fitting for racemization of L-Met
(dotted) and D-Met (full) using Km and Vmax shown in Table 3. Solvent: 95vol.%
100mM KPi-buffer, 5 vol.% MeOH, T=25 ◦C.
8Vmax(D-Met) is significantly higher (23%) than Vmax(L-Met) (Table 3).
Km values increase only slightly when rising the temperature from
20 to 40 ◦C (follow van’t Hoff relation, [25]) and fell with risen pH
values.
3.2.2. Asparagine
Kinetic parameters were determined for the racemization of
D- and L-Asn with PL in H2O at T=20–40 ◦C (with step of 5 ◦C).
Figs. 5 and 6 show the results of the kinetic studies for D- and L-Asn
racemization which were determined as described for methion-
Fig. 5. Experimental data for D-asparagine racemizationwith PL shown by symbols.
Lines show data calculated by non-linear fitting for racemization of D-Asn using Km
and Vmax shown in Table 4. Solvent: 100% H2O.
Fig. 6. Experimental data for L-asparagine racemization with PL shown by symbols.
Lines show data calculated by non-linear fitting for racemization of L-Asn using Km
and Vmax shown in Table 4. Solvent: 100% H2O.
ine. Similar to methionine racemization Vmax values increase with
higher temperatures (about 3.5-fold for L-Asn from 20 to 35 ◦C
and 5.2-fold for D-Asn from 20 to 40 ◦C). Km values also increase
significantly with rising temperatures which indicates a reduced
substrate affinity (follow van’t Hoff relation). Values for Vmax(L-Asn)
andVmax(D-Asn) strongly differ fromeach other. This apparent imbal-
ance should be adjusted by a consistent difference of Km values
(Eq. (2)). Here this requirement can only be met (excluding val-
ues determined at 30 ◦C) when considering the broad error ranges
(Table 4). A reasonable explanation for this might be the relatively
Table 3
Kinetic data for racemization of D- and L-methionine with CL at different temperatures and pH values. Km and Vmax were calculated by non-linear regression. Solvent: 95vol.%
100mM KPi-buffer, 5 vol.% MeOH.
Temperature [◦C] pH Km(D-Met) [mM] Vmax(D-Met) [U/gCL] Km(L-Met) [mM] Vmax(L-Met) [U/gCL]
20 7 25 (±13.0%) 1696 (±3.1%) 31 (±17.0%) 1889 (±4.5%)
25 7 22 (±11.5%) 1892 (±2.6%) 23 (±14.7%) 2150 (±3.3%)
30 7 23 (±10.6%) 2075 (±2.4%) 30 (±15.7%) 2296 (±4.0%)
35 7 30 (±8.9%) 2512 (±3.9%) 39 (±11.6%) 2833 (±3.5%)
40 7 32 (±8.4%) 2668 (±2.3%) 35 (±11.4%) 2847 (±3.2%)
25 6 42 (±14.6%) 1160 (±4.5%) 30 (±22.3%) 1174 (±5.9%)
25 8 28 (±4.5%) 3627 (±1.1%) 20 (±8.7%) 2951 (±1.9%)
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Table 4
Kinetic data for racemization of D- and L-asparagine with PL at different temperatures. Km and Vmax were calculated by non-linear regression. Solvent: 100% H2O.
Temperature [◦C] Km(D-Asn) [mM] Vmax(D-Asn) [U/gPL] Km(L-Asn) [mM] Vmax(L-Asn) [U/gPL]
20 18 (±26.1%) 770 (±4.8%) 30 (±19.3%) 1626 (±5.6%)
25 50 (±33.3%) 1299 (±11.4%) 47 (±19.6%) 2427 (±6.3%)
30 62 (±8.9%) 1881 (±3.1%) 76 (±10.0%) 3930 (±3.9%)
35 66 (±8.2%) 2585 (±2.8%) 101 (±17.5%) 5683 (±7.1%)
40 103 (±8.8%) 4032 (±3.3%) a a
a Due to the high racemization activity for L-Asn at 40 ◦C it was not possible to detect an activity at a substrate concentration where it is close to the expected Vmax (at least
70%) and therefore was not determinable with a tolerable error.
Fig. 7. Relative activity of CL in 95vol.% 100mM KPi-buffer (pH 7.0), 5 vol.% MeOH
at 35 ◦C over a period of 24h.
poor solubility of D-/L-Asn (ca. 290mM each at 35 ◦C). Due to this,
kineticmeasurements could not be carried out under substrate sat-
uration conditions (Vmax region) which lead to wide error ranges.
Due to the very high racemization activity for L-Asn at 40 ◦C (about
5000mol/(mingPL) at initial substrate concentration of 260mM)
it was not possible to perform a measurement at a substrate con-
centration where the activity is even close to the expected Vmax (at
least 70%ofVmax). In this case determineddatawas afflictedwith an
intolerable error and therefore is not included in the data analysis.
Another reason for aforementionedbroad error ranges, namely side
reactions that might have led to an enantiospecific degradation of
Fig. 8. Relative activity of PL in 500mM DL-Asn solution at 35 ◦C over a period of 7
days.
one enantiomer, could be ruled out due to constant mass balances.
Therefore the calculated kinetic parameters can only be considered
as approximate values. All kinetic parameters are summarized in
Table 4.
3.3. Enzyme stability
To investigate the enzyme stability in the presence of 5 vol.%
MeOH, 5mg CL were incubated at 35 ◦C in 1mL 95vol.% 100mM
KPi-buffer (pH 7), 5 vol.% MeOH over a period of 24h. At defined
times 100L of this solution were added to 100L of 300mM L-
Fig. 9. Combination of a physicochemical separation process with enzymatic racemization of the unwanted counterenantiomer. Either L-enantiomers (left side) or D-
enantiomers (right side) can be obtained from this process. A cyclic operation enables a theoretical yield of 100% of the target enantiomer (grey).
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Met in 95vol.% 100mM KPi-buffer (pH 7), 5 vol.% MeOH and initial
reaction rates were determined by HPLC. Fig. 7 shows the relative
activities fitted by non-linear regression using Eq. (3) where rrel is
the relative reaction rate giving an inactivation constant ktime of
0.0614h−1 (±8%) and a half-life time t1/2 of 11.3h (Eq. (4)).
rrel(t) = rrel(0) · e(−ktime ·t) (3)
t1/2 =
ln(0.5)
−ktime
(4)
To investigate the influenceof highly concentratedAsn solutions
on the enzyme activity 1mg PL was incubated at 35 ◦C in 1.5mL
aqueous 500mM DL-Asn solution over a period of 7 days. Initial
reaction rateswere determined as described above butwith 100L
of 200mM aqueous D-Asn solution as substrate (Fig. 8). Non-linear
regression gave a ktime of 0.0115h−1 (±5%) and a half-life time of
60.3h.
The medium composition and temperature of both stability
experiments were chosen in accordance to the planned reaction
design for each enzyme preparation. Since CL will be applied in
a process which implies chromatography for enantioseparation of
methioninewedetermined the stability in themobile phase (which
also has to serve as reaction medium). An according experiment
was performed with PL. In this case the reaction medium will be
a highly concentrated asparagine solution with only a very small
enantiomeric excess. We simulated this by storing the racemase in
an aqueous 500mM DL-Asn solution.
4. Conclusions
A plasmid containing an amino acid racemase gene was cloned
into E. coli BL21 (DE3) and overexpressed during a 20-L fed-batch
fermentation. The produced protein shall be used as biocatalyst
in an integrated physicochemical separation process with enzy-
matic racemization. Two differently pure enzyme preparations
were prepared from cell extract of which one was sufficient for
methionine racemization but still had impurities which led to
enzymatic asparagine degradation. Further purification yielded in
a pure racemase lyophilizate with no side reactions concerning
asparagine as substrate. We have investigated the kinetic param-
eters Km and Vmax for the racemization reactions of methionine
in 95vol.% 100mM KPi-buffer, 5 vol.% MeOH and of asparagine
in H2O at different temperatures and pH values with these two
preparations. We showed that Vmax and Km values for both reac-
tion systems increased with temperature. During stability studies
we have determined half-life times of crude lyophilizate in 95vol.%
100mM KPi-buffer (pH 7), 5 vol.% MeOH and of pure lyophilizate in
500mM DL-Asn (each at 35 ◦C). These reaction media and temper-
ature were chosen for prospective reactor design. Further studies
will concentrate on the reactor design for a combined enzymatic
racemization and physicochemical enantioseparation process as
depicted in Fig. 9. One major benefit will be the theoretical possible
yield of 100% of one enantiomer out of a racemic mixture.
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This contribution addresses the design and investigation of two hybrid enantioseparation processes in-
cluding an enzymatic racemization step in order to enhance the overall performance. Complementary to
part I where the manufacturing and the characterization of an amino acid racemase (EC 5.1.1.10) was
emphasized [Wu¨rges, K., Petrusevska, K., Serci, S., Wilhelm, S., Wandrey, C., Seidel-Morgenstern, A., Elsner,
M.P., Lu¨tz, S., 2009. Enzyme-assisted physicochemical enantioseparation processes—part I: production
and characterization of a recombinant amino acid racemase. J. Mol. Cat. B (in print), online available:
doi:10.1016/j.molcatb.2008.10.006.], the work presented in this paper tends more towards developing a
data base for potential process schemes for the manufacture of selected amino acids.
The first proposed process concept (P-I) couples preferential crystallization (PC) and racemization for the
production of l-asparagine (l-Asn) using racemic mixture of dl-asparagine (conglomerate-forming system)
as a starting material, while the second concept (P-II) integrates chromatography and racemization for the
preparation of l-methionine (l-Met) starting with racemic mixture of dl-methionine (compound-forming
system). As mentioned in part I, a racemization unit, where the unwanted enantiomer will be converted
into racemate, is incorporated into the hybrid processes for the sake of 100% yield, theoretically. Besides
the basic investigation according to the solid–liquid equilibria, PC and chromatography, the focus of
this paper is mainly on the kinetic studies of the racemization reaction. Initially, the solubility ternary
phase diagrams of both examined systems were determined, leading into the idea of combination of the
proposed process schemes. For P-I the concept of PC of l-Asn was experimentally proven and the kinetics
of the racemization was examined for d- and l-Asn in water using purified lyophilizate (PL). Concerning
P-II, for the chromatographic unit the impact on the separation of dl-Met on eremomycin based stationary
phase using KPi buffer and MeOH as mobile phase was evaluated in terms of resolution and selectivity
at three different temperatures by varying the content of methanol (MeOH) in the mobile phase and
the pH. The experiments for determination of the racemization kinetics were done for a compromised
parameter set using crude lyophilizate (CL). In both cases a Michaelis–Menten three-step model was used
to describe the enzymatic reaction.
© 2009 Elsevier Ltd. All rights reserved.
1. Introduction
Driven by the policy of regulatory authorities such as US Food and
Drug Administration and the EU Committee for Proprietary Medical
Products the manufacturing of pure enantiomers is distinguishably
increasing in several industrial branches: pharmaceuticals, alimen-
tary, etc. (Caner et al., 2004). As constituents of larger biomolecules
with essential importance for the nutrition and health subsistence,
∗ Corresponding author. Tel.: +493916110438; fax: +493916110626.
E-mail address: mpelsner@mpi-magdeburg.mpg.de (M.P. Elsner).
0009-2509/$ - see front matter © 2009 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ces.2009.02.025
optically pure amino acids follow the same trend. The amino acid
market and the perspectives, with special accent on their biotechno-
logical production, are reviewed by Leuchtenberger et al. (2005). So
far, most of the l-amino acids are produced using microbial methods.
However, the way how and in which form an amino acid is going
to be produced depends mainly on the process economics, available
raw material and the market, e.g. methionine is usually produced
as a racemic mixture (50/50 mixture of both enantiomers) (Scheper,
2003).
Regarding the basic approaches for the production of pure enan-
tiomers, the resolution of a racemic mixture is considered as an at-
tractive method since numerous preparative separation techniques
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can accompany the conventional organic synthesis as well as enzyme
catalysis methods (Ahuja, 1996). The most often utilized methods
and several novel resolution technologies are summarized in Sakai
et al. (2007) and Fogassy et al. (2006), respectively.
Amino acids differ in terms of their phase diagram (Jacques
et al., 1994) and that can predetermine the choice of a suitable
separation technique. In case of conglomerate-forming systems
(5–10% of all chiral substances belong to this group; Collet, 1999)
the cost-effective and quite simple preferential crystallization (PC)
holds great potential. Recently, PC in a cyclic operation mode for
water–threonine system (conglomerate) was studied in detail by
Elsner et al. (2005). Later on, an innovative configuration of coupled
crystallizers was proposed by the same author outperforming the
one-crystallizer mode by means of productivity and purity (Elsner
et al., 2009). For compound-forming systems ( > 90% of the chiral
substances are racemic compounds) the concept of PC is rather
limited. Shiraiwa et al. (1997) have resolved dl-methionine (dl-
Met; racemic compound) by converting dl-Met into dl-Met · HCl
(conglomerate) and then performing PC. In fact, the first approval
of applying PC for optical resolution of racemic compound in a
frame of a hybrid process was done recently by Lorenz et al. (2006).
Subsequently, they have shown that the enantiomers of methion-
ine can also be preferably crystallized (Polenske and Lorenz, 2008;
Kaemmerer et al., 2008). Concerning their study, before racemic
compound solution undergoes PC, preliminary enantiomeric en-
richment is required and usually, but not necessarily, the degree of
enrichment can be correlated with the eutectic composition of the
system.
The enrichment can be accomplished utilizing other methods
for amino acid enantioseparation, e.g. chromatography-based tech-
niques (HPLC, SMB) since among other conveniences, the develop-
ment of new chiral stationary phases broadens their range of appli-
cation (Petrusevska et al., 2006; Zhang et al., 2007). On the other
hand, those techniques are considered as quite expensive and their
use has to be justified.
The issue of using PC, when highly enriched solutions are re-
quired, implies several questions like for instance if it is really neces-
sary to combine sophisticated chromatography technique with PC or
enantioseparation only by chromatography might be more reason-
able? Is it more beneficial to combine less expensive techniques for
enrichment and PC, etc.? However, a lot of physicochemical and eco-
nomical parameters have to be taken into consideration before a de-
cision of using a single or an integrated process is made. The potential
of hybrid enantioseparation processes has been the subject of con-
siderable scientific activities in the recent years, with an emphasis
on the theoretical development of general design methods (Stro¨hlein
et al., 2003) as well as on the experimental challenges emerging
from the different operation windows of the single separation
methods being combined (Fung and Ng, 2006). For the evaluation
and design of a hybrid enantioseparation process using SMB and PC
recently a shortcut method was proposed by Kaspereit et al. (2005).
Unfortunately, the separation techniques suffer with a general
drawback of maximum 50% yield. Nevertheless, it is likely possi-
ble to overcome those limitations by performing racemization of
the unwanted enantiomer, feed the racemate to the separation
unit, and thus achieving 100% yield (Collet et al., 1980; May et al.,
2002). Comprehensive overview of racemization methods is given
by Ebbers et al. (1997). Due to the convenient reaction conditions,
the development of biocatalysts and their rising industrial applica-
tion (Bornscheuer and Buchholz, 2005), the use of an enzyme for
racemization (racemase) is a challenging task for the development
of efficient combined processes. So far, the functions on a molecular
level and the applications of several amino acid racemases have
been given by Yoshimura and Esaki (2003) and Schnell et al. (2003),
respectively.
Regarding integrated processes including racemization, recently
Bechtold et al. (2006a) introduced a novel process concept of cou-
pling continuous chromatography and enzyme reactor. The general
idea was analyzed in comprehensive studies with respect to the
chromatographic part (Bechtold et al., 2006b) and the racemization
(Bechtold et al., 2007).
Supplementing part I of this paper (Wu¨rges et al., 2009), based
on an evaluation of the ternary phase diagrams of two systems
(dl-Asn/water and dl-Met/solvent), two different process concepts
for the production of pure enantiomers are proposed. Particularly
with regard to manufacturing pure enantiomer of asparagine the in-
tegrated process consists of crystallization and racemization, whereas
for methionine chromatography and racemization are coupled. Since
the separation units are not the main subject of this work, we are
going to present in this paper a preliminary assessment of the con-
cept of PC for P-I and the chromatographic separation of dl-Met for
P-II accompanied with a more detailed investigation about the in-
fluence of certain parameters (pH and MeOH amount in the solvent
at different T) on the separation.
Distinct attention in this paper is paid on the reaction of racem-
ization. In that manner, the impact of several parameters (the same
as for the chromatographic part) was examined for the racemiza-
tion of d-Met. For the racemization of d-Asn only the temperature
was varied. Furthermore, for both systems the reaction kinetics was
studied in detail. For that purpose the racemization was performed
for different concentrations of the enantiomers and different en-
zyme concentrations. The experimental results were fitted into the
Michaelis–Menten three-step mechanism model in order to deter-
mine the constants of the reaction.
The goal of this work is to offer a data base allowing evaluat-
ing and confirming the feasibility of combined processes for enan-
tioseparation. The hybrid process concepts presented are not limited
to amino acids. In principle, they could be extended to other chiral
systems showing similar equilibrium characteristics.
2. Theory
2.1. Ternary phase diagram as a criterion for the choice of a separation
technique
The general form of the ternary phase diagram for conglomerate-
forming system is shown in Fig. 1a. As it was discussed before
for this kind of systems the concept of PC is rather convenient
for enantioseparation. Fig. 2 reveals a novel, promising and cost-
effective process scheme for the manufacture of pure enantiomers
by combining PC and racemization (P-I). The addition of a racem-
ization unit results in an increase of the concentration of the
wanted enantiomer and a decrease of the unwanted one in the
liquid phase at the same time. Therefore, as long as the racem-
ization is faster than the crystallization the composition moves
directly towards the eutectic point belonging to the crystalliza-
tion temperature Tcryst according to the straight trajectory in the
ternary phase diagram (assigned by thick black arrow in the right-
hand figure) increasing constantly the driving force for crystal-
lization of the desired enantiomer and suppressing the occurrence
of the counter enantiomer in comparison to the conventional PC
process.
The choice of a separation technique is slightly more difficult for
compound-forming systems. In this case the position of the eutec-
tic points in the ternary diagram can predetermine the choice of
a particular separation method or combination of few. When com-
bined processes are used, special accent falls on the costs and the
feasibility of the whole scheme. If the points tend to be more in the
inner part of the triangle, i.e. not far away from the 50/50 mixture
(Fig. 1b), poor enrichment is necessary in order to apply PC. In
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Fig. 1. Schemes of ternary phase diagrams for conglomerate-forming system (a) and two different compound-forming system (b) and (c).
Fig. 2. Process scheme (P-I) for the production of pure enantiomers starting with racemic mixture of a conglomerate-forming system.
contrary, when the eutectica are close to the axis (Fig. 1c), highly en-
riched solution is required for PC separation. As mentioned before,
when moderate excess of one of the enantiomers is required then
the powerful but at the same time expensive chromatographic tech-
niques can be coupled with PC. However, when high enantiomeric
excess is needed then the use of only chromatography for the enan-
tioseparationmight bemore reasonable. By upgrading the chromato-
graphic unit with racemization step of the unwanted enantiomer
the process of production of pure enantiomer can be distinguishably
improved (Fig. 3).
Since the presented process concepts consist of two process units
a compromised set of parameters is required. In that manner, a pro-
found investigation of the influence of the process parameters for
each unit is necessary.
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Fig. 3. Process scheme (P-II) for the production of pure enantiomer starting with
racemic mixture of a compound-forming system with eutectic points close to the
axes.
2.2. Kinetic model for the racemization reaction
As mentioned in the first part of the paper, by assuming that
the applied amino acid racemase follows a reversible three-step
Michaelis–Menten mechanism, the racemization reaction can be
schematically presented as (Cornish-Bowden, 1995)
E + L-AA
k1

k−1
E(L-AA)
k2

k−2
E(D-AA)
k3

k−3
E + D-AA (scheme 1)
where E is the enzyme, L-AA and D-AA are l- and d-amino acids,
respectively, and ki and k−i are the reaction constants for the forward
and the backward reactions.
The reaction rate for the supposed scheme 1 can be derived as
rL = CE
Vmax,D
Km,D
CD − Vmax,LKm,L CL
1 + CLKm,L +
CD
Km,D
and rD = −rL (1)
where
Km,L =
k−1k−2 + k−1k3 + k2k3
k1(k−2 + k2 + k3)
and
Km,D =
k−1k−2 + k−1k3 + k2k3
k−3(k−2 + k2 + k−1
(2)
In the relation given above rL and rD are reaction rates for the for-
mation of l and d amino acid, respectively, CE is the concentration of
the enzyme preparation, Vmax ,L/D are the maximum (mass specific)
reaction rates and Km,L/D are the dissociation constants for the sub-
strate/product binding to the enzyme for the forward and backward
reactions.
The equilibrium constant Keq is 1 in case of racemization which
is described by the Haldane relationship:
Keq = CLCD
= Vmax,D
Km,D
/
Vmax,L
Km,L
= 1. (3)
By taking this constraint into consideration Eq. (1) can be rewritten
as
rL = CE
k(CD − CL)
1 + CLKm,L +
CD
Km,D
. (4)
3. Experimental
3.1. Materials and equipment
Racemic mixtures and pure enantiomers of methionine and as-
paragine monohydrate were supplied by Sigma-Aldrich (Steinheim,
Germany). HPLC grade MeOH and K2HPO4 were purchased from
ROTH (Karlsruhe, Germany) and KH2PO4 and HClO4 from Merck
(Darmstadt, Germany). The water used for all experiments was pu-
rified using Milli-Q gradient system (Millipore, Molsheim, France).
The basic chromatographic investigations and the analysis for
the solubility of methionine were performed on analytical Diaspher-
Chirasel-E column (eremomycin based CSP, BioChemMack S&T,
Moscow, Russia), 10×0.46 cm, particle size 5m. For the analysis of
the solubility measurements for asparagine, Chirobiotic-T column,
250×4.6mm, 5m particles (Astec, Whippany, NJ, USA) was used.
The enzyme preparation used in this work is an amino acid race-
mase (EC 5.1.1.10), described and characterized in Wu¨rges et al.
(2009).
The quantity of CL from the first batch, specified in the first part of
the paper, was able to satisfy the requirements for the kinetic exper-
iments for the racemization of d- and l-Met, while for racemization
of the enantiomers of asparagine a new batch of PL was prepared.
The chromatographic experiments and the analysis of the sam-
ples after solubility measurements and racemization were carried
out using HP 1100 liquid chromatograph (Hewlett-Packard, Wald-
bronn, Germany). Enzyme assays were done at 850 rpm in 2mL Ep-
pendorf reaction vials placed in an Eppendorf Thermomixer (Ham-
burg, Germany).
3.2. Procedures
3.2.1. Solubility measurements and construction of the ternary phase
diagrams
The solubility of different mixtures between d- and l-Asn mono-
hydrate in water and d- and l-Met in solvent (0.1M KPi buffer,
pH = 7/MeOH = 95/5 v/v) was determined at 15, 25, 35, 40 and 45 ◦C.
The mass fraction of l-enantiomer in the d-/l-mixture was changed
from 0.5 to 1. The solutions with total mass of 10g were placed in
glass vessels and stirred by magnetic stirrer. The necessary isother-
mal conditions were achieved using thermostated double jacketed
vessels in which the temperature was constantly measured with a
PT-100 sensor. After complete dissolution of the solid phase, cool-
ing down to a certain temperature, ensuring equilibrium state by
providing several days for it and analysis of the liquid and the solid
phase, the solubility of each composition of the enantiomers was de-
termined. For both phases, high performance liquid chromatography
(HPLC) analysis was carried out. The analysis of the experimental
results for asparagine was carried out on the Chirobiotec-T column
at T = 25 ◦C using a mixture of ethanol/water = 30/70v/v as mobile
phase with flow rate of 0.5mL/min. The calibration of the UV/VIS
detector was performed at 210nm. For analysis of the methionine
samples the Diaspher-Chirasel-E column was used. The composition
of the mobile phase was the same as the solvent for this system,
T = 25 ◦C, the flow rate was 0.5mL/min and the detection at 230 and
240nm.
To validate the results of the HPLC analysis, additionally, the sol-
ubility concentrations were determined via measuring the density of
the liquid phase using a density meter (density meter DE40, Mettler-
Toledo, Gieen, Germany).
Based on the results obtained from the measurements of the
solubility, the ternary phase diagrams were constructed for both
systems.
3.2.2. PC runs
PC of l-Asn from aqueous solution of dl-Asn was carried out in a
batch mode, i.e. in a stirred jacketed glass vessel of 450mL total vol-
ume. Saturated solution (corresponding to a saturation temperature
Tsat = 36 ◦C) was prepared and placed in the crystallizer, heated up
approximately to 15◦ above the saturation temperature and main-
tained at this temperature for a while in order to assure complete
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dissolution. Shortly after the solution was cooled down to Tsat regu-
lated decrease of the temperature was applied using a cooling rate
of 10K/h until the crystallization temperature (Tcryst = 30 ◦C) was
reached. After the assurance that primary nucleation has not oc-
curred the PC was initiated by adding 0.6 g seeds of l-Asn. During
the whole time crystal-free solution was pumped out of the crystal-
lizer with a flow rate of 3.6mL/min by a circulation pump (Heidolph
PD 5201, SP Quick 1.6, Heidolph Electro GmbH & Co. KG, Kelheim,
Germany) via insulated lines through the polarimeter and density
meter and was led back to the vessel. Information about the process
were obtained by in-line measurement of the temperature (PT-100
sensor), on-line monitoring of the optical rotation angle using po-
larimeter (POLARmonitor, IBZMesstechnik, Hannover, Germany) and
on-line measurements of the density of the liquid phase (density
meter DE40, Mettler-Toledo, Gieen, Germany). In order to avoid re-
crystallization the temperature of the analytical devices and the lines
was about 10◦ higher than the crystallization temperature Tcryst.
3.2.3. Chromatographic separation of dl-Met (P-II)
For the chromatographic unit in P-II the separation of dl-Met
was performed on the Diaspher-Chirasel-E column. The experiments
were carried out at 25, 35 and 40 ◦C for different MeOH amount in
the solvent (0, 5, 10 and 20% at pH = 7) and different pH values (6, 7,
8 and 9 with 0% MeOH). To determine the influence of the examined
parameters on the separation, the selectivities  and the quality of
separation, i.e. the resolutions Rs were evaluated by injecting 1L
of solutions with CDL−Met = 1g/L in the column using flow rate of
0.5mL/min.
3.2.4. Racemization kinetics
3.2.4.1. d-/l-Asparagine. The simplicity in terms of process condi-
tions for P-I resulted in examination only of the influence of the
temperature on racemization reaction. The rates of racemization
for d-Asn were determined at T = 20–50 ◦C with step of 5 ◦C for
CD−Asn = 25g/L and CPL = 0.5 g/L.
The kinetic studies were performed at a temperature of 30 ◦C,
predetermined by the conditions already chosen for the PC unit. The
racemization of d- and l-Asn was done for different concentrations,
CD−/L−Asn = 15, 25 and 35g/L (the highest concentration is close to
the solubility limit of d-/l-Asn for the examined system) for two PL
concentrations (CPL = 0.5 and 1g/L) in a time range where no loss of
the PL-activity can be taken into consideration.
3.2.4.2. d-/l-Methionine. Since the MeOH amount in the solvent,
pH and the temperature played a major role on the chromato-
graphic separation, the influence of the same parameters on the
racemization reaction was investigated in order to determine a
compromised set of parameters for P-II. In that manner the ini-
tial rates of the reaction were measured for the following condi-
tions: 0%, 5%, 10% and 20% MeOH in the solvent (pH = 7, 25 ◦C,
CD−Met = 15g/L, CCL = 0.26g/L); at pH = 5–11 with step 1 (0% MeOH,
25 ◦C, CD−Met = 30g/L, CCL = 0.26g/L) and T = 20–45 ◦C with step
5 (pH = 7, 5% MeOH, CD−Met = 20g/L, CCL = 1g/L). Besides that, for
most of the mentioned conditions the stability of the CL was also
examined. Concerning the kinetics, the racemization of d-Met in
buffer (0.1M, KPi, pH = 7)/MeOH = 95/5 v/v at 25 ◦C was exten-
sively studied for four different concentrations, CD−Met = 5, 10, 20
and 30g/L, and each one of them mentioned for three different CL
concentrations, CCL = 0.5, 1 and 2.5 g/L (the results only for CCL = 1
and 2.5 g/L are shown). Furthermore, the racemization reaction
was performed at T = 20–45 ◦C with step 5 for CD−Met = 20g/L and
CCL = 1g/L. Additionally, l-Met was also racemized in the same
solvent at 25 ◦C using CL−Met = 5, 10, 20 and 30g/L and CCL = 1g/L.
4. Results and discussion
4.1. Ternary phase diagrams and feasibility of the process concepts
The correlation in terms of solubility between different mixtures
of d-, l-Asn and water is presented in Fig. 4. In the ternary phase
diagram five isotherms are shown. The ratio between the mass frac-
tion of the racemic mixture and measured pure enantiomer is ap-
proximately 2, meaning, the system shows nearly ideal behavior, i.e.
the solubility of one enantiomer is not going to be influenced by the
presence of the other enantiomer. The system reveals behavior of a
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Fig. 6. Preferential crystallization of l-Asn from supersaturated aqueous solution of
dl-Asn at 30 ◦C (saturated solution at 36 ◦C).
Fig. 7. Influence of different amounts of MeOH in the solvent on the chromatographic
resolution and the selectivity at different temperatures and pH = 7.
conglomerate and the concept of the process scheme P-I presented in
Fig. 2 seems convenient for production of pure enantiomers. Great
advantage of this process is the possibility of performing PC and
racemization in water. As an option, instead of utilizing two separate
units, one-tank process might also hold potential in this case.
In Fig. 5 the ternary phase diagram of d-, l-Met and solvent (0.1M
KPi buffer, pH = 7/MeOH = 95/5 v/v) is shown. As it is presented,
the eutectic points for this system are close to the axes (the ratio
l-/d-Met is approx. 90/10) justifying the concept of P-I.
4.2. PC runs
The feasibility of isothermal PC can be considered as proven since
one can clearly notice a decrease of the mass fraction of the wanted
(seeded) l-Asn and constant concentration profile of d-Asn in the
liquid phase in a period of approx. 150min (Fig. 6). The decrease of
the mass fraction of d-Asn designates the beginning of its crystal-
lization and at the same time decrease of the product purity.
Several experiments have been performed and stopped after 80,
100 and 120min in order to check the composition of the solid
phase. HPLC analyses of the harvested products resulted in purities
Fig. 8. Influence of pH on the chromatographic resolution and the selectivity at
different temperatures for 0% MeOH in the mobile phase.
Fig. 9. Effect of the temperature on the initial rate of racemization of d-Asn in
water, CD−Asn = 25g/L, CPL = 0.5 g/L.
higher than 98% and confirmed the on-line measurements of the
liquid phase composition.
4.3. Chromatographic separation of dl-Met (P-I)
Based on the previous studies for the enantioseparation of dl-
Met on eremomycin-based stationary phase a buffer (in this case
KPi) and MeOH were considered as main components of the mobile
phase for the chromatographic separation. The concentration of the
buffer was fixed to a value of 0.1M since lower concentrations were
not able to “buffer” high concentrations of methionine solutions in
case of pH = 7.
In Fig. 7 the influence of different amounts of MeOH in the sol-
vent on the resolution and the selectivity is presented for several
temperatures. The results indicate that the separation is better when
lower MeOH content is present, in contrary to the selectivity which
shows opposite trend.
K. Petruševska-Seebach et al. / Chemical Engineering Science 64 (2009) 2473 -- 2482 2479
Fig. 10. Change of the initial rate of racemization of d-Met in dependence of: (a) MeOH content in the solvent for pH = 7, CD−Met = 15g/L, CCL = 0.26g/L at 25 ◦C; (b) pH
for 0% MeOH in the solvent, CD−Met = 30g/L, CCL = 0.26g/L at 25 ◦C; (c) Temperature for pH = 7, 5% MeOH in the solvent, CD−Met = 20g/L and CCL = 1g/L.
Besides the positive impact on the resolution, additionally low
MeOH amount has other advantages, such as higher solubility of
methionine and from common knowledge it is well known that en-
zymes do not tolerate MeOH.
In that manner, further investigations for the resolution of me-
thionine were done for different pH values without presence of an
organic modifier. The results depicted in Fig. 8 show that acetic con-
ditions are preferable for the examined system.
In both cases the column performed better at 25 ◦C than at higher
temperatures.
In order to check the reproducibility of the column after treat-
ment with approx. 2 L of buffer with pH 7 and without MeOH, sev-
eral analytical injections of dl-Met were compared. Small difference
in the resolution was noticed but no effect on the selectivity. Never-
theless, in order to stay in the safer range of the reproducibility, the
amount of MeOH in the solvent was fixed to 5%.
4.4. Racemization kinetics
4.4.1. d-Asparagine
The results obtained from the influence of the temperature on
the rate of racemization for d-Asn, depicted in Fig. 9, indicate higher
rates for higher temperatures. In fact, at temperature of 30 ◦C the
enzyme preparation performs with less than half of its capacity.
Consequently, the temperature can be considered as a parameter of
great potential for the optimization of the process.
4.4.2. d-Methionine
The results presented in Figs. 10a–c show better performances of
the enzyme preparation at lower MeOH content and higher pH and
temperatures, respectively.
Referring to some of the mentioned restrictions (buffer concen-
tration and MeOH content) and the diverse trends for the effect
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Fig. 11. Experimental (symbols) and fitted curves (lines) for racemization of: (a) d-Asn and (b) l-Asn in water for CPL = 0.5 g/L and for different concentrations, CD−/L−Asn = 15,
25 and 35g/L at 30 ◦C.
Table 1
Estimated kinetic parameters and standard deviations for racemization of d-/l-Asn in water at 30 ◦C and d-/l-Met in solvent at 25 ◦C.
Racemization of CPL (gPL/L) Km,L (g/L) STDEV Km,D (g/L) STDEV k (L/(gPL min)) STDEV
d-Asn 0.5 2.44 1.17 2.19 0.67 0.436 0.13
l-Asn 0.5 18.57 1.56 3.22 0.19 0.219 0.01
Racemization of CCL (gCL/L) Km,L (g/L) STDEV Km,D (g/L) STDEV k (L/(gPL min)) STDEV
d-Met 1 2.11 0.22 3.4 0.34 0.122 0.01
l-Met 1 1.97 0.17 2.63 0.27 0.169 0.01
of T and pH for both units in P-II, a mixture of 0.1M KPi buffer,
pH = 7/MeOH = 95/5 v/v and temperature of 25 ◦C was chosen as a
compromised parameter set for further investigations.
The parameters of the racemization model (Eq. (4)) were deter-
mined using the parameter estimation tool gEST incorporated in
gPROMS (Process Systems Enterprise Ltd., London, UK). The model
was fitted to a set of experimental data by minimizing the maximum
likelihood objective function sub-determined by the constant vari-
ance model. The following expression characterizes the maximum
likelihood objective function:
= N
2
ln(2)
+ 1
2
min

⎧⎨
⎩
NE∑
i=1
NVi∑
j=1
NMij∑
k=1
[
ln(2ijk) +
(z˜ijk − zijk)2
2ijk
]⎫⎬
⎭ (5)
where N is the total number of experimental points,  is the set of
model parameters to be estimated, NE is number of experiments, NVi
number of variables measured in the i-th experiment and NMij is the
j-th variable in the i-th experiment. The variance of the k-th mea-
surement of the variable j in the experiment i and its k-th measured
and model predicted value in the i-th experiment are designated by
2ijk, z˜ijk and zijk, respectively.
As constraints in the constant variance model, where the mea-
surement error is determined by constant standard deviation, the
initial guess, the lower and the upper bounds of the standard devi-
ation were set to 1×10−2, 1×10−10 and 1×10−1, respectively.
4.4.3. Racemization of d-/l-Asparagine
Themodel parameters for racemization of d- and l-Asnwere esti-
mated for each enantiomer separately by simultaneous fitting of the
experimental data for CD−/L−Asn = 15, 25 and 35g/L and CPL = 0.5 g/L.
The results are depicted in Fig. 11a, b, showing a remarkable match
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Fig. 12. Model validation for racemization of d-Asn in water for CPL = 1g/L and
different concentrations of d-Asn (15, 25 and 35g/L) at 30 ◦C. Experimental data
(black symbols: d-Asn; open symbols: l-Asn) and calculated curves (lines) obtained
using the parameters shown in Table 1 for d-Asn.
between the experimental and fitted curves. The kinetic parame-
ters are presented in Table 1. Namely, higher parameters were ob-
tained for l-Asn in comparison to d-Asn, respectively, and rather
diverse values for Km,L and Km,D for l-Asn. The experimentally no-
ticeable difference of faster racemization for l-Asn, shown in Fig. 11,
might be the result of different reaction mechanism for both enan-
tiomers since side reactions could be excluded (Wu¨rges et al., 2009).
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Fig. 13. Experimental (symbols) and fitted curves (lines) for racemization of : (a)
d-Met and (b) l-Met in solvent for CCL = 1g/L and for different concentrations,
CD−/L−Met = 5, 10, 20 and 30g/L at 25 ◦C.
Additionally, the difference in the dissociation constants for l-Asn
may be explained by the restrictions given by the shape of the fit-
ted concentration curves which usually allow a reliable prediction of
maximum two parameters not being strongly correlated. However,
the chosen model equation can sufficiently describe the enzymatic
reaction in a wide concentration range (from diluted solutions up
to solutions close to the solubility limit) and provides an adequate
description of the racemization which is for engineering issues nec-
essary for further process developments.
Since the racemization of d-Asn is of interest in this study, the
validity of the model parameters was proven for CD−Asn = 15, 25 and
35g/L using CPL = 1g/L (Fig. 12).
4.4.4. Racemization of d-/l-methionine
The results of the experimental work and the model curves for
racemization of d- and l-Met are presented in Fig. 13a, b. The simul-
taneous fitting of four different concentrations resulted with signifi-
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Fig. 14. Model validation for racemization of d-Met in solvent for CCL = 2.5 g/L and
different concentrations of d-Met (5, 10, 20 and 30g/L) at 25 ◦C. Experimental data
(black symbols: d-Met; open symbols: l-Met) and calculated curves (lines) obtained
using the parameters shown in Table 1 for d-Met.
cant predictions in the whole range of the examined system (starting
from diluted up to solution close to the solubility limit of the enan-
tiomer in the given solvent, CCL = 1g/L). The values of the estimated
kinetic parameters are summarized in Table 1. From the presented
results, it is quite obvious that the dissociation constants are a bit
smaller and the k value is higher for the racemization of l-Met in
comparison to d-Met.
Like for the racemization of the enantiomers of asparagine the
validation of the fitted model parameters was also confirmed in this
case, i.e. the experimental results for racemization of d-Met were
predicted satisfactorily for CCL = 2.5 g/L (Fig. 14).
4.5. Feasibility of process schemes P-I and P-II
The experimental study presented in this work for two different
examples provides a useful data base and allows to draw general
conclusions about the feasibility of the process schemes P-I and P-II.
Concerning the working media and the time required for PC
(slower process) and racemization (the purified enzyme prepara-
tion performs quite fast), the process scheme P-I seems to be quite
promising and flexible. However, additional kinetic investigations
have to be carried out in order to design PC. Before both units are
integrated a choice of a proper reactor for racemization and opti-
mization of the process scheme is required. One can even consider
an attractive and simple one-tank process where the desired enan-
tiomer is going to be preferably crystallized while the racemization
reaction occurs in the liquid phase at the same time. On the other
hand, several difficulties might appear when the enzyme prepara-
tion is present in the crystallizer. For instance, one of the major ones
is the interruption of PC due to the presence of other components
in the system influencing the form of the solubility ternary phase
diagram.
Regarding the second examined (compound forming) system, the
availability of chiral stationary phases as well as solvents which can
be used as mobile phases for the chromatographic separation and
as medium for racemization renders process scheme P-II to an at-
tractive option. The experimental investigation shows that the enan-
tioseparation as well as the racemization is feasible in a wider range
of solvent compositions. Nevertheless, the authors are aware of the
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changes in the solvent compositions due to dilution after chromatog-
raphy and the complexity of the process scheme when a continuous
process is intended to be performed.
5. Conclusion
Based on the determined solubility ternary phase diagrams for
asparagine/water and methionine/solvent, two process concepts P-I
and P-II were proposed for the production of pure enantiomers. For
the conglomerate system (asparagine/water) the process scheme P-I
consists of the cost-effective and moderately simple PC and racem-
ization unit, while for the compound-forming system (methion-
ine/solvent), due to the position of the eutectica, the combination
of HPLC and racemization (process scheme P-II) was considered.
The feasibility of scheme P-I (just in pure water as solvent) led
to an investigation only of the temperature influence on the racem-
ization of d- and l-Asn, resulting in higher racemization rates at
higher temperatures. Additionally, this process scheme holds a great
potential of even greater simplification, since it can be realized as
a one-tank process. This idea might be considered as an upgrade of
the work presented in this paper.
For scheme P-II, the influence of particular process parameters,
such as MeOH content in the solvent, pH and the temperature was
studied for the chromatographic separation of dl-Met using ere-
momycin as chiral stationary phase as well as for the racemization
of d- and l-Met. Lower MeOH amount in the solvent was found to be
convenient for both units, while the effect of T and pH was diverse
(diminished separation, but higher enzyme preparation performance
for higher T and pH).
For the racemization of d-/l-Asn and d-/l-Met, aMichaelis–Menten
three-step model was able to describe the experimental results. In
all cases a highly satisfactory fit was obtained between the esti-
mated and the experimental data. An experimentally distinguish-
able difference in the performance of the PL was observed for the
racemization of d-Asn in comparison to l-Asn which is also notice-
able in the values of their kinetic parameters. On the contrary, for
the racemization of d- and l-Met only a slight difference was found
between the kinetic constants. The validity of the utilized model
was confirmed for both enantiomers for higher enzyme preparation
concentrations.
Both process schemes need to be further optimized for efficient
use.
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can accompany the conventional organic synthesis as well as enzyme
catalysis methods (Ahuja, 1996). The most often utilized methods
and several novel resolution technologies are summarized in Sakai
et al. (2007) and Fogassy et al. (2006), respectively.
Amino acids differ in terms of their phase diagram (Jacques
et al., 1994) and that can predetermine the choice of a suitable
separation technique. In case of conglomerate-forming systems
(5–10% of all chiral substances belong to this group; Collet, 1999)
the cost-effective and quite simple preferential crystallization (PC)
holds great potential. Recently, PC in a cyclic operation mode for
water–threonine system (conglomerate) was studied in detail by
Elsner et al. (2005). Later on, an innovative configuration of coupled
crystallizers was proposed by the same author outperforming the
one-crystallizer mode by means of productivity and purity (Elsner
et al., 2009). For compound-forming systems ( > 90% of the chiral
substances are racemic compounds) the concept of PC is rather
limited. Shiraiwa et al. (1997) have resolved dl-methionine (dl-
Met; racemic compound) by converting dl-Met into dl-Met · HCl
(conglomerate) and then performing PC. In fact, the first approval
of applying PC for optical resolution of racemic compound in a
frame of a hybrid process was done recently by Lorenz et al. (2006).
Subsequently, they have shown that the enantiomers of methion-
ine can also be preferably crystallized (Polenske and Lorenz, 2008;
Kaemmerer et al., 2008). Concerning their study, before racemic
compound solution undergoes PC, preliminary enantiomeric en-
richment is required and usually, but not necessarily, the degree of
enrichment can be correlated with the eutectic composition of the
system.
The enrichment can be accomplished utilizing other methods
for amino acid enantioseparation, e.g. chromatography-based tech-
niques (HPLC, SMB) since among other conveniences, the develop-
ment of new chiral stationary phases broadens their range of appli-
cation (Petrusevska et al., 2006; Zhang et al., 2007). On the other
hand, those techniques are considered as quite expensive and their
use has to be justified.
The issue of using PC, when highly enriched solutions are re-
quired, implies several questions like for instance if it is really neces-
sary to combine sophisticated chromatography technique with PC or
enantioseparation only by chromatography might be more reason-
able? Is it more beneficial to combine less expensive techniques for
enrichment and PC, etc.? However, a lot of physicochemical and eco-
nomical parameters have to be taken into consideration before a de-
cision of using a single or an integrated process is made. The potential
of hybrid enantioseparation processes has been the subject of con-
siderable scientific activities in the recent years, with an emphasis
on the theoretical development of general design methods (Stro¨hlein
et al., 2003) as well as on the experimental challenges emerging
from the different operation windows of the single separation
methods being combined (Fung and Ng, 2006). For the evaluation
and design of a hybrid enantioseparation process using SMB and PC
recently a shortcut method was proposed by Kaspereit et al. (2005).
Unfortunately, the separation techniques suffer with a general
drawback of maximum 50% yield. Nevertheless, it is likely possi-
ble to overcome those limitations by performing racemization of
the unwanted enantiomer, feed the racemate to the separation
unit, and thus achieving 100% yield (Collet et al., 1980; May et al.,
2002). Comprehensive overview of racemization methods is given
by Ebbers et al. (1997). Due to the convenient reaction conditions,
the development of biocatalysts and their rising industrial applica-
tion (Bornscheuer and Buchholz, 2005), the use of an enzyme for
racemization (racemase) is a challenging task for the development
of efficient combined processes. So far, the functions on a molecular
level and the applications of several amino acid racemases have
been given by Yoshimura and Esaki (2003) and Schnell et al. (2003),
respectively.
Regarding integrated processes including racemization, recently
Bechtold et al. (2006a) introduced a novel process concept of cou-
pling continuous chromatography and enzyme reactor. The general
idea was analyzed in comprehensive studies with respect to the
chromatographic part (Bechtold et al., 2006b) and the racemization
(Bechtold et al., 2007).
Supplementing part I of this paper (Wu¨rges et al., 2009), based
on an evaluation of the ternary phase diagrams of two systems
(dl-Asn/water and dl-Met/solvent), two different process concepts
for the production of pure enantiomers are proposed. Particularly
with regard to manufacturing pure enantiomer of asparagine the in-
tegrated process consists of crystallization and racemization, whereas
for methionine chromatography and racemization are coupled. Since
the separation units are not the main subject of this work, we are
going to present in this paper a preliminary assessment of the con-
cept of PC for P-I and the chromatographic separation of dl-Met for
P-II accompanied with a more detailed investigation about the in-
fluence of certain parameters (pH and MeOH amount in the solvent
at different T) on the separation.
Distinct attention in this paper is paid on the reaction of racem-
ization. In that manner, the impact of several parameters (the same
as for the chromatographic part) was examined for the racemiza-
tion of d-Met. For the racemization of d-Asn only the temperature
was varied. Furthermore, for both systems the reaction kinetics was
studied in detail. For that purpose the racemization was performed
for different concentrations of the enantiomers and different en-
zyme concentrations. The experimental results were fitted into the
Michaelis–Menten three-step mechanism model in order to deter-
mine the constants of the reaction.
The goal of this work is to offer a data base allowing evaluat-
ing and confirming the feasibility of combined processes for enan-
tioseparation. The hybrid process concepts presented are not limited
to amino acids. In principle, they could be extended to other chiral
systems showing similar equilibrium characteristics.
2. Theory
2.1. Ternary phase diagram as a criterion for the choice of a separation
technique
The general form of the ternary phase diagram for conglomerate-
forming system is shown in Fig. 1a. As it was discussed before
for this kind of systems the concept of PC is rather convenient
for enantioseparation. Fig. 2 reveals a novel, promising and cost-
effective process scheme for the manufacture of pure enantiomers
by combining PC and racemization (P-I). The addition of a racem-
ization unit results in an increase of the concentration of the
wanted enantiomer and a decrease of the unwanted one in the
liquid phase at the same time. Therefore, as long as the racem-
ization is faster than the crystallization the composition moves
directly towards the eutectic point belonging to the crystalliza-
tion temperature Tcryst according to the straight trajectory in the
ternary phase diagram (assigned by thick black arrow in the right-
hand figure) increasing constantly the driving force for crystal-
lization of the desired enantiomer and suppressing the occurrence
of the counter enantiomer in comparison to the conventional PC
process.
The choice of a separation technique is slightly more difficult for
compound-forming systems. In this case the position of the eutec-
tic points in the ternary diagram can predetermine the choice of
a particular separation method or combination of few. When com-
bined processes are used, special accent falls on the costs and the
feasibility of the whole scheme. If the points tend to be more in the
inner part of the triangle, i.e. not far away from the 50/50 mixture
(Fig. 1b), poor enrichment is necessary in order to apply PC. In
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Fig. 1. Schemes of ternary phase diagrams for conglomerate-forming system (a) and two different compound-forming system (b) and (c).
Fig. 2. Process scheme (P-I) for the production of pure enantiomers starting with racemic mixture of a conglomerate-forming system.
contrary, when the eutectica are close to the axis (Fig. 1c), highly en-
riched solution is required for PC separation. As mentioned before,
when moderate excess of one of the enantiomers is required then
the powerful but at the same time expensive chromatographic tech-
niques can be coupled with PC. However, when high enantiomeric
excess is needed then the use of only chromatography for the enan-
tioseparationmight bemore reasonable. By upgrading the chromato-
graphic unit with racemization step of the unwanted enantiomer
the process of production of pure enantiomer can be distinguishably
improved (Fig. 3).
Since the presented process concepts consist of two process units
a compromised set of parameters is required. In that manner, a pro-
found investigation of the influence of the process parameters for
each unit is necessary.
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Fig. 3. Process scheme (P-II) for the production of pure enantiomer starting with
racemic mixture of a compound-forming system with eutectic points close to the
axes.
2.2. Kinetic model for the racemization reaction
As mentioned in the first part of the paper, by assuming that
the applied amino acid racemase follows a reversible three-step
Michaelis–Menten mechanism, the racemization reaction can be
schematically presented as (Cornish-Bowden, 1995)
E + L-AA
k1

k−1
E(L-AA)
k2

k−2
E(D-AA)
k3

k−3
E + D-AA (scheme 1)
where E is the enzyme, L-AA and D-AA are l- and d-amino acids,
respectively, and ki and k−i are the reaction constants for the forward
and the backward reactions.
The reaction rate for the supposed scheme 1 can be derived as
rL = CE
Vmax,D
Km,D
CD − Vmax,LKm,L CL
1 + CLKm,L +
CD
Km,D
and rD = −rL (1)
where
Km,L =
k−1k−2 + k−1k3 + k2k3
k1(k−2 + k2 + k3)
and
Km,D =
k−1k−2 + k−1k3 + k2k3
k−3(k−2 + k2 + k−1
(2)
In the relation given above rL and rD are reaction rates for the for-
mation of l and d amino acid, respectively, CE is the concentration of
the enzyme preparation, Vmax ,L/D are the maximum (mass specific)
reaction rates and Km,L/D are the dissociation constants for the sub-
strate/product binding to the enzyme for the forward and backward
reactions.
The equilibrium constant Keq is 1 in case of racemization which
is described by the Haldane relationship:
Keq = CLCD
= Vmax,D
Km,D
/
Vmax,L
Km,L
= 1. (3)
By taking this constraint into consideration Eq. (1) can be rewritten
as
rL = CE
k(CD − CL)
1 + CLKm,L +
CD
Km,D
. (4)
3. Experimental
3.1. Materials and equipment
Racemic mixtures and pure enantiomers of methionine and as-
paragine monohydrate were supplied by Sigma-Aldrich (Steinheim,
Germany). HPLC grade MeOH and K2HPO4 were purchased from
ROTH (Karlsruhe, Germany) and KH2PO4 and HClO4 from Merck
(Darmstadt, Germany). The water used for all experiments was pu-
rified using Milli-Q gradient system (Millipore, Molsheim, France).
The basic chromatographic investigations and the analysis for
the solubility of methionine were performed on analytical Diaspher-
Chirasel-E column (eremomycin based CSP, BioChemMack S&T,
Moscow, Russia), 10×0.46 cm, particle size 5m. For the analysis of
the solubility measurements for asparagine, Chirobiotic-T column,
250×4.6mm, 5m particles (Astec, Whippany, NJ, USA) was used.
The enzyme preparation used in this work is an amino acid race-
mase (EC 5.1.1.10), described and characterized in Wu¨rges et al.
(2009).
The quantity of CL from the first batch, specified in the first part of
the paper, was able to satisfy the requirements for the kinetic exper-
iments for the racemization of d- and l-Met, while for racemization
of the enantiomers of asparagine a new batch of PL was prepared.
The chromatographic experiments and the analysis of the sam-
ples after solubility measurements and racemization were carried
out using HP 1100 liquid chromatograph (Hewlett-Packard, Wald-
bronn, Germany). Enzyme assays were done at 850 rpm in 2mL Ep-
pendorf reaction vials placed in an Eppendorf Thermomixer (Ham-
burg, Germany).
3.2. Procedures
3.2.1. Solubility measurements and construction of the ternary phase
diagrams
The solubility of different mixtures between d- and l-Asn mono-
hydrate in water and d- and l-Met in solvent (0.1M KPi buffer,
pH = 7/MeOH = 95/5 v/v) was determined at 15, 25, 35, 40 and 45 ◦C.
The mass fraction of l-enantiomer in the d-/l-mixture was changed
from 0.5 to 1. The solutions with total mass of 10g were placed in
glass vessels and stirred by magnetic stirrer. The necessary isother-
mal conditions were achieved using thermostated double jacketed
vessels in which the temperature was constantly measured with a
PT-100 sensor. After complete dissolution of the solid phase, cool-
ing down to a certain temperature, ensuring equilibrium state by
providing several days for it and analysis of the liquid and the solid
phase, the solubility of each composition of the enantiomers was de-
termined. For both phases, high performance liquid chromatography
(HPLC) analysis was carried out. The analysis of the experimental
results for asparagine was carried out on the Chirobiotec-T column
at T = 25 ◦C using a mixture of ethanol/water = 30/70v/v as mobile
phase with flow rate of 0.5mL/min. The calibration of the UV/VIS
detector was performed at 210nm. For analysis of the methionine
samples the Diaspher-Chirasel-E column was used. The composition
of the mobile phase was the same as the solvent for this system,
T = 25 ◦C, the flow rate was 0.5mL/min and the detection at 230 and
240nm.
To validate the results of the HPLC analysis, additionally, the sol-
ubility concentrations were determined via measuring the density of
the liquid phase using a density meter (density meter DE40, Mettler-
Toledo, Gieen, Germany).
Based on the results obtained from the measurements of the
solubility, the ternary phase diagrams were constructed for both
systems.
3.2.2. PC runs
PC of l-Asn from aqueous solution of dl-Asn was carried out in a
batch mode, i.e. in a stirred jacketed glass vessel of 450mL total vol-
ume. Saturated solution (corresponding to a saturation temperature
Tsat = 36 ◦C) was prepared and placed in the crystallizer, heated up
approximately to 15◦ above the saturation temperature and main-
tained at this temperature for a while in order to assure complete
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dissolution. Shortly after the solution was cooled down to Tsat regu-
lated decrease of the temperature was applied using a cooling rate
of 10K/h until the crystallization temperature (Tcryst = 30 ◦C) was
reached. After the assurance that primary nucleation has not oc-
curred the PC was initiated by adding 0.6 g seeds of l-Asn. During
the whole time crystal-free solution was pumped out of the crystal-
lizer with a flow rate of 3.6mL/min by a circulation pump (Heidolph
PD 5201, SP Quick 1.6, Heidolph Electro GmbH & Co. KG, Kelheim,
Germany) via insulated lines through the polarimeter and density
meter and was led back to the vessel. Information about the process
were obtained by in-line measurement of the temperature (PT-100
sensor), on-line monitoring of the optical rotation angle using po-
larimeter (POLARmonitor, IBZMesstechnik, Hannover, Germany) and
on-line measurements of the density of the liquid phase (density
meter DE40, Mettler-Toledo, Gieen, Germany). In order to avoid re-
crystallization the temperature of the analytical devices and the lines
was about 10◦ higher than the crystallization temperature Tcryst.
3.2.3. Chromatographic separation of dl-Met (P-II)
For the chromatographic unit in P-II the separation of dl-Met
was performed on the Diaspher-Chirasel-E column. The experiments
were carried out at 25, 35 and 40 ◦C for different MeOH amount in
the solvent (0, 5, 10 and 20% at pH = 7) and different pH values (6, 7,
8 and 9 with 0% MeOH). To determine the influence of the examined
parameters on the separation, the selectivities  and the quality of
separation, i.e. the resolutions Rs were evaluated by injecting 1L
of solutions with CDL−Met = 1g/L in the column using flow rate of
0.5mL/min.
3.2.4. Racemization kinetics
3.2.4.1. d-/l-Asparagine. The simplicity in terms of process condi-
tions for P-I resulted in examination only of the influence of the
temperature on racemization reaction. The rates of racemization
for d-Asn were determined at T = 20–50 ◦C with step of 5 ◦C for
CD−Asn = 25g/L and CPL = 0.5 g/L.
The kinetic studies were performed at a temperature of 30 ◦C,
predetermined by the conditions already chosen for the PC unit. The
racemization of d- and l-Asn was done for different concentrations,
CD−/L−Asn = 15, 25 and 35g/L (the highest concentration is close to
the solubility limit of d-/l-Asn for the examined system) for two PL
concentrations (CPL = 0.5 and 1g/L) in a time range where no loss of
the PL-activity can be taken into consideration.
3.2.4.2. d-/l-Methionine. Since the MeOH amount in the solvent,
pH and the temperature played a major role on the chromato-
graphic separation, the influence of the same parameters on the
racemization reaction was investigated in order to determine a
compromised set of parameters for P-II. In that manner the ini-
tial rates of the reaction were measured for the following condi-
tions: 0%, 5%, 10% and 20% MeOH in the solvent (pH = 7, 25 ◦C,
CD−Met = 15g/L, CCL = 0.26g/L); at pH = 5–11 with step 1 (0% MeOH,
25 ◦C, CD−Met = 30g/L, CCL = 0.26g/L) and T = 20–45 ◦C with step
5 (pH = 7, 5% MeOH, CD−Met = 20g/L, CCL = 1g/L). Besides that, for
most of the mentioned conditions the stability of the CL was also
examined. Concerning the kinetics, the racemization of d-Met in
buffer (0.1M, KPi, pH = 7)/MeOH = 95/5 v/v at 25 ◦C was exten-
sively studied for four different concentrations, CD−Met = 5, 10, 20
and 30g/L, and each one of them mentioned for three different CL
concentrations, CCL = 0.5, 1 and 2.5 g/L (the results only for CCL = 1
and 2.5 g/L are shown). Furthermore, the racemization reaction
was performed at T = 20–45 ◦C with step 5 for CD−Met = 20g/L and
CCL = 1g/L. Additionally, l-Met was also racemized in the same
solvent at 25 ◦C using CL−Met = 5, 10, 20 and 30g/L and CCL = 1g/L.
4. Results and discussion
4.1. Ternary phase diagrams and feasibility of the process concepts
The correlation in terms of solubility between different mixtures
of d-, l-Asn and water is presented in Fig. 4. In the ternary phase
diagram five isotherms are shown. The ratio between the mass frac-
tion of the racemic mixture and measured pure enantiomer is ap-
proximately 2, meaning, the system shows nearly ideal behavior, i.e.
the solubility of one enantiomer is not going to be influenced by the
presence of the other enantiomer. The system reveals behavior of a
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accumulation of D-Asn in solution could be avoided which
led to a sixfold yield-increase of L-AsnH2O (92%ee) up to
198mg. Furthermore, it was shown that the yield is
dependent on the enzyme concentration during DPE. The
use of higher enzyme concentrations kept the enantiomeric
composition in solution closer to the racemic composition
and thus prolonged the time until D-Asn crystallization
affected PC. Nevertheless, the crystal yield is rather low
(1.6% without racemization; 9.9% with 1mgPL/mL) when it
is related to the initial mass of racemic Asn in the overall
reaction volume of 20mL which was 1.992 g. This might be
circumvented by continuous feeding of racemic Asn into the
process, which provides steady state conditions and thus
allows a continuous process with 100% yield with respect to
the Asn feed. Measurements of racemase activity in solution
before and after crystallization experiments revealed no
decrease, which is advantageous for a prolonged process and
a potential reuse of the enzyme. For an efficient use, this
promising integrated process needs to be further optimized
with regard to crystallization and saturation temperatures,
seed-crystal properties as well as reactor design.
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Abstract. We present an efficient method for the production 
of D- and L-allo-threonine (allo-Thr) with very high purity by 
enzymatic isomerization of L- or D-threonine (Thr) and 
simultaneous crystallization. Isomerization of Thr to allo-
Thr is catalyzed by a purified amino acid racemase
(AArac12996) from Pseudomonas putida NBRC12996,
which can easily be obtained from a recombinant E. coli
strain by secretion into the medium and subsequent anion 
exchange chromatography. Crystallization of D- and L-allo-
Thr was performed in a repetitive batch mode over a period 
of up to 55 days at 30 °C. Total amounts of 30.8 g D-allo-
Thr and 32.4 g L-allo-Thr were obtained with a very good
diastereomeric excess of deD-allo >99.2 % and deL-allo >98.4 
%, respectively, and in good yields (D-allo-Thr: 83 %, L-
allo-Thr: 79 %). The enzyme’s remarkable high stability 
under process conditions resulted in enzyme specific yields 
of 2.56 g D-allo-Thr per mg AArac12996 and 1.62 g L-allo-
Thr per mg AArac12996.
In contrast to chemical multi-step syntheses of allo-Thr, our 
process consists of only one enzyme catalyzed reaction step 
with simultaneous product crystallization. The process is 
performed under low energy consumption (30 °C, 
atmospheric pressure) in water and avoids the use and 
production of any toxic or harmful compounds. Recovery 
of the enantiomerically pure products is performed by 
simple filtration which reduces downstream processing 
significantly compared to chromatographic methods which 
are usually applied.
Keywords: allo-threonine, amino acid racemase, 
crystallization
1 Introduction
allo-Threonine (allo-Thr) is part of many biologically
active peptides such as naturally occurring antibiotics 
as well as other therapeutic chiral molecules.[1-7] For 
example D-allo-Thr is used for chemical syntheses of 
key intermediates for the production of thienamycin, 
which is a potent antibiotic used against gram-
positive and gram-negative bacteria.[8, 9] Further, allo-
Thr is used as starting material in the chemical 
synthesis of lysobactin, an antibiotic used against 
methicillin-resistant Staphylococcus aureus
(MRSA).[10]
Several methods for the chemical as well as 
enzymatic synthesis of allo-Thr have been described.
[11-15] Kataoka et al.[2] reported a stereoselective C-C
bond formation between glycine and acetaldehyde 
using L-allo-Thr aldolase from Aeromonas jandaei
DK-39. The same reaction can be performed using 
the serine hydroxymethyltransferase GlyA from E.
coli.[16] Lim et al.[17] reported on an amino acid 
racemase from Pseudomonas putida ATCC 17642 
with a threonine--epimerase activity (EC 5.1.1.6), 
which, to our knowledge, is the first and only 
reference about an enzymatic isomerization of 
threonine (Thr) in the literature. Although several 
amino acid racemases show broad substrate 
specificity such as arginine racemase from P. 
graveolens[18] and amino acid racemases from A.
punctata[19] and P. putida[20], they usually do not act 
	
 
-methylene groups 
such as threonine, isoleucine and valine. We could 
demonstrate that the amino acid racemase from 
Pseudomonas putida NBRC12996 (AArac12996) 
also catalyzes the isomerization of these amino acids. 
Nevertheless, chemical methods[11-15] clearly 
outnumber the described enzymatic approaches. 
However, they consist of multi-step reaction cascades 
with only low yields. For example Blaskowich et al.
[12] described an 8-step synthesis of D- or L-allo-Thr 
starting from the respective threo-isomer with a total 
yield of 38 %. Although both enantiomers of allo-Thr 
are commercially available, they are extremely 
2expensive and, hence, not useful as starting material 
for large-scale syntheses.[21]
Here we describe an easy and inexpensive method for 
the production of high-priced allo-Thr starting from 
cheap Thr using AArac12996. This enzyme was 
chosen since Kino et al. [22] reported an activity on L-
Thr, although it is very low compared to the preferred 
substrate L-lysine (0.1 %). Separation of allo-Thr 
from Thr in our approach is performed by 
simultaneous crystallization in a simple batch reactor. 
In contrast to replacing crystallization[23, 24] or 
dynamic kinetic resolution processes, where 
enzymatic racemization is combined with preferential 
crystallization of single enantiomers from a saturated 
racemic solution,[25] the crystallization of allo-Thr is 
based on its lower solubility limit compared to Thr in 
water. 
AArac12996 has a broad substrate specificity which 
is comparable to other pyridoxal-5’-phosphate (PLP)-
dependent amino acid racemases.[26] This group of 
enzymes catalyzes the is-C atom. 
	
-C atom as the only chiral 
center this means interconversion of the L- and D-
forms, whereas diastereomers with two chiral centers 
 - 
 -positions, such as Thr, are converted to 
their diastereomeric forms (figure 1).
Figure 1: Isomerization of -C atom catalyzed by amino 
acid racemase. Top: amino acids with only one chiral 
center are converted to their counterenantiomer. Middle 

    -C atom so that L-Thr is 
converted to its diastereomer D-allo-Thr and D-Thr to its 
diastereomer L-allo-Thr.
2 Results and Discussion
Cloning, overexpression and purification of 
AArac12996
The coding gene of AArac12996 from P. putida
NBRC12996 was cloned into pET22b+ and over-
expressed in E. coli BL21(DE3).
Surprisingly, our studies on protein expression 
resulted in a progressive accumulation of racemase 
activity in the extracellular medium over time (Table 
1), indicating an intrinsic signal sequence in the 
coding gene. The full amino acid sequence 
(Supplementary Material) of AArac12996 was 
analyzed for a corresponding signal sequence using 
the program SignalP 3.0[27] and a specific cleavage 
site was found between Ala24 and Ala25. This signal 
sequence shows the typical tripartite structure of 
signal peptides, consisting of a hydrophobic core 
region (h-region) flanked by a positively charged n-
region and a polar c-region that contains the signal 
peptidase cleavage site.[28] The subsequent release of 
periplasmic racemase through the outer cell 
membrane is supposed to be an autolytic response to 
the stress caused by overexpression and secretion of a 
foreign protein.[29] Matsui et al.[30] proposed a trans-
location mechanism for an amino acid racemase 
ArgR from P. taetrolens, which has an amino acid 
sequence identity of 73 % compared to AArac12996. 
ArgR is thought to be translocated via the Sec 
pathway by cleavage of an N-terminal signal peptide. 
According to the physiological role of alanine 
racemase[31] it is assumed that also amino acid 
racemase plays an important role for the synthesis of 
D-alanine and D-glutamate in the murein layer.
Cultivation of the recombinant E. coli in 2 L LB-
medium yielded a total activity of 5900 U in the 
cultivation broth (medium and cells before cell
separation). Purification of the secreted enzyme from 
the medium by ultrafiltration and subsequent anion 
exchange chromatography resulted in pure enzyme 
(according to SDS-PAGE, see Supplementary 
Material) with a specific activity of 8.6 U mg-1. The 
freeze-dried protein (320 mg, protein concentration of 
~73 %) was stored at -20 °C.
Table 1: Development of the intracellular and extracellular 
activity of AArac12996 during expression in E. coli
BL21(DE3) cells in a 2 L cultivation. Activity was assayed 
using the standard assay as described in the experimental 
section.
expression time 
[h]
activity in medium 
[U]
activity in cells 
[U]
20.0 300 1225
42.5 419 2361
67.0 3504 527
Characterization of AArac12996
AArac12996 is a PLP-dependent dimeric enzyme 
with a molecular weight of 44.2 kDa per monomer. 
While AArac12996 shows maximum activity for L-
lysine (100 % relative activity), the activity for L-Thr 
isomerization is rather low (0.1 %). The enzyme was 
initially characterized by following the isomerization 
of L-asparagine (Asn), which was chosen because the 
i. Isomerization of Thr cannot be followed 
polarimetrically for easy activity measurements. ii. 
3Activity for L-Asn is ca. 20-fold higher than for L-
Thr. The pH-optimum was found in the range of pH 
8.6 - 9.7 (Figure 2). Investigation of the temperature 
dependency yielded a maximum initial rate activity at 
31 °C (Figure 3). For isomerization of Asn the 
activation energy Ea was calculated as 48.4 kJ mol-1,
which is comparatively high compared to related 
racemases, such as alanine racemases from P. 
fluorescens[32] (29.2 kJ mol-1 for L-alanine) and B. 
stearothermophilus[33] (7.54 kJ mol-1 for D-alanine). 
The stability of AArac12996 was studied over 7 days 
by following the residual activity of liquid enzyme 
samples between 20 °C and 47 °C (Figure 4). The 
enzyme is stable for 7 days at 20 and 30 °C, whereas
a rapid decay of activity was observed at 40 °C (6% 
residual activity in initial rate studies, Figure 3). 
Nevertheless, stability investigations at 40 °C (which 
assayed the residual activity at 30 °C) still showed a 
residual activity of about 16 % after 3 days. These 
results indicate a reversible inactivation of 
AArac12996 at temperatures between 31 °C and 
40 °C. At 47 °C AArac12996 was inactivated 
irreversibly and showed no residual activity after an 
incubation of 2 h. The influence of supplemented 
PLP, which is covalently bound as cofactor to the 
active site of AArac12996, was investigated in the 
concentration range between 0 and 50 µM. Within
this concentration range PLP had no influence on the 
enzyme activity; thus, it was omitted during 
biotransformations.
Figure 2: Determination of pH-optimum for AArac12996 
(0.1 mg mL-1) in glycine/NaCl buffer (90 mM) at 30 °C. 
Relative activities were determined polarimetrically by 
following the isomerization of L-Asn (25 mM) for 5 
minutes.
Kinetic parameters were determined for the 
isomerization of Thr. While the maximal velocities 
for the isomerization of both Thr-enantiomers are 
identical, their Km values differ by a factor of 2 with 
L-Thr being the preferred enantiomer (Table 2). 
Based on these parameter studies, AArac12996 was 
characterized in detail for its application in the 
production of allo-Thr.
Figure 3: Determination of the temperature dependency 
for AArac12996 (0.1 mg mL-1) in water. Residual activity 
was determined polarimetrically at 30 °C for the 
isomerization of L-Asn (90 mM) for 5 minutes.
Figure 4: Stability of AArac12996 in water. Enzyme 
solutions (1 mg mL-1) were stored at 20 °C – 47 °C. 
Aliquots were taken for polarimetric determination of 
residual activity (isomerization of L-Asn (90 mM) at 30 °C 
for 5 minutes).
Table 2: Kinetic parameters for the isomerization of Thr 
catalyzed by AArac12996 at 30 °C in water. Initial rate 
activities were determined by chiral HPLC. Vmax values 
were calculated per mg of protein in the lyophilizate. kcat 
corresponds to the turnover number per monomer.
reaction Vmax[U mg-1AArac12996]
Km [mM] kcat [s-1]
L-Thr 
D-allo-Thr 1.865 ± 0.154 92.5 ± 18.4 1.37
D-Thr 
L-allo-Thr 1.866 ± 0.069 185.5 ± 11.9 1.37
4Repetitive batch crystallization of allo-threonine
Both enantiomers of allo-Thr were produced and 
crystallized with very high purity starting from either 
D- or L-Thr. The process was performed in a 
repetitive batch mode, in which enzymatic 
isomerization of Thr to allo-Thr and crystallization of 
allo-Thr took place simultaneously in one single 
reaction vessel at 30 °C (Figure 5). Depending on the 
desired allo-Thr enantiomer, either L- or D-Thr was 
used as the substrate. The process consists of three 
main steps:
I) Start of the first batch by addition of AArac12996 
to a saturated Thr solution (119 g L-1 at 30 °C in 
water, pH was titrated to 8.5 using 10 n NaOH) 
containing undissolved excess Thr: Thr is converted 
to allo-Thr until the saturation limit of allo-Thr (83 g 
L-1 at 30 °C in water, pH 8.5) is reached. The 
concentration of Thr remains constant (due to 
progressive solubilization of excess Thr).
II) Crystallization of allo-Thr: allo-Thr starts to 
crystallize spontaneously upon exceeding the 
solubility limit. The composition of the solution is 
42 % D-allo-Thr and 58 % L-Thr due to different 
solubilities. This process is driven by the conversion 
of Thr to allo-Thr until depletion of excess Thr. 
III) Complete conversion of excess Thr to allo-Thr:
The process stops upon complete solution and 
isomerization of Thr to allo-Thr, which takes about 
1.5 days per gram Thr (thus the time per batch 
depends on the amount of added excess Thr). The 
overall Thr/allo-Thr concentration in the solution 
remains constant throughout phases II and III and is 
fixed by the solubility limits of both Thr species. 
allo-Thr crystals are separated by filtration and dried
at 60 °C. The next batch can be started by the 
addition of fresh Thr.
Steps II and III are repeated for a repetitive batch 
crystallization.
Figure 5: Repetitive batch crystallization (20 mL) of D-
allo-Thr in one single reaction vessel. I: AArac12996 is 
added to a saturated L-Thr solution (starting condition) II: 
dynamic process of crystallization (D-allo-Thr), solubili-
zation (L-Thr) and isomerization (L-Thr  D-allo-Thr) 
III: addition of fresh L-Thr when excess has depleted. 
Steps II and III are repeated for repetitive batch 
crystallization.
Repetitive batch processes (20 mL scale) were 
performed for the production of D- and L-allo-Thr, 
respectively. Process data and yields for both 
enantiomers are summarized in Tables 3 and 4. 
Production of D-allo-Thr was performed over 55 days 
and consisted of 12 batches with yields of 1.6 to 4.4 g 
D-allo-Thr per batch and a diastereomeric excess 
(deallo) between 96.9 and 100 %. A space time yield 
(STY) of 28 g L-1 d-1 and a final yield of 30.8 g D-
allo-Thr (deallo > 99.2 %) were achieved. An initial 
amount of 10 mg AArac12996 was applied and 
additional 2 mg of AArac12996 were added after 13 
days.
Production of L-allo-Thr was performed over 56 days 
and consisted of 12 batches with yields of 1.5 to 4.0 g 
L-allo-Thr per batch and a deallo between 94.6 and 
100 %. A STY of 28.8 g L-1 d-1 and a final yield of 
32.2 g L-allo-Thr (deallo > 98.4 %) were obtained 
using a total amount of 20 mg AArac12996.
The enzyme showed a remarkable high stability 
under process conditions yielding 2.56 g D-allo-Thr 
and 1.62 g L-allo-Thr per mg AArac12996, 
respectively.
Table 3: Production of D-allo-Thr by repetitive batch 
crystallization and enzymatic isomerization of L-Thr (V= 
20 mL, 30°C, pH 8.5, initial amount of AArac12996: 10 
mg, addition of 2 mg AArac12996 after 13 days).
batch
no.
process 
time [d]
added
L-Thr [g]
batch 
time [h]
yielda)
[g]
deallob)
[%]
1 5.9 7 141 3.05 100.0
2 8.8 2 69 1.68 100.0
3 13.8 4 120 3.55 98.0
4 16.0 2 53 1.97 96.9
5 19.9 3 94 3.08 98.3
6 23.8 3 93 2.84 100.0
7 26.8 2.5 74 2.08 99.7
8 30.8 3 94 2.6 99.3
9 34.0 2 77 1.83 100.0
10 37.0 2 73 1.63 99.4
11 47.8 4 258 4.41 99.9
12 54.8 2.5 168 2.10 99.7
sums 54.8 37.0 1314 30.82 99.2
a) yield of crystallized D-allo-Thr, b) diastereomeric excess of D-
allo-Thr in crystals
The activity of AArac12996 in the crystallization 
solution was monitored throughout the process. 
Figure 6 shows the relative activities of AArac12996 
during D-allo-Thr crystallization over a period of 55 
days. The deactivation constant kd was calculated 
from
where v0 is the initial enzyme activity.
5Half-life t1/2 of the enzyme was derived from
Table 4: Production of L-allo-Thr by repetitive batch 
crystallization and enzymatic isomerization of D-Thr (V= 
20 mL, 30°C, pH 8.5, AArac12996: 20 mg).
batch
no.
process 
time [d]
added
D-Thr [g]
batch 
time [h]
yielda)
[g]
deallob)
[%]
1 9.8 9 236 3.94 99.6
2 12.7 2 70 1.98 99.0
3 15.8 3 74 2.98 98.6
4 19.9 3 99 3.10 99.6
5 22.8 3 70 2.55 98.4
6 27.0 4 99 3.32 94.6
7 30.8 3 92 2.80 95.8
8 34.0 2 77 2.06 100.0
9 37.1 2 73 1.79 99.7
10 47.8 4 258 4.04 99.8
11 50.9 2.5 75 1.54 99.7
12 55.8 3 117 2.32 96.5
sums 55.8 40.5 1339 32.42 98.4
a) yield of crystallized L-allo-Thr, b) diastereomeric excess of L-
allo-Thr in crystals
Figure 6: Deactivation and half life (t1/2) of AArac12996 
during repetitive batch crystallization of D-allo-Thr. 
Activities were determined using the standard assay. 
kd=0.0218 d-1 (± 0.0035 d-1).
3 Conclusion
Enantiopure L- and D-allo-Thr were produced by 
enzymatic isomerization of either D- or L-Thr and 
simultaneous crystallization. Recovery of the 
enantiomerically pure products was performed by 
simple filtration which reduced downstream 
processing significantly compared to e.g. 
chromatographic methods.[34]
The reaction was catalyzed by AArac12996 from P. 
putida, which was cloned and overexpressed in E. 
coli. As the enzyme was secreted into the medium, its 
purification is easy. Vmax and Km values were 
determined for both Thr enantiomers. Vmax was found 
to be similar for both reactions (1.87 U mg-1AArac12996), 
whereas the Km value, which is a measure for the 
affinity for both enantiomers, differs by a factor of 2
(table 2), indicating a higher affinity for L-Thr (Km,L-
Thr=92.5 mM, Km,D-Thr=185.5 mM). AArac12996 
shows highest initial rate activity at a pH of about 9 
and a temperature of 31 °C. Surprisingly, the enzyme 
was completely stable at 30 °C for at least 7 days. 
Thus, this temperature was chosen for the production 
of D- and L-allo Thr.
D- and L-allo-Thr were crystallized with high purities 
in repetitive batch processes starting from saturated 
Thr solutions. Total amounts of 30.8 g D-allo-Thr 
and 32.4 g L-allo-Thr were obtained with a very good 
diastereomeric excess of deD-allo>99.2 % and deL-
allo>98.4 %, respectively, and in good yield (D-allo-
Thr: 83 %, L-allo-Thr: 79 %). Final space time yields 
of 28.0 g L-1 d-1 for D-allo-Thr and 28.8 g L-1 d-1 for 
L-allo-Thr were reached. A conversion of almost 100 
% could easily be achieved by additional batches. 
The enzyme’s remarkable high stability under 
process conditions resulted in enzyme specific yields 
of 2.56 g D-allo-Thr per mg AArac12996 and 1.62 g 
L-allo-Thr per mg AArac12996.
Compared to chemical synthesis methods for allo-
Thr, which contain several reaction steps each 
followed by chromatographic purification of the 
intermediate,[13] our process consists of only one 
enzyme catalyzed reaction (isomerization of bulk 
Thr) and simultaneous crystallization in one single 
reaction vessel. The process was carried out at 
moderate temperature (30 °C) in water and avoids 
any toxic or harmful compounds. Product recovery 
was performed by simple filtration of the 
crystallization solution and subsequent crystal drying, 
which made downstream processing very 
comfortable. In contrast to other biocatalytic 
production and separation methods for allo-Thr [34]
we could achieve very high purities with deallo>99% 
and theoretically approach complete conversion of 
the substrate.
4 Experimental Section
Cloning of AArac12996
The AArac12996 gene was amplified by standard 
PCR from the genomic DNA of Pseudomonas putida
NBRC12996 which was kindly provided by the 
Department of Biotechnology, Kansai University 
(Japan). Genomic DNA was isolated from an 
overnight culture grown at 30 °C in LB-Medium 
using the DNeasy Blood & Tissue Kit (Qiagen). 
6Following primers (Eurofins MWG Operon, 
Ebersberg, Germany) have been used for cloning:
The PCR-fragment was purified on an agarose gel 
(1%) and digested with NdeI and XhoI (Fermentas, 
St. Leon-Rot, Germany). Subsequently the 
AArac12996 gene was ligated into the NdeI/XhoI
digested vector pET22b+ (Novagen®, Merck KGaA, 
Darmstadt, Germany) yielding the final construct 
pET22b-AArac12996. The expression host E. coli
BL21(DE3) was transformed with pET22b-
AArac12996 by electroporation. Sequence identity 
was verified by DNA sequencing (Agowa, Berlin, 
Germany). For protein and DNA-sequences see
Supplementary Material.
Expression and purification
Cultivation of the recombinant E. coli BL21(DE3) 
strain was performed in 5 x 400 mL of LB medium 
(10 g L-1 peptone, 5 g L-1 yeast extract, 10 g L-1 NaCl) 
at 37 °C and 100 rpm in 2 L shaking flasks. Each
flask was inoculated with 4 mL of an overnight pre-
culture. At OD600~0.6 protein expression was induced 
by addition of IPTG (100 µM) and the temperature 
was decreased to 27 °C. 67 h after induction the cells
were separated from the racemase containing medium 
by centrifugation (15000 g, 20 min, 4 °C). Separation 
of AArac12996 from low molecular weight medium 
components was performed by ultrafiltration 
(ultrafiltration device manufactured by mechanical 
workshop of IBT, Forschungszentrum Jülich GmbH, 
Germany; membrane cutoff: 10 kDa) by 
concentrating the medium to 10 % of its initial 
volume three times and refilling with potassium 
phosphate buffer (10 mM KPi, 10 µM PLP, pH 7). 
Occurring precipitates were separated by 
centrifugation and the supernatant was filtered 
(syringe filter, 0.4 µm) before applying onto an 
anion-exchange column (DEAE-Sepharose FF, 5 x 25 
cm, column volume (CV): 500 mL, equilibrated with 
10 mM KPi (10 µM PLP, pH 7)). Unbound proteins 
were washed from the column with 2 CV of 10 mM 
KPi (10 µM PLP, pH 7). AArac12996 was eluted 
with 10 mM KPi (10 µM PLP, pH 7) containing 100 
mM NaCl after about 3.8 CV at a flow rate of 10 mL 
min-1. Enzyme containing fractions were detected at 
280 nm (absorption of aromatic side chains of 
proteins) and 420 nm (absorption of PLP). A total 
volume of 850 mL was desalted by ultrafiltration 
using 10 mM KPi (10 µM PLP, pH 7) as described 
above, concentrated to a final volume of 120 mL, 
frozen in liquid nitrogen and lyophilized for 24 h 
(freeze-dryer: Christ Alpha 2-4, Germany). The 
freeze-dried enzyme (320 mg, 73 % protein content) 
was stored at -20 °C.
Activity assay
The specific activity of AArac12996 was investigated 
by determination of the initial reaction rate for the 
isomerization of L-Asn. Therefore, the linear slope of 
product (D-Asn) formation was determined within a 
conversion range <10%. Specific activities were 
determined using a standard activity assay and 
following the increase of D-Asn by chiral HPLC.
One unit of activity was defined as the amount of 
AArac12996 which catalyzes the isomerization of 1 
µmol L-Asn to D-Asn per minute under standard 
conditions (190 mM L-Asn in water, 35 °C). Relative 
activities for investigation of pH-optimum and 
temperature dependency as well as for stability 
investigations were determined by following the 
decrease of optical rotation with a polarimeter. In 
order to allow optimal solubility and crystallization in 
the allo-Thr production process, all measurements 
(except for the determination of the pH-optimum) 
were performed in water without buffer salts. 
Assay conditions HPLC: 950 µL L-Asn in water (200 
mM), 50 µL AArac12996 containing solution. To 
stop the reaction 10 µL of assay solution were diluted 
with 990 µL HClO4 (pH 1) prior to injection. 
Column: Daicel Crownpak CR(+) 0.4 x 15 cm; 
mobile phase: HClO4 (pH 1); flow: 0.6 mL min-1;
column temperature: 0 °C. HPLC-system: Agilent
Series 1100.
Assay conditions polarimeter: 1 mL L-Asn solution in 
water (90 mM if not indicated otherwise), 110 µL 
AArac12996 solution (1 mg mL-1). Polarimeter: Jasco 
P-2000; cell length =  = 365 nm, t = 5 min, 
30 °C (varying temperatures for determination of 
temperature dependency).
Kinetic parameters
Vmax and Km for the isomerization reaction of Thr to 
allo-Thr were calculated by non-linear regression 
using Origin 7G (OriginLab Corporation, 
Northampton, USA). The turnover number kcat was 
derived from Vmax for a single monomer. All kinetic 
parameters are related to the relative protein mass 
determined (according to Bradford) in the enzyme 
preparation. The identity of allo-Thr was verified by 
1H-NMR spectroscopy (Bruker, Avance DR X 600)
in D2 !!"#$%-1.15 (d, 3H, J=6.42, 
CH3), 3.77-3.78 (d, 1H, J=3.77, CH), 4.28-4.32 (m, 
1H, CH)).
Determination of protein concentration
Protein concentrations were determined according to 
Bradford[35] using BSA as standard.
Investigation of temperature dependency and pH-
optimum
The temperature dependency of the initial rate 
activity of AARac12996 (0.1 mg mL-1) was 
7determined for L-Asn (90 mM) in water between 20 
°C and 40 °C. Initial reaction rates were measured 
polarimetrically.
The pH-optimum of AArac12996 (0.1 mg mL-1) was 
determined polarimetrically by initial rate 
measurements in glycine/NaCl buffer (90 mM each, 
titrated with NaOH) in the range of pH 8.1 to 12.6 
using L-Asn (25 mM) as a substrate. It has to be 
noted that the substrate concentration (25 mM) was 
significantly lower than the Km-value for L-Asn 
(>100 mM). However, higher concentrations of Asn 
could not be applied, because the capacity of the 
buffer was exceeded otherwise. Reaction rates were 
determined only from the linear part of the 
conversion curve. Since the activities were not 
obtained under Vmax conditions, initial reaction rates 
at different pH values are given as relative activities. 
All measurements were performed twice and relative 
activities were calculated as mean values.
The activation energy Ea of AArac12996 was derived 
from the Arrhenius plot (ln(v) vs. T-1) as the product 
of the slope m and the negative gas constant R (8.314 
J K-1 mol-1): Ea=m·(-R).
Stability investigations
Enzyme stabilities were investigated for AArac12996 
(1 mg mL-1) in water at temperatures between 20 and 
47 °C. Aliquots were taken over up to 7 days and 
residual activities were determined polarimetrically at 
30 °C for 5 min using L-Asn (90 mM) as a substrate.
Repetitive batch crystallization
Repetitive batch crystallization was performed for L-
and D-allo-Thr. Here we describe the process for the 
crystallization of D-allo-Thr, which is similar to the 
one for L-allo-Thr but starting from the other Thr 
enantiomer. Experiments were performed in a double 
jacketed 50 mL glass reactor which was tempered by 
a water thermostat to 30 °C. A saturated L-Thr 
solution was prepared by the addition of 7 g L-Thr to 
20 mL water and the pH was adjusted to 8.5 with 10 
n NaOH. Excess L-Thr remained as sediment. The 
conversion of L-Thr to D-allo-Thr was performed by 
12 mg AArac12996 (for L-allo-Thr crystallization 20 
mg AArac12996 were used). Crystallization of D-
allo-Thr started upon exceeding the solubility limit. 
The crystallization process was monitored by HPLC 
as described below. After complete solubilization of 
excess L-Thr, D-allo-Thr crystals were harvested by 
filtration, washed with 2 mL of ice cold water and 
dried for 1 h at 60 °C. The next batch was started by 
addition of fresh L-Thr to the remaining solution
(Figure 5).
Monitoring of the crystallization process
The composition of solution during allo-Thr 
crystallization and the diastereomeric excess (deallo)
of crystals were determined by HPLC employing an 
HP 1100 series equipped with a chiral column 
(Daicel Crownpak CR(+) 0.4 x 15 cm; mobile phase: 
HClO4 (pH 1); flow: 0.8 mL min-1; column 
temperature: 5 °C). deallo was calculated from
deallo=([allo-Thr]-[Thr])/([allo-Thr]+[Thr])
where [allo-Thr] and [Thr] are the crystal fractions of 
the respective diastereomer. Space time yields (STY)
were calculated from STY=yield/(t·V) where t is the 
process time and V is the reaction volume. The 
remaining activity of AArac12996 during allo-Thr 
crystallization was determined as described above 
with 50 µL of enzyme containing crystallization 
solution.
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Corrections 
 
Publication 1: 
 Introduction (page 10): The annual production rate of L-Met is given with ca. 600 
t/year which must be corrected to ca. 600000 t/year (Eggeling et al., 2006). 
 Introduction (page 11): “Met, which is a racemic compound forming system and thus 
can be enantioseparated by PC, …” must be corrected to: “Met, which is a racemic 
compound forming system and thus cannot be enantioseparated by PC, …” 
 
Publication 3: 
 Materials and Methods (page 1236): “In contrast to racemic compounds, where both 
enantiomers coexist in 1 U cell, …” must be corrected to “In contrast to racemic 
compounds, where both enantiomers coexist in 1 unit cell, …” 
 Scheme 1 (page 1237): Arrows and reaction rate constants ki are missing. Corrected 
scheme must be: 
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4 Discussion 
Context of publications 
The publications, which will be discussed in the following, have been prepared in the course 
of a doctoral thesis performed at the Institute of Bio- and Geosciences 1 (former Institute of 
Biotechnology 2) at the Forschungszentrum Jülich. Publications 1, 2 and 3 focus on strategies 
to overcome yield limitations in chiral resolutions by the combination of physicochemical 
separation processes and enzymatic racemization. They were published as a series, as the 
contents and results build up on each other. Publication 4 deals with enzymatic isomerization 
of Thr, a modified application of amino acid racemases, together with stereoselective 
crystallization of a single diastereomer. The results presented in publication 2 were mainly 
prepared by Katerina Petruševska-Seebach at the Max Planck Institute for Dynamics of 
Complex Technical Systems in Magdeburg, whereas the work presented in publications 1, 3 
and 4 was done almost exclusively by Kerstin Würges. 
Publication 1 describes cloning, overexpression and characterization of an amino acid 
racemase from Pseudomonas putida KT2440 (AArac2440). Kinetic parameters for the 
racemization of methionine and asparagine were determined. The reaction conditions were 
chosen according to two different applications: I) the racemization of D- and L-methionine 
(Met) in combination with chromatographic enantioseparation, and II) the racemization of D- 
and L-asparagine (Asn) in combination with preferential crystallization (PC). 
Publication 2: This paper addresses the design and theoretical investigation of the two 
enantioseparation processes introduced in publication 1 in order to enhance the overall 
performance. Besides basic investigations with respect to the solid-liquid equilibria of Met 
and Asn, PC as well as chromatography, the focus is mainly on the kinetic studies of 
AArac2440. It has to be noted that this paper does not describe classical enzyme kinetics in 
terms of Michaelis-Menten kinetics but models various racemization reactions at different 
initial substrate concentrations. The chosen model equation sufficiently describes the reaction 
of AArac2440 in a wide concentration range (from diluted up to nearly saturated substrate 
solutions). It provides an adequate description of the racemization, which for engineering 
issues, is necessary for further process development. 
Publication 3: A new method for the dynamic kinetic resolution of racemic AA is presented, 
which is able to overcome the usual yield limitation of 50 % of simple enantioseparation 
processes. This method applies PC for chiral resolution instead of a biocatalytic asymmetric 
transformation step. Racemization is performed enzymatically using AArac2440. An 
experimental proof for increasing the product yield of the chosen model substrate L-Asn from 
a racemic solution (compared to PC without racemization) is given. 
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Publication 4: The last paper investigates a novel process for biocatalytic production of chiral 
allo-Thr by enzyme catalyzed isomerization of Thr and stereoselective crystallization of allo-
Thr. This approach is a modification of the enzyme-assisted PC presented in publication 3. 
Due to the diastereomeric character of Thr, isomerization occurs as epimerization instead of 
racemization. The formed allo-Thr was separated by simple crystallization, thus offering an 
efficient method for the production of D- and L-allo-Thr with very high purities. In contrast to 
publications 1, 2 and 3, a different but related amino acid racemase AArac12996 was used, 
which originates from Pseudomonas putida NBRC12996. 
 
4.1 Amino acid racemases AArac2440 and AArac12996 
4.1.1 Overexpression and secretion 
AArac2440 and AArac12996 from different Pseudomonas putida strains (KT2440 and 
NBRC12996) were cloned into pET-22b(+) as described in publications 1 and 4 and 
overexpressed in E. coli BL21(DE3). During expression studies, a progressive secretion of 
both enzymes into the cultivation medium was observed (Table 2). Sequence analyses 
demonstrated respective N-terminal signal peptides (see Appendix, section III). These results 
suggest that the enzymes are naturally secreted into the periplasmic space (chapter 4.1.4).  
Table 2: Development of the intracellular and extracellular activity of AArac2440 and AArac12996 during 
expression in E. coli. Standard activity assay was carried out using 190 mM L-Asn at 35 °C. 
 AArac2440  AArac12996 
expression 
[h]  
medium 
[U/mL] 
cells 
[U/g]  
medium 
[U/mL] 
cells 
[U/g] 
20.0  0.6 99  0.15 58 
42.5  1.5 145  0.21 78 
67.0  1.9 168  1.75 44 
 
Similar results have been discussed for amino acid racemase ArgR from Pseudomonas 
taetrolens, where a translocation mechanism via the Sec pathway over the inner cell 
membrane into the periplasm by cleavage of the N-terminal signal peptide was proposed 
(Matsui et al., 2009). The Sec pathway is a membrane associated pathway over the inner cell 
membrane for the secretion of unfolded proteins (Driessen et al., 1998). As the signal peptide 
as well as the size of ArgR are comparable to AArac2440 and AArac12996, a similar 
secretion pathway can be assumed. The release of periplasmic racemase through the outer cell 
membrane into the medium is supposed to be an autolytic response to the stress caused by 
overexpression and secretion of a foreign protein (Suominen et al., 1987). A similar protein 
secretion system using bacterial strains derived from E. coli K12 called ESETEC® was 
presented by Wacker Biotech GmbH (Muecke et al., 2009). It uses the Sec pathway for active 
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protein transport from the cytosol across the inner cell membrane. After cleavage of the signal 
peptide by a signal peptidase, the premature protein is folded in the periplasm and transferred 
over the outer cell membrane (Leonhartsberger et al., 2009). 
About the physiological role of the racemase secretion into the medium can only be 
speculated, as no further investigations have been done and no literature concerning the 
secretion of amino acid racemase EC 5.1.1.10 is available. However, it is well known that 
other racemases (e.g. alanine racemase) play an important role in the bacterial growth by 
providing D-Ala and D-Glu, which are central compounds of the murein layer (Figure 5) of all 
bacterial cell walls (Yoshimura et al., 2003), as was already described in the introduction. 
Therefore, it is likely that periplasmic amino acid racemase is involved in the isomerization of 
the respective proteinogenic L-AA in the periplasmic space. 
 
Figure 5: Schematic drawing of murein layer (E. coli). GlcNAc (N-acetylglucosamine) and MurNAc (N-
acetylmuramic acid) are cross-linked by AA-tetramers. Besides DAP (diaminopimelic acid), D-Ala and D-Glu 
are main components of these tetramers. 
 
 
4.1.2 Purification from cell extract and medium 
Enzyme purification was performed using two different methods starting from either cell 
extract or medium. Figure 6 gives an overview about the enzyme sources, the purity of the 
enzyme samples and their applications. Different purity grades were necessary due to side 
reactions that occurred using the crude cell extract. While this unpurified enzyme sample was 
sufficient for Met racemization, it led to enzymatic degradation processes of Asn and Thr that 
were identified by decreasing overall concentrations of Asn and Thr, respectively. 
Degradation of Asn and Thr was not characterized any further, but could be avoided by 
purification of the applied enzyme sample. 
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a) Purification from cell extract (publication 1). The harvested cells were disrupted 
by sonication. After separation of cell debris by centrifugation the clear racemase 
containing cell extract was either directly lyophilized or subjected to further 
purification via fractioned precipitation using ammonium sulfate, desalting and 
subsequent ion exchange chromatography. The crude racemase preparation, which 
additionally contained an undefined variety of the host cells’ metabolic enzymes, 
is termed CL (Crude cell extract Lyophilisate), whereas the pure racemase 
preparation PL (Pure Lyophilisate) contained no protein impurities. 
b) Purification from medium (publication 4). Due to the secretion of the enzyme 
into the cultivation medium, the second approach for enzyme purification was 
developed based on the medium. After protein expression, the cells were separated 
from the racemase containing medium by centrifugation and all low molecular 
weight components were removed by ultrafiltration. The medium was exchanged 
against potassium phosphate buffer (KPi) prior to applying the concentrated 
racemase solution to DEAE column chromatography. The racemase containing 
fractions were pooled, desalted and lyophilized. 
 
Figure 6: Overview of racemase purification procedures applied in this thesis, 
classified by source, purity grade (CL: lyophilisate of crude cell extract; PL: 
lyophilisate of purified racemase) and application. 
 
As can be seen in Figure 7 the distribution of racemase activity between cells and medium 
after 67 hours of expression is almost equivalent. For enzyme purification from the cells only 
soluble racemase within the cell extract is accessible. However, the major part of racemase 
activity (ca. 80 % of initial cell activity) was found in the cell debris indicating some kind of 
membrane association. Attempts to solubilize this racemase fraction, e.g. by using detergents 
like Tween 20, have not been successful. Direct purification from the cultivation medium 
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(final yield ca. 21 %) was much more efficient than purification from the cell extract (final 
yield ca. 1 %; Tables 3 a and b). The purity of this racemase preparation was demonstrated by 
SDS-PAGE analysis (Figure 8). 
 
 
 
Figure 7: Distribution of racemase activity during a cultivation of AArac2440-
expressing E. coli (shaking flask, V=200 mL, expression for 67 h at 27 °C). Activity 
was determined using standard activity assay (190 mM L-Asn, 35 °C; publication 4). 
 
 
Tables 3 a) and b): Yields of AArac2440 purified from medium (a) and cell extract (b). Activity was 
determined using the standard activity assay (190 mM L-Asn, 35 °C; publication 4). 
a) 
200 mL shaking flask, 
70 h expression 
activity 
[U] 
yield 
 
 b) 
20 L biostat, 
24 h expression 
activity 
[U] 
yield 
 
complete cultivation 5043 100.0%  complete cultivation 513641 100.0% 
medium 2003 39.7%  cell extract 10957 2.1% 
concentrated medium* 2559 50.7%  concentrated cell extract* 6268 1.2% 
active fraction** 1559 30.9%  active fraction** 6384 1.2% 
lyophilisate 1056 20.9%  lyophilisate 5348 1.0% 
*before chromatography, **after chromatography *before chromatography, **after chromatography 
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Figure 8: SDS-PAGE (4-12 % Bis-Tris, silver staining) of pure racemase 
preparations (PL) purified from cultivation medium. Left and right lanes: protein 
standard SeeBlue® Plus2, Invitrogen. 
 
 
4.1.3 Enzyme characterization 
AArac2440 and AArac12996 (purified from medium as described in chapter 4.1.2 b) were 
characterized with respect to the temperature optimum, pH dependency, thermostability, 
substrate spectrum, and the influence of PLP. Relative activities were measured as described 
in publication 4. 
Both enzymes show a maximum activity toward the basic amino acids L-lysine (100 % 
relative activity) and L-arginine, whereas the relative activities for L-Asn (AArac2440: 4.5 %; 
AArac12996: 1.9 %) and L-Thr (AArac2440: 0.5 %; AArac12996: 0.1 %) are comparatively 
low (Figure 9). The temperature optima and pH dependencies have been determined between 
20 °C and 55 °C and pH 8 to pH 10.5, respectively (Figure 10). AArac2440 exhibits a 
maximum initial rate activity at 47.5 °C and at pH-values between 8.6 and 9.7. In contrast, 
AArac12996 shows maximum initial rate activity at 31 °C while having the same pH 
tolerance. 
The thermostability of both enzymes was studied over a period of 7 days by incubating 
enzyme samples between 20 °C and 47 °C (Figure 11). The half life of AArac2440 dropped 
continuously from ca. 20 days, for samples stored at 20 °C, to ca. 3 days for samples stored at 
47 °C. AArac12996 shows a quite different behavior. While samples stored at 20 °C and 
30 °C exhibited an extraordinary stability (no activity loss over 7 days), incubation at higher 
temperatures resulted in a drastically decreased half life of the enzyme. Nevertheless, 
although the temperature screening (Figure 10) showed a rapid loss of initial activity for 
temperatures ≥31 °C, stability investigations for samples kept at 40 °C still exhibited a 
residual activity of about 16 % after 3 days when assayed at 30 °C. These results indicate a 
68 Discussion  
 
 
 
reversible inactivation of AArac12996 at temperatures between 31 °C and 40 °C. At 47 °C 
AArac12996 was inactivated irreversibly and showed no residual activity after only 2 h of 
incubation. 
The influence of additional PLP, which is covalently bound as a cofactor to the active center 
of both racemases, was investigated in the concentration range between 0 and 50 µM. Within 
this range PLP had no influence on the enzyme activity. 
 
Figure 9: Substrate spectrum of AArac2440 (black bars) and AArac12996 (grey bars). Relative initial rate 
activities for all chiral proteinogenic AA (initial substrate concentration=190 mM (unless otherwise indicated), 
T=30 °C). 
 
  
Figure 10: Temperature and pH dependency of AArac2440 () and AArac12996 (). Relative initial rate 
activities were measured between 20 °C and 55 °C and between pH 8 and pH 10.5, respectively. Measurements 
were performed in duplicates (initial substrate concentration=190 mM L-Asn, T=30 °C,  Publication 4, Figures 2 
and 3). 
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Figure 11: Temperature stability. Half lifes of AArac2440 (black bars) and AArac12996 (grey bars) between 
20 °C and 47 °C. Arrows indicate longer half lifes than 20 days. Residual activities were determined at 30 °C 
using 190 mM L-Asn as substrate. 
 
 
The kinetic parameters were determined for crude and purified lyophilisates of AArac2440 as 
well as for purified AArac12996 under reaction conditions according to their catalytic 
approach. The following substrate/reaction conditions have been investigated: 
AArac2440: 1 a-e) Crude lyophilisate (CL), D- and L-Met: 95 vol.% 100 mM KPi, 
5 vol.% methanol, pH 7, T=20-40 °C with steps of 5 °C 
2 a-b) Crude lyophilisate (CL), D- and L-Met: 95 vol.% 100 mM KPi, 
5 vol.% methanol, T=25°C, pH 6 and pH 8 
3 a-e) Pure lyophilisate (PL), D- and L-Asn: 100 vol.% H2O, T=20-40 °C with 
steps of 5 °C 
4) Pure lyophilisate (PL), D- and L-Thr: 100 vol.% H2O, T=30 °C 
AArac12996: 5) Pure lyophilisate (PL), D- and L-Asn: 100 vol.% H2O, T=34 °C 
6) Pure lyophilisate (PL), D- and L- Thr: 100 vol.% H2O, T=30 °C 
 
Table 4 lists all determined Km and Vmax values for the racemization (isomerization) of D- and 
L-isomers according to the enzymes’ catalytic applications. All kinetic parameters were 
determined by non-linear regression using Origin 7.0. Due to the limited substrate solubility, 
kinetic measurements were not possible at optimal substrate concentrations, where the 
maximum enzyme activity (Vmax) is achieved. As a reason, non-linear regression calculations 
of the kinetic parameters resulted in quite broad error ranges for Vmax and Km values. 
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4.1.4 Structural homologies 
As already mentioned in the introduction, AArac2440 and AArac12996 show major 
homologies of their AA and DNA sequences as well as of their quaternary structures. AA and 
DNA sequence alignments of AArac2440 and AArac12996 were done with Clone Manager 9 
Professional Edition and resulted in a 94 % homology of the AA sequences and a 91 % 
homology of the DNA sequences (see Appendix sections IV and V ). There are no 3D-crystal 
structures available for AArac2440 and AArac12996. Justified by a high sequence identity of 
ca. 73 % to the well-known alanine racemase from Pseudomonas aeruginosa (pdb ID: 1SFT), 
homology models of both enzymes were calculated using the internet tool EasyPred3D 
(Figure 12). 
Figure 12:. A: Structure of alanine racemase from Pseudomonas aeruginosa (pdb ID: 1SFT) with PLP bound 
covalently in each active center (red). B: Homology models of monomers of amino acid racemases AArac2440 
(blue) and AArac12996 (purple) calculated with EasyPred3D (Lambert et al., 2002). 
 
Motivated by the unexpected enzyme secretion during cultivation (chapter 4.1.1), the full 
amino acid sequences of both enzymes were analyzed using SignalP 3.0. N-terminal signal 
peptides (probability of 1.000) and specific cleavage sites (probability of 0.92-0.93) between 
amino acids Ala24 and Ala25 were found in both cases. The sequences show the typical 
tripartite structure of signal peptides, consisting of a hydrophobic core region (h-region) 
flanked by a positively charged n-region and a polar c-region that contains the signal 
peptidase cleavage site (Ebbers et al., 1997). SignalP 3.0 uses virtual machines based on 
neural networks (NN) and Hidden Markov Models (HMM) for signal prediction (Nielsen et 
al., 1998; Bendtsen et al., 2004). For detailed information see Appendix section III. 
 
A B 
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4.1.5 Rational protein design of AArac2440 
Both wildtype enzymes, AArac2440 and AArac12996, exhibit only low activities toward the 
isomerization of Thr (Figure 9). In order to improve the activity toward Thr the active site of 
AArac2440 was modified using site-directed mutagenesis. 
To identify possible AA residues in the active center of AArac2440, which might hamper the 
optimal binding of Thr or a fast substrate release, the calculated homology model (Figure 12 
B) was superimposed with the structure of the similar alanine racemase complexed with 
alanine phosphonate (substrate homologue, covalently bound to PLP in the active center, 
pdb ID: 1BD0). Thr was then modeled into the active site of AArac2440 in a congruent 
position like alanine phosphonate using PYMOL. From these studies a possible sterical 
hindrance for the binding of Thr by the side chain of Met349 was proposed (Figure 13 A). 
Therefore, Met349 was exchanged in silico by alanine and glycine, respectively. These 
models revealed a larger binding pocket for Thr (Figure 13 B and C). 
Figure 13: In silico modeling of the active center of AArac2440 with threonine/PLP-complex (purple/blue). 
A: Wildtype (Met349): Thr residue clashes into the side chain of Met349. B: Variant 1 (Met349Ala): reduced 
sterical hindrance of Thr residue by Ala349. C: Variant 2 (Met349Gly): no sterical hindrance of Thr residue by 
Gly349. 
 
Based on these models, the variants were constructed using the QuikChange® method by 
Stratagene according to the instruction manual (Stratagene, 2004). Up- and down-primers 
were designed using the QuikChange® Primer Design program and synthesized by Eurofins 
MWG GmbH. The gene encoding AArac2440 was amplified by standard PCR in an 
Eppendorf thermocycler and cloned into the expression vector pBC SK+, which was then 
used as a template plasmid for the QuikChange® PCR. Competent E. coli XL1-blue cells were 
transformed with the mutation carrying plasmids by electroporation, incubated in LB-medium 
and transferred to LB-plates. Variants 1 (Met349Ala) and 2 (Met349Gly) formed 
homogeneous colonies, while the negative control did not show any growth. The correct point 
mutations of both variants were confirmed by AA sequencing (Agowa, Berlin): 
Variant 1 (Met349Ala)  A1049G, T1050C, G1051G 
Variant 2 (Met349Gly)  A1049G, T1050G, G1051G 
Competent E. coli BL21(DE3) cells, used for overexpression of proteins cloned under the T7 
expression system, were transformed with the mutation carrying plasmids. One colony of 
A B C 
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each variant was grown in LB-medium and protein expression was induced with IPTG. 
Detailed information can be found in the appendix (section VI). 
Activity measurements for the racemization of L-Asn and the epimerization of L-Thr were 
performed as described in publication 4. However, this approach was not successful as both 
variants were inactive and did not show any activity toward L-Asn or L-Thr. Thus, the 
exchange of Met349 led to complete inactivation of AArac2440. 
 
4.2 Crystallization of amino acids 
4.2.1 Conglomerates vs. racemic compounds 
Amino acids differ in terms of their phase diagrams, as they can occur as conglomerates, 
racemic compounds or solid solutions (Jacques et al., 1994). In case of conglomerate forming 
systems (ca. 10 % of all racemic substances), cost-efficient and quite simple PC holds great 
potential, whereas for racemic compound forming systems (ca. 90 % of all racemic 
substances) the application of PC is rather limited. 
 A  B 
Figure 14: Examples for ternary phase diagrams of conglomerate forming systems (A) and racemic compound 
forming systems (B) showing different phase regions (D, L, rac: solid crystals of D-, L-isomers and racemate; E: 
eutectic point). 
 
PC is only possible for systems being in the two-phase region of the respective ternary phase 
diagram, where liquid solution and solid crystals of one enantiomer are coexisting (Figure 
14). For conglomerate forming systems this means PC of both enantiomers is possible starting 
from a racemic solution. When looking at the ternary phase diagram of systems forming 
racemic compounds, it becomes obvious that PC is more complex. In this case the positions 
of the eutectic points E and E’ (solution compositions, where saturated solution and two 
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different solid phases coexist in equilibrium) within the diagram are important for the 
required enantiomeric starting composition of the liquid phase. If these points are close to the 
racemic composition, even poor enrichment of one enantiomer is sufficient to reach the two-
phase region and to apply PC. However, systems with eutectic points far away from the 
racemic composition require highly enriched solutions for PC. 
Considering the high costs of enantioseparation techniques that are employed for the 
enrichment of systems forming racemic compounds (such as advanced chromatographic 
methods like simulated moving bed chromatography (Bechtold et al., 2006)), PC is only 
useful, if a low enantiomeric excess of the solution is sufficient (publication 2). In other cases 
the use of different enantioseparation methods, such as chromatography (alone or in 
combination with racemization of the undesired enantiomer; see publication 3, Fig. 3) as well 
as asymmetric biotransformations, may be more promising. 
 
4.2.2 Preferential crystallization of asparagine 
Asn is one of the two proteinogenic AA acids that form conglomerates and therefore was 
chosen as a model substrate for enzyme-assisted preferential crystallization. Due to the lack of 
reliable literature concerning crystallization properties of proteinogenic AA, solubility 
experiments with potential conglomerate forming AA were necessary beforehand. Besides 
Thr, whose crystallization properties have been investigated in detail by Elsner and Lorenz 
(Elsner et al., 2005; Lorenz et al., 2006; Elsner et al., 2007; Bäckvall, 2008), two further 
proteinogenic AA were claimed to form conglomerates (Klussmann et al., 2006). Klussmann 
and coworkers argued that arginine (Arg) exhibits a typical racemic composition (0 % ee) at 
the eutectic point; and Asn was described as conglomerate forming AA in “Enantiomers, 
Racemates, and Resolutions” (Jacques et al., 1994), which is one of the few comprehensive 
textbooks covering enantioseparation of racemates by crystallization. A common and easy 
method to obtain first evidence about the expected crystallization type is to determine the 
solubilities of the racemate and the single enantiomers. Conglomerate forming systems ideally 
exhibit a relative solubility of two between the racemate [rac] and the enantiopure compound 
[ep] (double solubility rule (Meyerhoffer, 1904)). This solubility ratio α has been defined 
according to Equation 1. 
Ƚ ൌ
ሾሿ
ሾሿ
 
Equation 1 
In order to evaluate crystallization properties of Arg and Asn in H2O, the respective α-values 
were determined. Saturated solutions of racemic and enantiopure species of both AA were 
prepared at 30 °C and the concentrations of each enantiomer were determined by chiral HPLC 
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(column: Crownpak CR(+), 0.4x15 cm; mobile phase: HClO4, pH 1, T=30 °C (for Arg) / 
T=0 °C (for Asn), 0.4 mL/min). The following solubility ratios αArg and αAsn were determined: 
Solubility of arginine (30 °C, H2O): D-Arg: 1008 mM 
 L-Arg: 1020 mM 
 DL-Arg: 1208 mM 
  αArg ≈ 1.2 
 
Solubility of asparagine (30 °C, H2O): D-Asn: 257 mM 
 L-Asn: 256 mM 
 DL-Asn: 512 mM 
  αAsn ≈ 2.0 
Only Asn showed the typical solubility ratio αAsn≈2 and thus ideal behavior, i.e. the solubility 
of one enantiomer is not influenced by the presence of the other enantiomer. For more 
detailed information about the crystallization properties of Asn, the ternary phase diagram of 
Asn in H2O was constructed at different temperatures. Therefore, solubilities of different 
mixtures of D- and L-Asn were determined at 25, 30, 35, 40 an 50 °C, with mass fractions of 
one enantiomer in the D-/L-mixture varying from 0.5 to 1. After saturation of the solution at 
distinct temperatures for at least 20 h, solid Asn was removed by filtration and the solution 
composition was determined via chiral HPLC. The resulting ternary phase diagram shows the 
typical structure of conglomerate forming systems with a racemic eutectic composition 
(Figure 15). 
 
Figure 15: Ternary phase diagram of DL-Asn in H2O at 25, 30, 35, 40 and 50 °C with typical racemic 
composition at eutectic point. 
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4.2.3 Crystallization of allo-threonine from diastereomeric solutions 
Both, Thr (Elsner et al., 2005) and allo-Thr belong to the group of conglomerate forming 
systems (Miyazaki et al., 1994). Since crystallization was only performed from 
diastereomeric solutions, no further investigations of the preferential crystallization behavior 
or the construction of a ternary phase diagram were performed. Simple crystallization of allo-
Thr from diastereomeric solutions consisting of allo-Thr and Thr is possible due to the low 
solubility limit of allo-Thr compared to Thr (Figure 16). 
The crystallization of allo-Thr from diastereomeric solutions (consisting of 50 % allo-Thr and 
50 % Thr) was investigated, in order to determine the reaction parameters for the planned 
allo-Thr production processes (chapter 4.4). Thereby, the main focus was laid on the 
crystallization yield and purity as a function of pH, while the temperature was fixed. To 
reduce the solubility of allo-Thr (Sapoundjiev et al., 2006) for better crystallization yields, 
additional crystallization experiments were performed, where ethanol was added in different 
concentrations between 0 and 20 vol.%. To investigate the influence of the pH on the 
crystallization of allo-Thr, 1 mL of water was saturated with D-allo-Thr and L-Thr at 40 °C 
and the pH was adjusted with diluted NaOH or HCl. The solubility of both isomers 
(determined by HPLC) increased with pH whereas their ratio in the solution remained almost 
constant. Crystallization was performed in 500 µL samples by subcooling of the saturated 
solutions to 34 °C under constant shaking at 1400 rpm for 20 h. The precipitated crystals were 
separated from the solution by filtration, washed with 50 µL ice cold water, and re-suspended 
in water for subsequent HPLC analysis. A good diastereomeric excess (de) of the produced 
crystals could be achieved at all pH-values (Table 5). 
Table 5: Solubility of D-allo-Thr and L-Thr at 40 °C and diastereomeric excess (deallo) of produced 
crystals. 
pH 
D-allo-Thr 
[mM] 
L-Thr 
[mM] 
ratio of D-allo-Thr 
in solution 
deallo of 
crystals 
5.5 295.4 350.2 45.8 % 95.4 % 
6 286.4 341.4 45.6 % 93.3 % 
7 289.1 336.9 46.2 % 97.0 % 
8 331.9 391.0 45.9 % 97.0 % 
8.8 444.7 579.3 43.4 % 87.4 % 
 
The solubilities of D-allo-Thr and L-Thr were investigated at pH 8.5, which was chosen with 
respect to the pH-optimum of AArac12996 (Figure 10). Therefore, saturated solutions of D-
allo-Thr and L-Thr were prepared between 20 °C and 40 °C and analyzed by HPLC. As can 
be seen in Figure 16, the solubility of Thr is significantly higher compared to the solubility of 
allo-Thr. Due to identical physical properties of enantiomeric compounds the respective 
counter-enantiomers L-allo-Thr and D-Thr have the same solubility. 
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An increase of the ethanol concentration from 0 to 20 vol.% in saturated allo-Thr/Thr 
solutions, led to a drastic decrease of solubility of ca. 40 %, which may be beneficial for 
better crystallization yields. However, deallo dropped to ca. 40 % and thus crystallization of 
pure allo-Thr was not possible with ethanol as cosolvent. 
 
Figure 16: Solubility of L-Thr () and D-allo-Thr () in H2O (pH-value was 
adjusted to pH 8.5) between 20 °C and 40 °C. The given data represent the mean 
values of four individual solubility measurements at each temperature with standard 
deviations <1 %. 
 
 
4.3 Enzyme-assisted preferential crystallization of asparagine 
In contrast to simple preferential crystallization (PC) as described in chapter 4.2.2, the 
combination of PC with a racemization step results in a concurrent relative increase of the 
desired enantiomer and a decrease of the undesired one in the liquid phase. As long as 
racemization is faster than crystallization the composition of the liquid phase moves directly 
toward the eutectic point associated with the chosen crystallization temperature. Thereby the 
driving force for crystallization of the desired enantiomer is constantly increased while the 
crystallization of the counter-enantiomer is suppressed. The “recycling” of the undesired 
enantiomer by racemization allows overcoming the usual yield limitation of 50 % for classical 
resolution methods (chapter 1.3.1). This enzyme-assisted PC is a variation of the classical 
dynamic kinetic resolution (DKR), in which the asymmetric transformation of one enantiomer 
is replaced by PC, and in situ racemization is performed using an amino acid racemase from 
Pseudomonas putida (Figure 17). 
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Figure 17: Principle of enzyme-assisted preferential crystallization at the 
example of L-Asn from a supersaturated racemic solution. While L-Asn is 
removed from the system by crystallization, the resulting excess of D-Asn in 
solution (aq) is racemized enzymatically. 
 
Enzymatic racemization instead of chemically (acid/base) or temperature induced 
racemization, together with self-contained crystallization from a supersaturated solution 
without solvent evaporation, make this process an environmentally friendly approach and led 
to a significant increase of crystallized L-Asn. Publication 3 summarizes the experiments 
which have been performed for the crystallization of L-Asn (batch mode) and results in a first 
experimental proof of enzyme-assisted PC as a new process concept. 
 
4.3.1 Reactor setups 
Enzyme-assisted PC of L-Asn has been studied in a batch and in a semi-continuously operated 
reactor, respectively: 
a) Batch 
The reactor setup consisted of a tempered crystallization vessel with a polarimeter-bypass, in 
which the excess of the counter-enantiomer was monitored online in the crystallization 
solution (Figure 18). The crystallization vessel was equipped with a glass frit (pore size of 
16-40 µm) for crystal retention at its outlet and with an overhead mixer for homogeneous 
mixing of the crystals in solution. The temperature of the crystallizer was controlled by a 
water filled thermostat. The crystallization solution was pumped through a polarimetric cell 
and back into the crystallizer using a peristaltic pump. To prevent blocking of the tubings by 
crystal nucleation the complete system was placed in an incubator and tempered to the 
solution saturation temperature (Tsat). Detailed reactor parameters are described in publication 
3. The crystallization process stopped when the concentration of Asn has reached the 
saturation concentration at the crystallization temperature (Tcryst) and the solution was no 
longer supersaturated. 
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Figure 18: Reactor setup for enzyme-assisted batch crystallization of L-Asn. The crystallization vessel was 
cooled down to the crystallization temperature (Tcryst=32 °C) for solution supersaturation, while the remaining 
reactor parts are tempered to a higher saturation temperature (Tsat=35 °C). The formation of an enantiomeric 
excess in solution was monitored online with a polarimeter. 
 
b) Semi-continuous 
In order to increase the possible crystal yield of enzyme-assisted PC, it is necessary to feed 
racemic Asn to the system. Therefore, three requirements must be considered: 
1) No substrate feed in form of solid DL-Asn crystals is possible, since they would act 
as seed crystals and interrupt PC of L-Asn. 
2) No substrate feed in form of an aqueous DL-Asn solution is possible, since this would 
increase the overall reaction volume making water removal necessary. 
3) To maintain a constant concentration of the solution, the applied DL-Asn feed must 
compensate the L-Asn crystallization velocity. 
Given requirements were met by a stainless steel filter module integrated in the polarimeter 
bypass that contained a racemic Asn crystal stock (Figure 19). By pumping the solution 
through the filter module, dynamic re-saturation with racemic Asn at Tsat was achieved. 
 
Figure 19: Reactor setup for enzyme-assisted semi-continuous crystallization of L-Asn. A racemic Asn 
feed is supplied by an additional integrated filter module containing a racemic Asn stock. 
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4.3.2 Process performance 
a) Batch 
To demonstrate the superior properties of enzyme-assisted PC in terms of yield increase, 
20 mL of a supersaturated racemic Asn solution (ΔT=-3°C) were seeded with mseed=5 mg of 
enantiopure L-asparagine monohydrate (L-Asn*H2O) crystals as described in publication 3 
(batch mode). In situ racemization of the liquid phase was catalyzed by purified AArac2440. 
The influence of the enzyme concentration on the ee of crystallized L-Asn was investigated by 
increasing the concentration of AArac2440 from 0 to 1 mg/mL. PC alone (without 
AArac2440) yielded a maximum of 31 mg L-Asn*H2O (≥99.5 % ee) after the process was 
interrupted before the counter-enantiomer started to crystallize. In contrast, the addition of 
1 mg/mL AArac2440 led to a ca. six fold yield increase (198 mg L-Asn*H2O). However, the 
ee dropped to about 92 %. Furthermore, it could be shown that the product ee increases with 
the concentration of AArac2440 (Figure 20). Fast racemization velocities kept the 
composition of the solution closer to racemic (compared to slow racemization), and thus 
suppressed D-Asn crystallization more efficiently. As an example, Figure 21 shows the ee of 
the crystallization solution during PC without racemization and enzyme-assisted PC with 
0.5 mg/mL AArac2440. The crystals of L-Asn, that were grown on seed crystals, can be 
distinguished clearly from the fine crystals of D- and L-Asn, which were formed by secondary 
nucleation (Figure 22). 
 
 
Figure 20: Product yields (black bars: L-Asn*H2O, grey bars: D-Asn*H2O) and eeL () of enzyme-assisted PC 
with AArac2440, applied in different concentrations from 0 to 1 mg/mL (batch mode). The product eeL reached 
ca. 92 % when 1 mg/mL AArac2440 was applied. Process parameters: Tsat=35 °C, Tcryst=32 °C, V=20 mL, 
mseed=5 mg. 
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Figure 21: Monitoring of excess D-Asn in the 
crystallization solution during PC without racemization 
(black) and enzyme-assisted PC with 0.5 mg/mL 
AArac2440 (grey). Data was determined online by 
optical rotation measurement. 
 
Figure 22: Product crystals of enzyme-assisted PC 
with 1 mg/mL AArac2440. Grown seed crystals of 
L-Asn can be distinguished clearly from fine 
secondary crystals of D- and L-Asn (scale in cm). 
 
b) Semi-continuous 
For semi-continuous enzyme-assisted PC, a filter module with a feed-stock of racemic Asn 
was implemented in the reactor setup (chapter 4.3.1 b). The concentration decrease of Asn in 
the solution, caused by crystallization of L-Asn, was compensated by dynamic re-saturation in 
the filter module. Thus, the absolute product yield was increased by the amount of fed Asn up 
to ca. 700 mg. Similar to the results presented for the batch process, the eeL of the produced 
crystals increased with the amount of applied AArac2440. 
 
Figure 23: Product compositions and yields (black bars: L-Asn*H2O, grey bars: D-Asn*H2O) and eeL () 
obtained by semi-continuous enzyme-assisted PC in the absence and presence of AArac2440 (0.5 to 2 mg/mL). 
Product eeL did not exceed 64 % when 2 mg/mL AArac2440 was applied. Process parameters: mfeed=500 mg DL-
Asn, Tsat=35 °C, Tcryst=32 °C, V=20 mL, mseed=5 mg. 
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However, the maximum eeL that was reached during semi-continuous enzyme-assisted PC 
using 2 mg/mL AArac2440 did not exceed 64 % (Figure 23). Hence, no product purities 
comparable to the ones reached during batch crystallization of L-Asn could be achieved. 
 
4.3.3 Benefits and limits 
Enzyme-assisted PC has the potential of overcoming yield limitations of classical resolution 
processes by “recycling” the undesired enantiomer, so that a theoretical yield of 100 % 
becomes possible. However, in the present example the possible yield is limited by the 
relatively small degree of supersaturation of the Asn solution during PC, which determines 
the maximum possible yield (Equation 2): 
୮୰୭ୢ୳ୡ୲ ൌ ሺୱୟ୲ െ ୡ୰୷ୱ୲ሻ ή  
Equation 2 
with mproduct being the maximum possible yield, V being the reaction volume, and csat/cryst 
being the solubility limits of Asn at saturation and crystallization temperatures, respectively. 
Consequently, the yield of the process can only be increased by a continuous feed of the 
racemic substrate, which theoretically could yield 100 % enantiopure product (in relation to 
racemic feed). Promising results using this approach were demonstrated by semi-continuous 
enzyme-assisted PC, where the product yield could be increased by the amount of the racemic 
feed. 
To evaluate the efficiency of the biocatalyst, the residual enzyme activity of applied 
AArac2440 was determined after enzyme-assisted PC. Four independent experiments 
revealed no loss of activity after a process time of 20 h. Easy enzyme recovery by 
ultrafiltration (membrane cutoff: 10 kDa) and lyophilization additionally contribute to an 
attractive new process for the chiral resolution of AA. However, further optimization of the 
reactor setup as well as of the process parameters (e.g. degree of supersaturation, type and 
velocity of stirring, reactor volume, and product recovery) are necessary to achieve satisfying 
results in terms of optical purity. 
In contrast to DKR or deracemization processes by stereoselective biotransformations 
(Turner, 2004), the production of both isomers with only one racemase is possible. This is a 
considerable advantage, since no adaption of the enzyme’s stereoselectivity or the use of 
another enzyme is required for the production of the second enantiomer. In fact, only the 
chirality of the used seed crystals determines the final product chirality. 
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4.4 Production of chiral allo-threonine 
As was already mentioned in the introduction, various chemical multi-step reactions have 
been described for the production of racemic and chiral allo-Thr. Their complexity and 
usually low yields render these processes very cost-intensive, whereas enzymatic approaches 
are rather rare (Pons et al., 1990; Beaulieu, 1991; Blaskovich et al., 1993; Lloyd-Williams et 
al., 1997; Cardillo et al., 1998). 
In the course of this project, valuable chiral L- and D-allo-Thr was produced by enzymatic 
isomerization of the cheap starting material Thr with AArac12996 (PL) in combination with 
simple product crystallization from aqueous solutions. AArac12996 was preferred for the 
application as a process enzyme, since it exhibits an excellent stability at 30 °C (chapter 
4.1.3). 
Two different process strategies for the production of chiral allo-Thr were investigated, which 
will be discussed in chapter 4.4.2. 
 
4.4.1 Identification of threonine isomers 
Enzymatic isomerization (epimerization) of diastereomeric Thr by amino acid racemases does 
not yield the respective counter-enantiomers, as it is the case during isomerization of AA with 
only one chiral center. Since only the stereoconformation of the α-amino group is affected by 
the isomerization reaction while the β-hydroxy group remains unchanged, Thr is 
interconverted to allo-Thr (publication 4, Figure 1). 
The identity of the reaction products of D- and L-Thr was verified by chiral HPLC and 1H-
NMR spectroscopy in D2O. Chiral HPLC was able to separate three peaks, which could be 
assigned to D-Thr/D-allo-Thr, L-allo-Thr and L-Thr (Figure 24). Since it was not possible to 
distinguish D-Thr and D-allo-Thr by HPLC, only the ratio a between D- and L-isomers could 
be determined. 
 ൌ
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Equation 3 
Due to the different chemical environments in diastereomeric molecules, epimers can be 
distinguished from each other by 1H-NMR spectroscopy, while enantiomers show the same 
peak pattern (Figure 25). The ratio b between Thr and allo-Thr could be determined from the 
peak areas by Equation 4. 
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Equation 4 
 
The absolute concentrations [D-Thr] and [D-allo-Thr] could then be calculated from Equation 
3 and Equation 4. [L-Thr] and [L-allo-Thr] can be determined in an equivalent way. 
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Equation 5 
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Equation 6 
 
 
 
Figure 24: HPLC chromatograms of threonine isomers (column: Crownpak CR(+), mobile phase: HClO4 (pH1), 
flow: 0.8 mL/min, T=5 °C). Retention times tr: tr(D-Thr) =1.85 min, tr(D-allo-Thr)=1.88 min, tr(L-allo-Thr)=2.04 
min and tr(L-Thr)=2.89 min. 
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Figure 25: 1H-NMR-spectra (Bruker, Avance DR X 600, 600 MHz) of Thr (top), allo-Thr (middle) and the 
reaction product of Thr isomerization (bottom) in D2O showing peaks for α-, β- and γ-protons (Thr: 600 MHz, 
ppm: δ= 1.23-1.24 (d, 3H, J=6.42, CH3), 3.49-3.50 (d, 1H, J=4.91, CH), 4.14-4.18 (m, 1H, CH); allo-Thr: 600 
MHz, ppm: δ= 1.14-1.15 (d, 3H, J=6.42, CH3), 3.77-3.78 (d, 1H, J=3.77, CH), 4.28-4.32 (m, 1H, CH)). 
 
4.4.2 Process modes 
Both enantiomers of allo-Thr have been produced by enzymatic isomerization of Thr and 
simultaneous crystallization. For a better understanding, this process may be separated into 
three individual physical and biocatalytic reaction steps, which all take place simultaneously 
in one reaction vessel and result in a dynamic interaction (Figure 26): 
 “removal” of Thr from the saturated solution by isomerization to allo-Thr 
 solution of excess (solid) D- or L-Thr 
 crystallization of accumulating D- or L-allo-Thr upon exceeding the solubility limit 
D- and L-threonine 
D- and L-allo-threonine 
reaction product of threonine isomerization 
α 
β 
γ 
β 
α 
γ 
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The dynamic interaction of these three steps yields a constant solution composition of about 
42 % D- or L-allo-Thr and 58 % L- or D-Thr, respectively. 
 
Figure 26: Production of chiral allo-Thr by enzymatic 
isomerization and crystallization. The dynamic process consists of 
three steps: isomerization (Thr  allo-Thr), crystallization (allo-
Thr) and solution of excess Thr. 
 
In contrast to enzyme-assisted PC of Asn, where the reaction process could be monitored 
polarimetrically, here the solution composition as well as the optical purity of the crystals 
were determined by chiral HPLC and 1H-NMR (chapter 4.4.1). 
The production of D- and L-allo-Thr was investigated in a repetitive batch ans in a 
continuously operated reactor. 
 
a) Repetitive batch production in one single reaction vessel 
Both enantiomers of allo-Thr were produced separately starting from either D- or L-Thr as a 
substrate. Enzymatic isomerization of Thr to the respective allo-Thr enantiomer using 
AArac12996 was performed in a tempered 30 mL reaction vessel as described in publication 
4. Therefore, the reaction solution was saturated with the respective chiral Thr until a 
sediment was formed (Figure 27, I). Crystallization of the accumulating enantiomer of allo-
Thr occurred in the same reaction vessel and started upon exceeding its solubility limit, which 
is lower compared to the one of Thr in water (Figure 16). As a result, an equilibrium 
concentration of ca. 42 % allo-Thr and 58 % Thr was formed in the solution (Figure 27, II). 
Upon complete solution of the excess Thr, the described dynamic process was interrupted and 
only allo-Thr remained in crystalline form (Figure 27, III). The crystals were separated by 
filtration and dried at 60 °C. By the addition of fresh Thr the next batch was started. Steps II 
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and III were repeated for a repetitive batch crystallization. Figure 27 depicts a repetitive batch 
process for the production of D-allo-Thr starting from a saturated L-Thr solution. 
 
Figure 27: Repetitive batch crystallization of D-allo-Thr in one single reaction vessel. I: AArac12996 is added 
to a saturated L-Thr solution (starting condition) II: dynamic process of crystallization (D-allo-Thr), solution (L-
Thr) and isomerization (L-Thr  D-allo-Thr) III: addition of fresh L-Thr when excess has depleted. Steps II and 
III are repeated for repetitive batch crystallization. 
 
Repetitive batch processes (20 mL scale) were performed for the production of D- and L-allo-
Thr, respectively. The process data and yields for both enantiomers are summarized in 
publication 4. The production of D-allo-Thr was performed over 55 days and consisted of 12 
batches with yields of 1.6 to 4.4 g D-allo-Thr per batch and a deallo between 96.9 and 100 %. 
A space time yield (STY) of 28 g/(L·d) and a final yield of 30.8 g D-allo-Thr (deallo > 99.2 %) 
were achieved. The production of L-allo-Thr was performed over 56 days and consisted of 12 
batches with yields of 1.5 to 4.0 g L-allo-Thr per batch and a deallo between 94.6 and 100 %. 
A STY of 28.8 g/(L·d) and a final yield of 32.2 g L-allo-Thr (deallo > 98.4 %) were obtained 
using a total amount of 20 mg AArac12996. The enzyme showed a remarkable high stability 
(t1/2=32 d) under process conditions yielding 2.56 g D-allo-Thr and 1.62 g L-allo-Thr per mg 
AArac12996, respectively. 
 
b) Continuous production with separate crystallization vessel 
Another process concept was investigated where crystallization of allo-Thr and solution of 
excess Thr were performed in two separate reaction vessels. Thereby, a continuous product 
separation should be enabled. Figure 28 depicts the reactor setup, which consisted of two 
tempered 150 mL reaction vessels (25 °C and 30 °C, connected by silicon tubings), each 
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having two inner glass circlets. These circlets break the stirring turbulences and prevent the 
crystals from being flushed out of the vessel. Both vessels were separated by a third small 
vessel (volume of ca. 20 mL), that was heated to 40 °C and served as a solution trap for 
flushed crystals. The reaction solution was pumped from vessel 1 (solution of Thr) through 
vessel 2 (solution of small, flushed crystals) into vessel 3 (crystallization of allo-Thr), from 
where it was led back to vessel 1. 
For a continuous product separation, crystallization of D- or L-allo-Thr may only occur in 
reaction vessel 3. Therefore, the allo-Thr concentration must be below the solubility limit at 
Tsat (vessel 1). This can only be provided by a sufficiently low temperature in vessel 3 (Tcryst) 
leading to fast crystallization of allo-Thr. 
The described process was performed for a continuous D-allo-Thr production, where Tsat was 
30 °C and Tcryst was varied between 20 °C and 30 °C. For isomerization of Thr, enzyme 
concentrations between 0.1 mg/mL and 1 mg/mL were applied. Table 6 summarizes the 
diastereomeric excesses and yields of D-allo-Thr in both reaction vessels at different 
crystallization temperatures using 0.35 mg/mL AArac12996. As expected, the amount of 
crystallized D-allo-Thr in vessel 3 increased by cooling. However, at all investigated 
temperatures even more D-allo-Thr precipitated in vessel 1, and thus making a continuous 
product separation from vessel 3 impossible. Since very good yields and purities could be 
achieved during repetitive batch crystallizations of allo-Thr (chapter 4.4.2 a), the continuous 
process was not further optimized. 
 
Table 6: Summary of D-allo-Thr production with continuous product separation at different crystallization 
temperatures. Tsat= 30 °C, AArac12996: 0.35 mg/mL. 
vessel 3 vessel 1 
Tcryst 
[°C] 
reaction time 
[d] 
yield (D-allo-Thr) 
[g] 
deallo 
[%] 
yield (D-allo-Thr) 
[g] 
deallo 
[%] 
20 2 3.18 86.8 8.41 15.0 
25 3 2.56 99.4 11.07 99.4 
30 3 0.13 90.2 19.44 55.8 
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Figure 28: Reactor setup for the continuous production of allo-Thr by enzymatic isomerization of Thr and 
crystallization of allo-Thr in separated reaction vessels. Top and bottom (left): Scheme and photo of reactor 
setup. 1) solution of excess Thr, 30 °C, 2) crystal trap, 40 °C, 3) crystallization of allo-Thr, 25 °C. The reaction 
solution was adjusted to pH 8.5 (using NaOH) and pumped with a peristaltic pump (10 mL/min) from vessel 1 
(solution of Thr) through vessel 2 (solution of small, flushed crystals) into vessel 3 (crystallization of allo-Thr), 
from where it was led back to vessel 1. For enzymatic Thr isomerization, 0.35 mg/mL AArac12996 were added 
to the solution. All three vessels were stirred with magnetic bars. Bottom (right): tempered reaction vessel with 
inner glass circlets for crystal retention. A distinct border between turbulent (cloudy solution) and non-turbulent 
area (clear solution) is detectable. 
 
4.4.3 Benefits and limits of the new allo-threonine process 
As already stated in the introduction, the use of allo-Thr for large-scale syntheses is hampered 
by the high costs of the currently applied chemical multi-step syntheses, which require careful 
purification of each reaction step. Besides, there are also biocatalytic syntheses described in 
the literature. Kataoka (Kataoka et al., 1998) reported a stereoselective C-C bond formation 
between glycine and acetaldehyde using L-allo-Thr aldolase from Aeromonas jandaei DK-3. 
The same reaction is catalyzed by the serine hydroxymethyltransferase GlyA from E. coli 
(Makart et al., 2007). Lim (Lim et al., 1993) reported on an amino acid racemase from 
1 
3 
2 crystal retention by inner 
glas circlets 
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Pseudomonas putida ATCC 17642 with a threonine-α-epimerase activity (EC 5.1.1.6), which 
is the only reference of an enzymatic isomerization of Thr in the literature. γ-halogenated 
derivatives of Thr were synthesized using L- and D-threonine aldolases from Pseudomonas 
putida starting from glycine and the corresponding halogenated aldehydes yielding a de up to 
97 % (Steinreiber et al., 2007). Nevertheless, chemical methods clearly outnumber the 
described enzymatic approaches. For example Blaskovich (Blaskovich et al., 1993) described 
an 8-step synthesis of D- and L-allo-Thr starting from the respective cis-isomers with a total 
yield of 38 %. 
The repetitive batch process, which has been developed in this thesis, offers an extraordinary 
simple method for the production of optically pure allo-Thr using the same amino acid 
racemase for both enantiomers. Compared to chemical synthesis methods for allo-Thr this 
process consists of only one enzyme catalyzed reaction (isomerization of bulk Thr) and 
simultaneous crystallization of allo-Thr in one single reaction vessel. The process is carried 
out at moderate temperatures in water and avoids any toxic or harmful compounds, thus being 
environmentally friendly. The product recovery is performed by simple filtration and 
subsequent crystal drying, which makes downstream processing very comfortable. In contrast 
to other biocatalytic production and separation methods for allo-Thr (Makart et al., 2008), 
very high product purities with deallo>99% can be achieved. The excellent stability of the 
biocatalyst AArac12996 in the process easily allows for several batches with the same 
enzyme sample, and thus makes complete conversion of the substrate possible. As 
demonstrated in chapter 4.4.2, a repetitive batch mode is advantageous over a continuous 
process due to the simple and robust process control. 
 
4.4.4 Added value by threonine isomerization 
Valuable chiral allo-Thr can be produced by the described simple process from low-priced 
Thr. In case of D-allo-Thr, cheap bulk L-Thr (ca. 1 €/g, catalogue price VWR 2010), which is 
mainly produced by fermentation with optimized strains of Escherichia coli and Serratia 
marcescens (Hermann, 2003; Leuchtenberger et al., 2005), is the starting material. The high 
enzyme stability, as well as low maintenance of the running repetitive batch process, result in 
a profitable added value. Easy purification of AArac12996 from the culture medium yielded 
ca. 160 mg purified enzyme preparation per liter cultivation medium (chapter 4.1.2). The 
enzyme consumption during D-allo-Thr production was ca. 0.39 mg/gD-allo-Thr (publication 4). 
Therefore, one batch of AArac12996 (160 mg) purified from 1 liter cultivation medium is 
sufficient for the production of ca. 410 g D-allo-Thr with a market value of more than 
150000 € (catalogue price Jan. 2011, IRIS Biotech GmbH, Germany). Besides D- and L-allo-
Thr, there are several derivatives commercially available (Table 7) ranging between 110 and 
575 €/g. 
 Discussion 91 
 
 
Table 7: Commercially available derivatives of allo-Thr (catalogue prices Jan. 2011, IRIS Biotech GmbH, 
Germany). 
Derivative D-enantiomer  L-enantiomer 
D/L-allo-Thr 
  390 €/g 
 
  225 €/g 
    
D/L-allo-Thr(Et)-OH 
 575 €/g 
 
 550 €/g 
    
D/L-allo-Thr(Me)-OH 
 575 €/g 
 
 550 €/g 
    
L-allo-Thr(tBu)-OH 
  
  250 €/g 
    
Boc-D/L-allo-Thr-OH*DCHA 
 
      250 €/g 
 
 
      200 €/g 
    
Fmoc-D/L-allo-Thr-OH 
 
      110 €/g 
 
 
      200 €/g 
    
Fmoc-L-allo-Thr(tBu)-OH 
  
 
      200 €/g 
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5 Conclusions 
Two different approaches for enzyme-assisted crystallization of chiral amino acids have been 
investigated in this thesis. Both approaches use purified amino acid racemases from 
Pseudomonas putida, which have been characterized in detail. While in approach 1 the 
racemase is applied for racemization of the proteinogenic amino acid Asn, approach 2 uses 
the enzyme for the isomerization of Thr to allo-Thr. 
Approach 1: Enzyme-assisted preferential crystallization of L-Asn from a racemic 
solution 
A new method, based on the combination of enzymatic racemization and preferential 
crystallization of single enantiomers from racemic solutions, was investigated. The ternary 
system DL-Asn in water was found to form conglomerates upon crystallization from racemic 
solutions and thus to allow enantioseparation by preferential crystallization. Purified 
AArac2440 was used for in situ racemization of the crystallization solution, thus keeping the 
solution ee close to racemic and thereby prolonging preferential crystallization. This process 
is the first successful demonstration of enzyme-assisted preferential crystallization. However, 
further optimization of the reactor setup as well as of the process parameters (e.g. degree of 
supersaturation, type and velocity of stirring, reactor volume, and product recovery) are 
necessary to achieve satisfying results in terms of optical product purity. 
Approach 2: Enzymatic production of chiral allo-Thr by isomerization of Thr and 
crystallization 
Valuable chiral D- and L-allo-Thr were produced by isomerization of the respective Thr 
enantiomers with AArac12996 and simultaneous crystallization from aqueous solutions. The 
repetitive batch process, which integrates isomerization and crystallization in one single 
reaction vessel, was superior to a continuous process with two separate isomerization and 
crystallization vessels. Both enantiomers of the produced allo-Thr were obtained with very 
good diastereomeric excess (deallo>98 %). The high stability of AArac12996 under process 
conditions (t1/2=32 d) as well as low process maintenance effort, offer a simple and 
economically interesting method for the production of high-priced allo-Thr for synthetic 
applications in the pharmaceutical industry. 
To expand the general scope of application of the presented processes, enzymatic 
racemization, which is the process’ bottleneck, must be the focus of intensive research. By the 
use of improved catalysts the possible substrate spectrum might not be limited to natural 
amino acids but also non-proteinogenic amino acids or even other substance groups may 
become available. Especially modern evolutionary methods or rational protein design for 
altered substrate spectra of wild type racemases (Kino et al., 2007) might lead to new 
production processes for chiral compounds. 
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I DNA sequences 
AArac2440 
1 ATGCCCTTTCGCCGTACCCTTCTGGCTGCATCCCTGGCACTTCTGATCACCGGACAGGCC 
61 CCCCTGTATGCGGCACCACCGTTGTCGATGGACAACGGCACCAACACCCTGACCGTGCAA 
121 AACAGCAATGCCTGGGTCGAAGTCAGCGCCAGCGCCCTGCAGCACAACATCCGCACGCTG 
181 CAGGCCGAGCTGGCCGGCAAGTCCAAGCTGTGCGCCGTGCTCAAGGCCGATGCCTATGGC 
241 CACGGTATCGGCCTGGTAATGCCATCGATCATCGCCCAAGGCGTGCCCTGCGTGGCGGTG 
301 GCCAGCAACGAGGAGGCCCGCGTGGTCCGCGCCAGTGGCTTCACCGGGCAACTGGTGCGG 
361 GTACGCCTGGCCAGCCTCAGCGAGCTGGAAGATGGCTTGCAGTACGACATGGAAGAGCTG 
421 GTGGGCAGCGCGGAATTTGCCCGCCAGGCCGATGCCATCGCCGCGCGCCATGGCAAGACC 
481 TTGCGCATTCACATGGCGCTCAACTCCAGCGGCATGAGCCGCAACGGGGTGGAGATGGCC 
541 ACCTGGTCCGGCCGTGGCGAAGCGCTGCAGATCACCGACCAGAAGCACCTCAAGCTGGTC 
601 GCGCTGATGACCCACTTCGCCGTGGAAGACAAGGACGATGTACGCAAGGGCCTGGCGGCA 
661 TTCAACGAGCAGACCGACTGGTTGATCAAGCACGCCAGGCTGGACCGCAGCAAGCTCACC 
721 CTGCACGCCGCCAACTCGTTCGCTACGCTGGAAGTGCCGGAAGCGCGCCTGGACATGGTA 
781 CGAACGGGTGGCGCGCTGTTCGGCGACACCGTGCCGGCGCGCACCGAGTACAAACGTGCG 
841 ATGCAGTTCAAATCGCACGTGGCGGCGGTGCACAGCTATCCGGCCGGCAACACCGTGGGC 
901 TATGACCGCACCTTCACCCTGGCCCGTGATTCGCGGCTGGCCAACATTACGGTCGGGTAC 
961 TCCGATGGCTACCGCCGGGTATTCACCAACAAGGGCCATGTGCTGATCAACGGCCACCGT 
1021 GTGCCGGTCGTGGGCAAGGTGTCGATGAACACGCTGATGGTCGATGTCACCGACTTCCCT 
1081 GATGTGAAGGGGGGTAACGAAGTGGTGCTGTTCGGCAAGCAGGCCGGGGGCGAAATCACC 
1141 CAGGCCGAGATGGAAGAAATCAACGGCGCGTTGCTCGCCGATTTGTACACCGTATGGGGC 
1201 AATTCCAACCCGAAGATACTCGTCGACTGA 
 
AArac12996 
1 ATGCAATTTAGCCGTACCCTCCTGGCTGCATCCCTCGCTCTGCTGATCACTGGCCAGGCC 
61 CCGCTGTACGCCGCACCGCCCCTGTCGATGGACAACGGCACCACCGCCCTGACCGCGCAG 
121 AACAGCAACGCCTGGGTCGAAATCAGTGCCGGCGCACTGCAACACAACATCCGTACCTTG 
181 CAGGCCGAGTTGGGCGGCAAGTCCAAGCTGTGCGCCGTGCTCAAGGCCGACGCCTATGGC 
241 CACGGTATCGGCCTGGTGATGCCGTCGATCATCGCCCAGGGCGTGCCCTGCGTGGCGGTG 
301 GCCAGCAACGAGGAGGCACGCGTGGTCCGCGCCAGTGGCTTCACCGGGCAACTGGTGCGG 
361 GTACGCCTGGCCAGCCTCGGCGAAGTGGAAGATGCCTTGCAGTACGACATGGAAGAGCTG 
421 GTTGGCAGCGCCGAGTTCGCCCGCCAGCTCGATGCCATCGCCGAACGCCACGGCAAGACC 
481 CTGCGCATTCACATGGCGCTCAATTCCAGCGGCATGAGCCGCAACGGCGTGGAAATGACC 
541 ACCTGGTCCGGCCGGGGTGAAGCGCTGCAGATCACTGACCAGAAGCACCTCCAGCTGGTC 
601 GCGCTGATGACTCACTTCGCCGTGGAAGACAAGGACGATGTGCGCAAAGGCCTGGCAGCG 
661 TTCAACGAACAGACCGACTGGCTGATCAAGCACGCGAAGCTTGATCGCAGCAAGCTCACC 
721 CTGCATGCCGCCAACTCCTTCGCTACGCTGGAAGTGCCGGAAGCGCACCTGGACATGGTG 
781 CGTACCGGTGGCGCGCTGTTCGGCGACACCGTGCCGACGCGCACCGAATACCAACGTGTC 
841 ATGCAGTTCAAGTCGCACGTGGCGGCGGTGCACAGCTACCCGGCAGGCAACACCGTCGGC 
901 TACGACCGCACCTTCACCCTGGCGCGTGATTCGCGCCTGGCCAACATCACCGTGGGTTAC 
961 TCCGATGGCTACCGCCGGGTGTTCACCAACAAGGGCCATGTGCTGATCAACGGCCACCGA 
1021 GTGCCAGTGGTGGGCAAGGTGTCGATGAACACCTTGATGGTCGATGTCACCGATTTCCCC 
1081 GATGTGAAGGGGGGCAACGAAGTGGTGCTGTTCGGCAAACAGGCCGGGAGGGAGATCACC 
1141 CAGGCCGAGATAGAAGAAATCAACGGCGCGCTGCTCGCCGACCTCTACACCGTATGGGGC 
1201 AGTTCCAACCCGAAGATTCTCGTCGACTGA 
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II AA sequences 
AArac2440 
1 MPFRRTLLAASLALLITGQAPLYAAPPLSMDNGTNTLTVQNSNAWVEVSASALQHNIRTL 
61 QAELAGKSKLCAVLKADAYGHGIGLVMPSIIAQGVPCVAVASNEEARVVRASGFTGQLVR 
121 VRLASLSELEDGLQYDMEELVGSAEFARQADAIAARHGKTLRIHMALNSSGMSRNGVEMA 
181 TWSGRGEALQITDQKHLKLVALMTHFAVEDKDDVRKGLAAFNEQTDWLIKHARLDRSKLT 
241 LHAANSFATLEVPEARLDMVRTGGALFGDTVPARTEYKRAMQFKSHVAAVHSYPAGNTVG 
301 YDRTFTLARDSRLANITVGYSDGYRRVFTNKGHVLINGHRVPVVGKVSMNTLMVDVTDFP 
361 DVKGGNEVVLFGKQAGGEITQAEMEEINGALLADLYTVWGNSNPKILVD 
 
AArac12996 
1 MQFSRTLLAASLALLITGQAPLYAAPPLSMDNGTTALTAQNSNAWVEISA 
51 GALQHNIRTLQAELGGKSKLCAVLKADAYGHGIGLVMPSIIAQGVPCVAV 
101 ASNEEARVVRASGFTGQLVRVRLASLGEVEDALQYDMEELVGSAEFARQL 
151 DAIAERHGKTLRIHMALNSSGMSRNGVEMTTWSGRGEALQITDQKHLQLV 
201 ALMTHFAVEDKDDVRKGLAAFNEQTDWLIKHAKLDRSKLTLHAANSFATL 
251 EVPEAHLDMVRTGGALFGDTVPTRTEYQRVMQFKSHVAAVHSYPAGNTVG 
301 YDRTFTLARDSRLANITVGYSDGYRRVFTNKGHVLINGHRVPVVGKVSMN 
351 TLMVDVTDFPDVKGGNEVVLFGKQAGREITQAEIEEINGALLADLYTVWG 
401 SSNPKILVD 
 
N-terminal signal peptides are highlighted in red. 
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III N-terminal signal sequences 
The full amino acid sequences of AArac2440 and AArac12996 were analyzed by SignalP 3.0 
and N-terminal signal peptides were found with a probability of 1.000. Specific cleavage sites 
were found between Ala24 and Ala25 with a probability of 0.930 and 0.923, respectively. 
SignalP 3.0 uses virtual machines based on neural networks (NN) and Hidden Markov 
Models (HMM) for signal prediction (Nielsen et al., 1998; Bendtsen et al., 2004). 
 
AArac2440: 
NN result:              HMM result: 
  
 
Measure Position Value Cutoff signal peptide? 
 
Prediction Signal peptide 
max. C 25 0.451 0.32 YES  Signal peptide probability: 1.000 
        
max. Y 25 0.611 0.33 YES  Signal anchor probability: 0.000 
        
max. S 12 0.984 0.87 YES  Max cleavage site  0.930 between  
      probability: pos. 24 and 25 
mean S 1-24 0.908 0.48 YES    
        
D 1-24 0.759 0.43 YES    
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AArac12996: 
NN result:              HMM result: 
  
 
Measure Position Value Cutoff signal peptide? 
 
Prediction Signal peptide 
max. C 25 0.451 0.32 YES  Signal peptide probability: 1.000 
        
max. Y 25 0.605 0.33 YES  Signal anchor probability: 0.000 
        
max. S 12 0.985 0.87 YES  Max cleavage site  0.923 between  
      probability: pos. 24 and 25 
mean S 1-24 0.902 0.48 YES    
        
D 1-24 0.754 0.43 YES    
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VI Rational protein design of AArac2440 
Up- and down-primers were designed using the QuikChange® Primer Design program and 
synthesized by Eurofins MWG GmbH (Ebersberg) as shown in the synthesis report below. The 
gene encoding AArac2440 was amplified by standard PCR (Tables I and II) in an Eppendorf 
thermocycler and cloned into the expression vector pBC SK+, which was then used as a 
template plasmid for the QuikChange® PCR. A negative control without primers was carried 
along. The template DNA was digested twice with the restriction enzyme DpnI (New England 
BioLabs) for 2 h at 37 °C, and the PCR-product was purified with the QIAquick PCR 
Purification Kit according to the manufacturer’s instructions (QIAGEN, 2002). The absolute 
DNA concentrations were determined by absorption measurement using the NanoDrop method. 
Variant 1 (Met349Ala):  40.3 ng/µL 
Variant 2 (Met349Gly):  39.6 ng/µL 
Negative control:    5.5 ng/µL 
Gel-electrophoresis (1 % agarose, 140 V, 30 min) of the digested and purified PCR-products 
confirmed the presence of the mutation carrying construct pBC SK+rac (4630 base pairs). 
Competent E. coli XL1-blue cells were transformed by electroporation (Bio-Rad Gene Pulser: 
25 µF, 1.5 kV, 800 Ω, ca. 15 ms), incubated for 2 h at 37 °C in LB-medium (50 µg/mL 
chloramphenicol, Cm), transferred to LB-plates (50 µgCm/mL) and incubated at 37 °C. For 
protein expression competent E. coli BL21(DE3) cells, used for overexpression of proteins 
cloned under the T7 expression system, were transformed with the mutation carrying plasmids. 
One colony of each variant was grown in 5 LB-medium (50 µgCm/mL) and induced with 400 
µM IPTG (2 h, 37 °C). 
 
Oligonucleotide synthesis report of PCR primers.
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Table I: Pipetting table for QuikChange® PCR 
volume [µL] concentration 
H2O 19,7   
10x buffer for KOD Hot Start Polymerase 4 1x 
dNTPs (2 mM each) 2 0,2 mM 
Up-primer (2,5 µM) 4 0,25 µM 
Down-primer (2,5 µM) 4 0,25 µM 
MgSO4 (25 mM) 1,6 1 mM 
Betain (5 mM) 1,2 0.15 mM 
KOD Hot Start Polymerase 1 0,025 U/µL 
Template plasmid: pBC SKrac (46,2 ng/µL) 2,5 2,9 ng/µL 
 
 
Table II: Thermocycler program for QuikChange® PCR 
cycle no. hot start denaturing annealing elongation final elongation 
1 94 °C         
2   3 min / 94 °C       
3-28   1 min / 94 °C 1 min / 65 °C 5 min / 72 °C   
29       10 min / 72 °C   
Hold         4 °C 
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VII Plasmids 
pET-22b(+) 
High copy plasmid for overexpression of AArac2440 and AArac12996. Genes were cloned into 
pET-22b(+) after digestion with NdeI / XhoI. 
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pBC SK+ 
Template plasmid for rational protein design of AArac2440. Gene was cloned into pBC SK+ 
after digestion with EcoRV / HindIII. 
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